0001999371-23-000211.txt : 20231114 0001999371-23-000211.hdr.sgml : 20231114 20231114163253 ACCESSION NUMBER: 0001999371-23-000211 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NANOPHASE TECHNOLOGIES Corp CENTRAL INDEX KEY: 0000883107 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 363687863 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-22333 FILM NUMBER: 231407108 BUSINESS ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 BUSINESS PHONE: 6303231200 MAIL ADDRESS: STREET 1: 1319 MARQUETTE DRIVE CITY: ROMEOVILLE STATE: IL ZIP: 60446 FORMER COMPANY: FORMER CONFORMED NAME: NANOPHASE TECHNOLOGIES CORPORATION DATE OF NAME CHANGE: 19970305 10-Q 1 nanx-10q_093023.htm QUARTERLY REPORT
0000883107 false --12-31 2023 Q3 http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member 0000883107 2023-01-01 2023-09-30 0000883107 2023-11-14 0000883107 2023-09-30 0000883107 2022-12-31 0000883107 2023-07-01 2023-09-30 0000883107 2022-07-01 2022-09-30 0000883107 2022-01-01 2022-09-30 0000883107 us-gaap:ProductMember 2023-07-01 2023-09-30 0000883107 us-gaap:ProductMember 2022-07-01 2022-09-30 0000883107 us-gaap:ProductMember 2023-01-01 2023-09-30 0000883107 us-gaap:ProductMember 2022-01-01 2022-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2022-07-01 2022-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-09-30 0000883107 us-gaap:PreferredStockMember 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-12-31 0000883107 2021-12-31 0000883107 us-gaap:PreferredStockMember 2022-12-31 0000883107 us-gaap:CommonStockMember 2022-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000883107 us-gaap:RetainedEarningsMember 2022-12-31 0000883107 2023-06-30 0000883107 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000883107 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000883107 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000883107 2022-01-01 2022-03-31 0000883107 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000883107 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000883107 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000883107 2022-04-01 2022-06-30 0000883107 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000883107 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000883107 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000883107 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000883107 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000883107 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000883107 2023-01-01 2023-03-31 0000883107 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000883107 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000883107 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000883107 2023-04-01 2023-06-30 0000883107 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000883107 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000883107 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000883107 us-gaap:PreferredStockMember 2022-03-31 0000883107 us-gaap:CommonStockMember 2022-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000883107 us-gaap:RetainedEarningsMember 2022-03-31 0000883107 2022-03-31 0000883107 us-gaap:PreferredStockMember 2022-06-30 0000883107 us-gaap:CommonStockMember 2022-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000883107 us-gaap:RetainedEarningsMember 2022-06-30 0000883107 2022-06-30 0000883107 us-gaap:PreferredStockMember 2022-09-30 0000883107 us-gaap:CommonStockMember 2022-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000883107 us-gaap:RetainedEarningsMember 2022-09-30 0000883107 2022-09-30 0000883107 us-gaap:PreferredStockMember 2023-03-31 0000883107 us-gaap:CommonStockMember 2023-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000883107 us-gaap:RetainedEarningsMember 2023-03-31 0000883107 2023-03-31 0000883107 us-gaap:PreferredStockMember 2023-06-30 0000883107 us-gaap:CommonStockMember 2023-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000883107 us-gaap:RetainedEarningsMember 2023-06-30 0000883107 us-gaap:PreferredStockMember 2023-09-30 0000883107 us-gaap:CommonStockMember 2023-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000883107 us-gaap:RetainedEarningsMember 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2023-07-01 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2022-07-01 2022-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-09-30 0000883107 nanx:LibertyvilleBankAndTrustMember 2023-09-30 0000883107 nanx:LibertyvilleBankAndTrustMember 2022-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-09-30 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2022-12-31 0000883107 nanx:StrandlerLLCMember 2023-09-30 0000883107 nanx:StrandlerLLCMember 2022-12-31 0000883107 nanx:BeachcorpLLCOneMember 2023-09-30 0000883107 nanx:BeachcorpLLCOneMember 2022-12-31 0000883107 nanx:BeachcorpLLCTwoMember 2023-09-30 0000883107 nanx:BeachcorpLLCTwoMember 2022-12-31 0000883107 nanx:BeachcorpLLCThreeMember 2023-09-30 0000883107 nanx:BeachcorpLLCThreeMember 2022-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember us-gaap:PrimeRateMember 2023-01-01 2023-09-30 0000883107 nanx:LibertyvilleBankAndTrustOneMember us-gaap:PrimeRateMember 2023-01-01 2023-09-30 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-01-01 2023-09-30 0000883107 nanx:StrandlerLLCMember us-gaap:PrimeRateMember 2023-01-01 2023-09-30 0000883107 nanx:StrandlerLLCMember 2023-01-01 2023-09-30 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2022-01-26 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember us-gaap:RevolvingCreditFacilityMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember nanx:InventoryFacilityMember nanx:BeachcorpLLCMember 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember nanx:InventoryFacilityMember nanx:BeachcorpLLCMember 2022-01-27 2022-01-28 0000883107 nanx:BusinessLoanAgreementMember nanx:InventoryFacilityMember nanx:BeachcorpLLCMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 nanx:TIPromissoryNoteMember nanx:BeachcorpLLCMember 2023-05-01 0000883107 nanx:TIPromissoryNoteMember nanx:BeachcorpLLCMember us-gaap:PrimeRateMember 2023-04-30 2023-05-01 0000883107 nanx:TIPromissoryNoteMember nanx:BeachcorpLLCMember 2023-04-30 2023-05-01 0000883107 nanx:BridgeNoteMember nanx:StrandlerLLCMember us-gaap:SubsequentEventMember 2023-11-13 0000883107 nanx:BridgeNoteMember nanx:StrandlerLLCMember us-gaap:PrimeRateMember us-gaap:SubsequentEventMember 2023-11-12 2023-11-13 0000883107 nanx:BridgeNoteMember nanx:StrandlerLLCMember us-gaap:SubsequentEventMember 2023-11-12 2023-11-13 0000883107 us-gaap:SubsequentEventMember nanx:PromissoryNoteMember nanx:StrandlerLLCMember 2023-11-12 2023-11-13 0000883107 nanx:InventoryFacilityMember nanx:StrandlerLLCMember us-gaap:SubsequentEventMember 2023-11-13 0000883107 nanx:InventoryFacilityMember nanx:StrandlerLLCMember us-gaap:SubsequentEventMember 2023-11-12 2023-11-13 0000883107 nanx:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0000883107 nanx:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-07-01 2022-09-30 0000883107 nanx:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0000883107 nanx:CustomerOneMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-09-30 0000883107 nanx:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0000883107 nanx:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-07-01 2022-09-30 0000883107 nanx:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0000883107 nanx:CustomerTwoMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-09-30 0000883107 nanx:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0000883107 nanx:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-07-01 2022-09-30 0000883107 nanx:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0000883107 nanx:CustomerThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-09-30 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-07-01 2023-09-30 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-07-01 2022-09-30 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-09-30 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-09-30 0000883107 nanx:CustomerOneMember 2023-09-30 0000883107 nanx:CustomerOneMember 2022-09-30 0000883107 nanx:CustomerTwoMember 2023-09-30 0000883107 nanx:CustomerTwoMember 2022-09-30 0000883107 nanx:CustomerThreeMember 2023-09-30 0000883107 nanx:CustomerThreeMember 2022-09-30 0000883107 us-gaap:SupplyCommitmentMember 2023-09-30 0000883107 us-gaap:NonUsMember 2023-07-01 2023-09-30 0000883107 us-gaap:NonUsMember 2023-01-01 2023-09-30 0000883107 us-gaap:NonUsMember 2022-07-01 2022-09-30 0000883107 us-gaap:NonUsMember 2022-01-01 2022-09-30 0000883107 nanx:SolesenceMember 2023-07-01 2023-09-30 0000883107 nanx:SolesenceMember 2022-07-01 2022-09-30 0000883107 nanx:SolesenceMember 2023-01-01 2023-09-30 0000883107 nanx:SolesenceMember 2022-01-01 2022-09-30 0000883107 nanx:PersonalCareIngredientsMember 2023-07-01 2023-09-30 0000883107 nanx:PersonalCareIngredientsMember 2022-07-01 2022-09-30 0000883107 nanx:PersonalCareIngredientsMember 2023-01-01 2023-09-30 0000883107 nanx:PersonalCareIngredientsMember 2022-01-01 2022-09-30 0000883107 nanx:AdvancedMaterialsMember 2023-07-01 2023-09-30 0000883107 nanx:AdvancedMaterialsMember 2022-07-01 2022-09-30 0000883107 nanx:AdvancedMaterialsMember 2023-01-01 2023-09-30 0000883107 nanx:AdvancedMaterialsMember 2022-01-01 2022-09-30 0000883107 2022-01-01 2022-12-31 0000883107 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2022-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

Form 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended: September 30, 2023 
or 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) of
the Securities Exchange Act of 1934

 

For the transition period from to _______ to  _______ 

 

Commission File Number: 000-22333

 

Nanophase Technologies Corporation
(Exact name of registrant as specified in its charter)

 

Delaware 36-3687863
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

 

1319 Marquette Drive, Romeoville, Illinois 60446 
(Address of principal executive offices, and zip code) 

 

Registrant’s telephone number, including area code: (630) 771-6708

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑  No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
   
Non-accelerated filer ☐ Smaller reporting company ☑
   
  Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

 

As of November 14, 2023, there were 49,627,254 shares outstanding of common stock, par value $.01, of the registrant.

 

 

 

 

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

QUARTER ENDED SEPTEMBER 30, 2023

 

INDEX

 

      Page  
PART I – FINANCIAL INFORMATION  
  Item 1. Financial Statements 3
    Consolidated Balance Sheets (Unaudited Consolidated Condensed) as of September 30, 2023, and December 31, 2022 3
    Consolidated Statements of Operations (Unaudited Consolidated Condensed) for the three and nine months ended September 30, 2023, and 2022 4
    Consolidated Statements of Stockholders’ Equity (Unaudited Consolidated Condensed) for the three and nine months ended September 30, 2023, and 2022 5
    Consolidated Statements of Cash Flows (Unaudited Consolidated Condensed) for the nine months ended September 30, 2023, and 2022 6
    Notes to Unaudited Consolidated Condensed Financial Statements 7
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
  Item 3. Quantitative and Qualitative Disclosures About Market Risk 15
  Item 4. Controls and Procedures 15
     
PART II – OTHER INFORMATION 15
  Item 1. Legal Proceedings 15
  Item 1A. Risk Factors 15
  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 15
  Item 3. Defaults Upon Senior Securities 15
  Item 4. Mine Safety Disclosures 15
  Item 5. Other Information 15
  Item 6. Exhibits 16
     
SIGNATURES 17

 

2

 

 

PART I – FINANCIAL INFORMATION

 

Item 1.  Financial Statements

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED BALANCE SHEETS
(Unaudited Consolidated Condensed) 

 

               
   (in thousands except share
and per share data)		 
ASSETS  September 30,
2023		   December 31,
2022		 
Current assets:          
Cash  $1,188   $2,186 
Trade accounts receivable, less allowance for doubtful accounts of $270 for September 30, 2023, and $139 for December 31, 2022   3,199    4,734 
Inventories, net   10,123    8,839 
Prepaid expenses and other current assets   1,040    866 
Total current assets   15,550    16,625 
           
Equipment and leasehold improvements, net   8,607    7,949 
Operating leases, right of use   8,187    8,978 
Other assets, net   3    6 
Total assets  $32,347   $33,558 
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Lines of credit, related party  $6,338   $7,282 
Accounts payable   6,270    6,363 
Current portion of operating lease obligations   1,303    — 
Current portion of deferred revenue   2,619    2,167 
Accrued expenses   1,130    1,023 
Total current liabilities   17,660    16,835 
           
Long-term portion of operating lease obligations   9,475    9,823 
Long-term debt, related party   1,000    1,000 
Long-term portion of deferred revenue   45    21 
Asset retirement obligations   236    230 
Total long-term liabilities   10,756    11,074 
           
Shareholders’ equity:          
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding   —    — 
Common stock, $.01 par value, 60,000,000 shares authorized; 49,627,254 and 49,320,680 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively   496    493 
Additional paid-in capital   105,970    105,226 
Accumulated deficit   (102,535)   (100,070)
Total shareholders’ equity   3,931    5,649 
Total liabilities and shareholders’ equity  $32,347   $33,558 

 

See Notes to Consolidated Condensed Financial Statements

 

3

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF OPERATIONS 
(Unaudited Consolidated Condensed)

 

(in thousands except share and per share data)

 

                             
   Three months ended
September 30,		   Nine months ended
September 30,		 
   2023   2022   2023   2022 
                 
Revenue:                    
Product revenue  $7,746   $9,673   $28,925   $28,515 
Other revenue   212    5    361    541 
Total revenue   7,958    9,678    29,286    29,056 
                     
Operating expense:                    
Cost of revenue   6,428    7,185    21,932    21,659 
Gross profit   1,530    2,493    7,354    7,397 
                     
Research and development expense   1,057    848    3,052    2,310 
Selling, general and administrative expense   1,695    2,279    5,951    5,493 
Loss from operations   (1,222)   (634)   (1,649)   (406)
Interest expense   214    116    613    232 
Loss before provision for income taxes   (1,436)   (750)   (2,262)   (638)
Provision for income taxes   —    —    —    — 
Net loss  $(1,436)  $(750)  $(2,262)  $(638)
                     
Net loss per basic share  $(0.03)  $(0.02)  $(0.05)  $(0.01)
                     
Weighted average number of basic common shares outstanding   49,598,581    49,174,673    49,532,395    49,068,709 
                     
Net loss per diluted share  $(0.03)  $(0.02)  $(0.05)  $(0.01)
                     
Weighted average number of diluted common shares outstanding   49,598,581    49,174,673    49,532,395    49,068,709 

 

See Notes to Consolidated Condensed Financial Statements

 

4

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(Unaudited Consolidated Condensed)

 

                                         
   Preferred Stock   Common Stock   Additional
Paid-in		   Accumulated     
Description  Shares   Amount   Shares   Amount   Capital   Deficit   Total 
Balance on December 31, 2021   —   $—    48,893,573   $489   $104,423   $(97,447)  $7,465 
Issuance of shares and stock option exercises   —    —    133,168    1    72    —    73 
Stock-based compensation   —    —    —    —    148    —    148 
Net income for the three months ended March 31, 2022   —    —    —    —    —    62    62 
Balance on March 31, 2022   —   $—    49,026,741   $490   $104,643   $(97,385)  $7,748 
                                    
Issuance of shares and stock option exercises   —    —    110,289    1    33    —    34 
Stock-based compensation   —    —    —    —    155    —    155 
Net income for the three months ended June 30, 2022   —    —    —    —    —    50    50 
Balance on June 30, 2022   —   $—    49,137,030   $491   $104,831   $(97,335)  $7,987 
                                    
Issuance of shares and stock option exercises   —    —    79,150    1    31    —    32 
Stock-based compensation   —    —    —    —    150    —    150 
Net loss for the three months ended June 30, 2022   —    —    —    —    —    (750)   (750)
Balance on September 30, 2022   —   $—    49,216,180   $492   $105,012   $(98,085)  $7,419 
                                    
Balance on December 31, 2022   —   $—    49,320,680   $493   $105,226   $(100,070)  $5,649 
Issuance of shares and stock option exercises   —    —    199,891    2    99    —    101 
Stock-based compensation   —    —    —    —    209    —    209 
Cumulative effect of accounting changes related to expected credit losses   —    —    —    —    —    (203)   (203)
  Net loss for the three months ended March 31, 2023   —    —    —    —    —    (1,159)   (1,159)
Balance on March 31, 2023   —   $—    49,520,571   $495   $105,534   $(101,432)  $4,597 
                                    
Issuance of shares and stock option exercises   —    —    68,633    1    33    —    34 
Stock-based compensation   —    —    —    —    195    —    195 
Net income for the three months ended June 30, 2023   —    —    —    —    —    333    333 
Balance on June 30, 2023   —   $—    49,589,204   $496   $105,762   $(101,099)  $5,159 
                                    
Issuance of shares and stock option exercises   —    —    38,050    —    19    —    19 
Stock-based compensation   —    —    —    —    189    —    189 
Net loss for the three months ended September 30, 2023   —    —    —    —    —    (1,436)   (1,436)
Balance on September 30, 2023   —   $—    49,627,254   $496   $105,970   $(102,535)  $3,931 

 

See Notes to Consolidated Condensed Financial Statements.

 

5

 

 

NANOPHASE TECHNOLOGIES CORPORATION 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS 
(Unaudited Consolidated Condensed)

 

               
   Nine months ended September 30, 
   2023   2022 
   (in thousands) 
Operating activities:          
Net loss  $(2,262)  $(638)
Adjustments to reconcile net loss to cash used in operating activities:          
Depreciation and amortization   524    413 
Share-based compensation   593    453 
Changes in assets and liabilities related to operations:          
Trade accounts receivable   1,333    (1,431)
Inventories   (1,284)   (3,501)
Prepaid expenses and other assets   (174)   (69)
Accounts payable   (422)   1,398 
Accrued expenses   113    401 
Deferred revenue   476    (75)
Change in right-of-use asset and lease liability, net   1,747    652 
Net cash provided by (used in) operating activities   644    (2,397)
           
Investing activities:          
Acquisition of equipment and leasehold improvements   (852)   (1,798)
Net cash used in investing activities   (852)   (1,798)
           
Financing activities:          
Principal payments on finance leases   —    (100)
Proceeds from line of credit, related party   23,304    25,075 
Payments to line of credit, related party   (24,248)   (21,068)
Proceeds from term loan, related party   1,338    — 
Payments to term loan, related party   (1,338)   — 
Proceeds from exercise of stock options   154    141 
Net cash (used in) provided by financing activities   (790)   4,048 
Decrease in cash and cash equivalents   (998)   (147)
Cash and cash equivalents at beginning of period   2,186    657 
Cash and cash equivalents at end of period  $1,188   $510 
           
Supplemental cash flow information:          
 Interest paid  $553   $232 
           
Supplemental non-cash investing and financing activities:          
Accounts payable incurred for the purchase of equipment and leasehold improvements  $329   $432 
Early termination of operating lease   —    73 
Right-of-use assets obtained in exchange for lease liabilities  $36   $— 

 

See Notes to Consolidated Condensed Financial Statements.

 

6

 

 

NANOPHASE TECHNOLOGIES CORPORATION

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited Consolidated Condensed)
(in thousands, except share and per share data or as otherwise noted herein)

 

(1) Basis of Presentation

 

The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly-owned subsidiary, Solésence, LLC (“Solésence,” or our “Solésence® subsidiary”). Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

 

These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission.

 

(2) Description of Business

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets. Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy. We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary. In terms of our life sciences focus, we have seen demand significantly decrease for our medical diagnostics ingredients. Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category.  

 

 We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies. Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 

 

 (3) Revenues

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.

 

 Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows:

 

      Accounts Receivable     Contract Assets     Contract Liabilities  
Balance, December 31, 2021     $ 3,937     $ 179     $ 1,444  
Balance, December 31, 2022       4,734       —       2,188  
Balance, September 30, 2023       3,199       —       2,664  

 

7

 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $414 and $295, for the three months ended September 30, 2023 and 2022, respectively, and $2,438 and $507 for the nine months ended September 30, 2023 and 2022, respectively.

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Other revenue recognized over time was $212 and $5, for the three months ended September 30, 2023 and 2022, respectively, and $361 and $191 for the nine months ended September 30, 2023 and 2022, respectively. Other revenue recognized at a point in time was $350 for the nine months September 30, 2022.

 

(4) Earnings Per Share

 

Options to purchase approximately 853,000 and 728,000 shares of common stock that were outstanding as of September 30, 2023 were not included in the computation of diluted earnings per share for the three and nine-months ended September 30, 2023. The inclusion of these shares for the three and nine months ended September 30, 2023 would have resulted in an anti-dilutive effect and were thus omitted from disclosure. Options to purchase approximately 1,871,000 and 1,901,000 shares of common stock that were outstanding as of September 30, 2022 were not included in the computation of earnings per share for the three months and nine months ended September 30, 2022, respectively, as inclusion would have had an anti-dilutive impact due to losses.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: 

 

                             
   Three months ended September 30,   Nine months ended September 30, 
   2023   2022   2023   2022 
                 
Numerator: (in Thousands)                    
Net loss  $(1,436)  $(750)  $(2,262)  $(638)
                     
Denominator:                    
Weighted average number of basic shares outstanding   49,598,581    49,174,673    49,532,395    49,068,709 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares and assumed repurchase of common shares by the Company   —    —    —    — 
Weighted average number of diluted common shares outstanding   49,598,581    49,174,673    49,532,395    49,068,709 
                     
Basic earnings per common share:                    
Net loss per share – basic  $(0.03)  $(0.02)  $(0.05)  $(0.01)
Diluted earnings per common share:                    
Net loss per share – diluted  $(0.03)  $(0.02)  $(0.05)  $(0.01)

 

 

(5) Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

 Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 6. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature of these accounts. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.

 

There were no financial instruments adjusted to fair value on September 30, 2023 and December 31, 2022.

 

(6) Notes and Lines of Credit

 

 Notes and lines of credit consist of the following:

 

       As of September 30, 2023   As of December 31, 2022 
   Rate   Total Borrowing Capacity   Outstanding Borrowed Balance   Total Borrowing Capacity   Outstanding Borrowed Balance 
Libertyville Bank & Trust (1)   9.50%  $30   $—   $—   $— 
Libertyville Bank & Trust (2)   9.50%   500    —    —    — 
Strandler, LLC(3)   9.25%   1,000    1,000    1,000    1,000 
Beachcorp, LLC (4)   9.25%   3,229    2,338    4,392    4,282 
Beachcorp, LLC (5)   9.25%   4,000    4,000    4,000    3,000 
Beachcorp, LLC (6)   9.25%   —    —    —    — 

 

8

 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.

 

2)The Company maintains a credit agreement with Libertyville to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2023. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.

 

4)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.

 

5)On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.

 

6)On May 1, 2023 the Company entered into a non-revolving promissory note (“TI Promissory Note”) with Beachcorp, LLC. The maximum borrowing amount under the TI Promissory Note is $1,750. The interest rate for the TI Promissory Note is at the prime rate plus 0.75%, and it matures on September 30, 2023. This loan is for work being done at the Bolingbrook facility which is expected to be reimbursed from the landlord as part of the lease agreement. On July 21, 2023, the TI Promissory Note and accrued interest was repaid in full after reimbursement from the landlord for approved tenant improvements.

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank & Trust.

 

9

 

 

On November 13, 2023, as part of a comprehensive financing transaction, the Company entered into a non-revolving promissory note (Bridge Note) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is $2,000. The interest rate for the Bridge Loan is at the prime rate plus 0.75%, and it matures on the earlier of May 13, 2024 or the closing of the Rights Offering. The Company is required to repay the Bridge Note upon completion of a planned Rights Offering, or at maturity, whichever comes first. As part of this financing transaction, the maturity dates of the New Term Loan Agreement, A/R Loan Agreement and Inventory Facility were extended to March 31, 2025. Additionally, the maximum borrowing amount under the Inventory Facility was increased to $5,200, and the borrowing base was increased to up to 55% of the value of qualified inventory of the Company.

 

Related party interest summary:

 

                             
   Three months ended September 30,   Nine months ended September 30, 
   2023   2022   2023   2022 
                 
Interest expense, related parties  $199   $111   $560   $218 
Accrued interest expense, related parties   57    39    57    39 

 

 

(7) Inventories

 

Inventories consist of the following:

 

   September 30,
2023		   December 31,
2022		 
         
Raw materials  $7,013   $6,797 
Finished goods   3,110    2,041 
Total inventories, net  $10,123   $8,839 

 

        The Company had reserves for excess and obsolete inventory of $670 and $500 as of September 30, 2023 and December 31, 2022, respectively.

 

(8) Significant Customers and Contingencies

 

The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022:

 

       Three months ended
September 30,		   Nine months ended
September 30,		 
Customer #   Product Category  2023   2022   2023   2022 
1   Personal Care Ingredients   30%   30%   31%   30%
2   Solésence®   18%   18%   14%   17%
3   Solésence®   21%   19%   14%   16%
    Total   69%   67%   59%   63%

 

10

 

 

Accounts receivable balances for these three customers were approximately:

 

Customer #   Product Category  September 30,
2023		   September 30,
2022		 
1   Personal Care Ingredients  $320   $943 
2   Solésence®   545    439 
3   Solésence®   1,047    1,717 
    Total  $1,912   $3,099 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in “triggering” the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the equipment sale mentioned above, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.

 

 (9) Business Segmentation and Geographical Distribution

 

Revenue from international sources approximated $731 and $2,918 for the three and nine months ended September 30, 2023, respectively, compared to $495 and $955 for the three and nine months ended September 30, 2022, respectively. All of this revenue was product revenue.  

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows:

 

   Three months ended September 30,   Nine months ended September 30, 
Product Category  2023   2022   2023   2022 
Solésence  $5,016   $5,932   $17,839   $18,591 
Personal Care Ingredients   2,364    2,903    8,944    8,589 
Advanced Materials   578    843    2,503    1,876 
Total Sales  $7,958   $9,678   $29,286   $29,056 

 

 

11

 

 

(10) Commitments and Contingencies 

 

On August 9, 2022, BASF filed a complaint against Nanophase in New Jersey state court (the “New Jersey Complaint”), alleging that Nanophase had breached the 1999 Zinc Oxide Supply Agreement (the “Agreement”). BASF alleges several issues, the one having the biggest potential impact on Nanophase being a claim that our sales through Solésence violate the exclusivity provision of the Agreement. BASF seeks an unspecified amount of damages, a permanent injunction enjoining sales to any party (other than BASF) of a broad range of zinc oxide products that BASF contends are within the scope of the exclusivity provision, counsel fees and litigation expenses. On September 7, 2022, Nanophase filed a Complaint for Declaratory Judgement in Illinois state court (the “Illinois Complaint”), asking for a declaration that contrary to BASF’s allegation, the exclusivity provision of the Agreement does not apply to all products containing zinc oxide as an ingredient for uses designated under the Agreement, nor does the exclusivity provision prohibit Nanophase’s sales of Solésence products containing zinc oxide as an ingredient. Both companies filed Motions to Dismiss (MTD) the other’s respective complaint. Nanophase’s MTD BASF’s New Jersey Complaint was denied on procedural grounds on February 10, 2023, with the New Jersey court superficially noting that it did not consider whether BASF could prove its claims. On February 28, 2023, Nanophase filed its answer to BASF’s New Jersey Complaint, denying all wrongdoing and, as mandated by New Jersey procedural requirements, counterclaims including a request for a declaration similar to that Nanophase sought in its Illinois Complaint. On March 16, 2023, the Illinois court granted BASF’s MTD Nanophase’s Illinois Complaint, finding it duplicative of the New Jersey litigation. Discovery in that litigation is ongoing. Management believes at this time that the allegations of BASF’s complaint are without merit and are unsupported by the terms of the Agreement and governing law. Per ASC 450 for the period ending September 30, 2023, an estimated contingent loss was not recorded, and an estimated range of loss is not disclosed as the outcome is not probable at this time and nor is a range of loss estimable. 

 

 

(11) Accounting Standards Adopted During 2023

 

On January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.

 

This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Overview

 

Nanophase is a health-oriented, science-driven company, which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets. Our primary skin health products are fully developed prestige skin care formulations with mineral-based UV protection, marketed and sold through our Solésence beauty science subsidiary, enabled by our proprietary Active Pharmaceutical Ingredients (“APIs”) which are also marketed as APIs for sale to manufacturers of other types of skin health products, including sunscreens and daily care products. In terms of our life sciences focus, we have seen demand significantly decrease for our medical diagnostics ingredients. Additionally, we continue to sell products in legacy markets including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications— all of which, along with medical diagnostics, currently fall into the advanced materials product category.  

 

 Leveraging a platform of integrated patented and proprietary technologies, we create products with unique performance to enhance end-consumers’ health and well-being. We offer soup-to-nuts production, from engineered materials, formulation development, and finished product development, to commercial manufacturing and packaging capabilities. Our expertise in materials engineering allows us to effectively coat and disperse materials on a nano and “non-nano” scale for use in a variety of markets in skin health, including for use in sunscreens as APIs and as fully developed prestige skin care products, marketed and sold through our Solésence beauty science subsidiary.  We believe that we have developed technological advantages with respect to our APIs sold for use as ingredients, while our Solésence beauty science technologies lead to enhanced efficacy and aesthetics in our finished products, which have received broad acceptance in the marketplace. Due to the enhanced efficacy and aesthetic qualities offered by our proprietary technology platform, Solésence finished products satisfy growing consumer demands around “clean” and inclusive beauty. Solésence beauty science also benefits from the Company’s vertical integration with each product’s key active ingredient that delivers its point-of-difference. This vertical integration helps us to improve efficiency and avoid potential major supply chain challenges while also addressing ongoing sustainability efforts.  

 

Given our technological position, in addition to the historical market acceptance of our APIs for use in skin health products and sunscreens and, rapidly growing sales for our suite of Solésence® finished products, in 2021 we announced that we reoriented our Company strategy. We continue to see unprecedented demand in the beauty science. The market has shown an appetite for what we are producing, and management believes that this growth is happening now due to a confluence of our technology, market conditions that favor what we produce, and our expanded expertise in these areas.  

 

Nanophase, primarily through Solésence, now partners with brands to develop, manufacture, and market products and ingredients that enhance lives through healthy skin. We are focusing our combined business, ingredient, and product development capabilities on products with unique performance in this area. While we will continue to produce and sell materials to our other advanced materials customers, it is not our strategic focus. We may develop additional technologies or find unique applications outside of our core markets in the future, but to maximize the use of our resources today, we plan on expanding efforts in areas where we have proven we can deliver innovation and growth. 

 

Results of Operations

 

Total revenue decreased to $7,958 for the three months ended September 30, 2023, compared to $9,678 for the same period in 2022. Total revenue increased to $29,286 for the nine months ended September 30, 2023, compared to $29,056 for the same period in 2022. A substantial majority of our revenue was from our three largest customers for the three- and nine-month periods ended September 2023, and 2022, respectively. This reflects sales of APIs to our largest customer in skin care and sunscreen applications and, our two largest customers for our finished skin health products marketed through our Solésence subsidiary.  This is the revenue breakdown, as a percentage of total revenue, from the three customers referenced above:

 

          Three months ended
September 30,		     Nine months ended
September 30,		  
Customer #     Product Category   2023     2022     2023     2022  
1     Personal Care Ingredients     30 %     30 %     31 %     30 %
2     Solésence®     18 %     18 %     14 %     17 %
3     Solésence®     21 %     19 %     14 %     16 %
      Total     69 %     67 %     59 %     63 %

 

Product revenue, the primary component of our total revenue, decreased to $7,746 for the three months ended September 30, 2023, compared to $9,673 during the same period of 2022, and increased to $28,925 for the nine months ended September 30, 2023, compared to $28,515 during the same period of 2022. The three-month decrease in product revenue was due to lower sales in our Solésence®, Personal Care Ingredients and Advanced Materials product categories. The nine-month increase was due to sales to our Advanced Materials customers and to our largest Personal Care Ingredients customer.  

 

Other revenue increased and decreased to $212 and $361 for the three- and nine-month periods ended September 30, 2023, respectively, compared to $5 and $541 for the same periods in 2022, respectively. Other revenue is typically comprised primarily of developmental or licensing fees. 

 

12

 

  

Cost of revenue generally includes costs associated with commercial production and customer development arrangements.  Cost of revenue decreased to $6,428 for the three months ended September 30, 2023, compared to $7,185 for the same period in 2022, and increased to $21,932 for the nine months ended September 30, 2023, compared to $21,659 for the same period in 2022.  The decrease for the three months in the cost of revenue was due to better labor utilization compared to the previous year and a lower sales volume. The increase for the nine months in cost of revenue was primarily driven by increased volume and price inflation on materials and manufacturing inefficiencies related to Solésence® product launches. While we typically pass-through costs to our customers, we sometimes cannot pass through 100% of pricing increases on raw materials, and even with pass throughs, our gross margin percentage is negatively impacted by higher material costs.

 

Our business has a certain cyclicality of demand, often based upon seasonal demands, industry launch cycles, or a confluence of both. Our lack of burst capacity has created strains, in terms of people and costs, when new product launches occur at the same time that we are experiencing demand from previously launched products. Since late 2020, the Company has found itself in a situation where our ability to produce and ship materials has frequently been exceeded by customer demand. It is a key area of focus to increase throughput first, followed quickly by increased cost efficiency once we can achieve greater scale. Our planning has had us adding to our current fixed manufacturing cost structure through 2023 to accommodate additional growth, and to build a better base for further growth beyond that level. The extent to which margins grow, as a percentage of total revenue, will be dependent upon revenue mix, revenue volume, our ability to cut costs and pass commodity market-driven raw materials increases on to customers, and the speed and efficiency with which we are able to scale up production for our Solésence products. We expect that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow. Our most critical operational issue today, is reducing controllable variable product manufacturing costs.

 

Research and development expense, which includes all expenses relating to the technology and advanced engineering groups, primarily consists of costs associated with the development or acquisition of new finished product formulations for skin care, new product applications for our skin care ingredients, advancement of our medical diagnostics ingredient knowledge, and the cost of enhancing our manufacturing processes. As an example, we are currently focusing the bulk of our resources on developing new product formulations, and related new technologies, as we expand marketing and sales efforts relating to our Solésence products. This work has led to several new products and additional potential new products. Our efforts in research and development, cosmetic formulating, process engineering and advanced engineering groups are focused in three major areas: 1) application development for our products; 2) creating or obtaining additional core materials technologies and/or materials that have the capability to serve multiple skin health-related markets; and 3) continuing to improve our core technologies to improve manufacturing operations and reduce costs.

 

Research and development expense increased to $1,057 for the three months ended September 30, 2023, compared to $848 for the same period in 2022. For the nine months ended September 30, 2023 research and development expense increased to $3,052 compared to $2,310 for the same period in 2022. Most of this increase was due to expanded staffing to aid in supporting new product development for current and future customers. Management expects research and development expense to remain flat or slightly decrease during the balance of 2023 while continuing to support continued revenue- and customer-expansion.

 

Selling, general and administrative expense decreased to $1,695 for the three months ended September 30, 2023, compared to $2,279 for the same period in 2022. For the nine months ended September 30, 2023, selling, general and administrative expense increased to $5,951, compared to $5,493 for the same period in 2022.  The increase is due in large part to increased legal costs in 2023 compared to 2022 and increased employee related costs when compared to 2022.

 

Inflation

 

We believe inflation has had an incremental impact on our costs of operations and financial position to date. However, supplier price increases and wage and benefit inflation, both of which represent a significant component of our costs of operations, could have a material effect on our operations and financial position in 2023 if we are unable to pass through any applicable increases under our present contracts or through to our markets in general. We have begun to increase pricing where possible and continue to adjust our pricing to the extent supported by the markets we are in, and under any contract limitations we may have. 

 

Liquidity and Capital Resources

 

Cash, cash proceeds and use of cash for the nine months ended September 30, 2023, 2022, and year ended December 31, 2022 were:

 

   Nine months ended
 September 30, 2023		   Nine months ended 
September 30, 2022		   Year ended
December 31, 2022		 
Total cash  $1,188   $510   $2,186 
Cash provided by (used in) operating activities   644    (2,397)   (1,650)
Net cash used in investing activities   (852)   (1,798)   (2,823)
Net cash (used in) provided by financing activities   (790)   4,048    6,002 

 

13

 

 

The net cash used during the nine months ended September 30, 2023 was primarily due to net loss and increased accounts payables. Net cash used in investing activities was attributable to expenditures on capital equipment for all periods presented above

 

On November 13, 2023, the Company and Strandler, LLC entered into a non-revolving promissory note (Bridge Note). The maximum borrowing amount under the Bridge Note is $2,000. The interest rate for the Bridge Note is at the prime rate plus 0.75%, and it matures the earlier of May 13, 2024 or the closing of the Rights Offering. The Company is required to repay the Bridge Note upon completion of a planned Rights Offering, or at maturity, whichever comes first. As part of this financing transaction, the maturity dates of the New Term Loan Agreement, A/R Loan Agreement and Inventory Facility were extended to March 31, 2025. Additionally, the maximum borrowing amount under the Inventory Facility was increased to $5,200, and the borrowing base was increased to up to 55% of the value of qualified inventory of the Company.

 

 Our actual future capital requirements in 2023 and beyond will depend on many factors, including customer acceptance of our current and potential finished Solésence  products, APIs sold as ingredients in to the skin health markets, medical diagnostics ingredients, and other engineered materials, applications, and products, continued progress in research and development activities and product testing programs, the magnitude of these activities and programs, and the costs necessary to increase and expand our manufacturing capabilities and to market and sell these products and ingredients. Other important issues that will drive future capital requirements will be the development of new markets and new customers as well as the potential for significant unplanned growth with existing customers. Depending on the success of certain projects, and conditions within the markets supplying labor and materials for capital equipment, we expect that capital spending relating to currently known capital needs for 2023 will be between $0.2 million and $0.5 million, to be funded by profit from operations, our existing loans and lines of credit, and possible new debt financing. If those projects are delayed or ultimately prove unsuccessful, or if we fail to be able to support the additional cost of funding them in the near term, we expect our capital expenditures may fall below the lower end of the range. Similarly, substantial success in business development projects may cause the actual 2023 capital investment to exceed the top of this range.

 

Additional Consideration

 

We had federal net operating loss carryforwards for tax purposes of approximately $56 million on December 31, 2022. Because the Company may experience “ownership changes” within the meaning of the U.S. Internal Revenue Code (“IRC”) in connection with any future equity offerings, future utilization of this carryforward may be subject to certain limitations as defined by the IRC. If not utilized, $51 million of this loss carryforward will expire between 2023 and 2037. Given changes to the IRC, net operating loss carryforwards generated after January 1, 2018 do not expire, therefore, $5 million in net operating losses generated since January 1, 2018 do not expire. We have Illinois net loss deduction carryforwards for tax purposes of approximately $21 million on December 31, 2022. Due to the provisions of Illinois Public Act 102-0669 signed November 16, 2021, Illinois net loss deductions expire between 2029 and 2039.

 

Off-Balance Sheet Arrangements

 

We have not created, and are not party to, any special-purpose or off-balance sheet entities for the purposes of raising capital, incurring debt or operating our business. We do not have any off-balance sheet arrangements or relationships with entities that are not consolidated into our financial statements that are reasonably likely to materially affect our liquidity or the availability of capital resources.

 

Safe Harbor Provision

 

We want to provide investors with more meaningful and useful information. As a result, this Quarterly Report on Form 10-Q (the “Form 10-Q”) contains and incorporates by reference certain “forward-looking statements”, as defined in Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements reflect our current expectations of the future results of our operations, performance, and achievements. Forward-looking statements are covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We have tried, wherever possible, to identify these statements by using words such as “anticipates”, “believes”, “estimates”, “expects”, “plans”, “intends” and similar expressions. These statements reflect management’s current beliefs and are based on information now available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies that could cause our actual results, performance, or achievements in 2023 and beyond to differ materially from those expressed in, or implied by, such statements. These risks, uncertainties and factors include, without limitation: our ability to be consistently profitable despite the losses we have incurred since our incorporation; a decision by a customer to cancel a purchase order or supply agreement in light of our dependence on a limited number of key customers; the terms of our supply agreements with BASF which could trigger a requirement to transfer technology and/or sell equipment to that customer; our potential inability to obtain working capital when needed on acceptable terms or at all; our ability to obtain materials at costs we can pass through to our customers, including Rare Earth elements, specifically cerium oxide, as well as high purity zinc; uncertain demand for, and acceptance of, our Solésence products, and our advanced materials; our manufacturing capacity and product mix flexibility in light of customer demand; our limited marketing experience, including with our suite of Solésence products; changes in development and distribution relationships; the impact of competitive products and technologies; our dependence on patents and protection of proprietary information; our ability to maintain an appropriate electronic trading venue for our securities; the impact of any potential new governmental regulations, especially any new governmental regulations focusing on the processing, handling, storage or sale of nanomaterials, that could be difficult to respond to or costly to comply with; business interruptions due to unexpected events or public health crises, including viral pandemics such as COVID-19; and the resolution of litigation or other legal proceedings in which we may become involved. In addition, our forward-looking statements could be affected by general industry and market conditions and growth rates. Readers of this Quarterly Report on Form 10-Q should not place undue reliance on any forward-looking statements. Except as required by federal securities laws, we undertake no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

 

14

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for a smaller reporting company.

 

Item 4. Controls and Procedures

 

Disclosure controls

 

We are responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports filed by us under the Exchange Act is: (a) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and (b) accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosures. It should be noted that in designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and that our management necessarily was required to apply its judgment regarding the design of our disclosure controls and procedures. As of the end of the period covered by this report, we conducted an evaluation, under the supervision (and with the participation) of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective at reaching that level of reasonable assurance. 

 

Internal control over financial reporting

 

The Company’s management, including the CEO (who is also currently acting as both the Company’s principal executive officer and the Company’s principal financial officer), confirm that there was no change in the Company’s internal control over financial reporting during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1.  Legal Proceedings

 

On August 31, 2022, counsel for Nanophase Technologies Corporation (“Nanophase”) received a letter from lawyers representing BASF Corporation (“BASF”) stating that BASF had filed a complaint against Nanophase in the Superior Court of New Jersey (“SCNJ”) on August 9, 2022 (the “New Jersey Complaint”) and that Nanophase’s registered agent for service of process had been served with the New Jersey Complaint on August 11, 2022. The August 31, 2022 letter from BASF’s lawyers was Nanophase’s first notice of the New Jersey Complaint.

 

The New Jersey Complaint claims that Nanophase breached the Zinc Oxide Supply Agreement dated as of September 16, 1999 between Nanophase and BASF, as assignee, as amended through January 1, 2019 (the “Agreement”). The New Jersey Complaint specifically alleges that Nanophase breached the exclusivity provision of the Agreement by selling zinc oxide to entities other than BASF, including sales to Nanophase’s subsidiary Solésence, LLC (“Solésence”), in markets designated as being in the field of use (the “Field”) under the Agreement. The New Jersey Complaint also relatedly alleges that Nanophase breached the capacity and inventory provisions of the Agreement. In addition, the New Jersey Complaint alleges claims for unjust enrichment and violation of the duty of good faith and fair dealing. The New Jersey Complaint seeks an unspecified amount of damages, a permanent injunction, counsel fees, and litigation expenses. The New Jersey Complaint is not seeking termination of the Agreement.

 

Management believes that the allegations of BASF’s New Jersey Complaint are without merit and are unsupported by the terms of the Agreement and governing law. On September 8, 2022, Nanophase filed a Motion to Dismiss (“MTD”) the New Jersey Complaint with the SCNJ, arguing that BASF’s claims in its New Jersey Complaint are not supported by the terms of the Agreement. Following completion of briefing and a hearing on the MTD, the SCNJ denied Nanophase’s MTD on February 10, 2023, finding that under the “liberality” standards of New Jersey procedure, the allegations of BASF’s complaint were “sufficient to survive” the MTD. The SCNJ specifically noted that it did not consider whether BASF could prove its claims. Thereafter, on February 28, 2023, Nanophase answered BASF’s New Jersey Complaint, denying all wrongdoing and, as mandated by New Jersey procedural requirements, filed two counterclaims: (1) a request for a declaration that contrary to BASF’s views, the exclusivity provision of the Agreement does not apply to all products containing zinc oxide as an ingredient for uses designated under the Agreement nor does the exclusivity provision prohibit Nanophase’s sales of Solésence products containing zinc oxide as an ingredient; and (2) a claim that BASF had breached its obligations under the Agreement to buy from Nanophase at least 70% of BASF’s zinc oxide requirements for use in the Field. On April 17, 2023, BASF moved to dismiss Nanophase’s counterclaims, arguing that the declaratory judgment claim duplicated BASF’s claim for Nanophase’s alleged breach of contract and Nanophase’s claim for BASF’s breach of its zinc oxide purchase requirements was procedurally insufficient. Following briefing and a hearing on October 6, 2023, the SCNJ: (1) denied BASF’s motion to dismiss Nanophase’s declaratory judgment counterclaim, finding that it did not duplicate BASF’s breach of contract claim and that BASF’s litigating its claim would not provide Nanophase with complete relief as to the exclusivity issues raised in the counterclaim; and (2) granted BASF’s motion to dismiss Nanophase’s claim for BASF’s breach of its zinc oxide purchase requirements on procedural grounds. On October 31, 2023, BASF filed its answer to Nanophase’s declaratory judgment counterclaim, denying the counterclaim. Discovery in the New Jersey litigation is ongoing.

 

On September 7, 2022, Nanophase filed a Complaint for Declaratory Judgment against BASF in the Circuit Court of Cook County, Illinois (the “Illinois Complaint”). The Illinois Complaint asked the court for a declaration similar to that subsequently sought in Nansphase’s counterclaim in the New Jersey litigation. On November 3, 2022, BASF moved to dismiss Nanophase’s Illinois Complaint, arguing that it duplicates the New Jersey litigation. Following briefing and a hearing, the Illinois court granted BASF’s motion on procedural grounds on March 16, 2023.

 

Given our view of the New Jersey litigation and its status, we have decided that it is not appropriate to record a contingent liability relating to this action at this time.

 

Nanophase intends to continue negotiating with BASF in good faith to resolve these issues. In the event that an acceptable solution is not reached, and litigation proceeds, the ultimate resolution cannot now be determined with certainty.

 

Item 1A. Risk Factors

 

Not required for a smaller reporting company.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.     

 

Item 5. Other Information

 

None.  

 

15

 

 

Item 6. Exhibits

 

  Exhibit 31.1 Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act.
     
  Exhibit 31.2 Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Exchange Act.
     
  Exhibit 32

Certification of the Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350. 

 

  Exhibit 10.1 First Amendment to Amended and Restated Business Loan Agreement with Beachcorp, LLC
     
  Exhibit 10.2

Replacement Promissory Note with Beachcorp,LLC

 

  Exhibit 10.3

First Amendment to Business Loan Agreement with Beachcorp, LLC

 

  Exhibit 10.4

First Amendment to Business Loan Agreement with Strandler, LLC

 

  Exhibit 10.5 Promissory Note with Strandler, LLC
     
  Exhibit 101 The following materials from Nanophase Technologies Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in XBRL (Extensible Business Reporting Language): (1) the Balance Sheets, (2) the Statements of Operations, (3) the Statements of Shareholders Equity, (4) the Statements of Cash Flows, and (5) the Notes to Unaudited Consolidated Condensed Financial Statements.

 

16

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  NANOPHASE TECHNOLOGIES CORPORATION
       
Date: November 14, 2023   By: /s/ JESS A. JANKOWSKI
            Jess A. Jankowski
        President and Chief Executive Officer
        (principal executive officer, and principal financial officer)

 

17

 

 EX-10.1 2 ex10-1.htm FIRST AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT WITH BEACHCORP, LLC

 

Nanophase Technologies Corporation 10-Q

 

Exhibit 10.1

 

FIRST AMENDMENT TO 

AMENDED AND RESTATED BUSINESS LOAN AGREEMENT

 

This First Amendment is dated as of November 13, 2023 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Amended and Restated Business Loan Agreement dated as of January 28, 2022 between Borrower and Lender (as amended from time to time, the “Loan Agreement”).

 

1.       Borrower and Lender hereby agree to amend the Loan Agreement as follows:

 

(b)    Section 7.1 is hereby amended by amending the definition of “Revolving Maturity Date” in its entirety to read as follows:

 

“Revolving Maturity Date. The words “Revolving Maturity Date” mean March 31, 2025.”

 

2.       Borrower represents to the Lender that it has no defenses, setoffs, claims or counterclaims of any kind or nature whatsoever against Lender in connection with the Loan Agreement or any Related Documents (as defined therein (collectively with the Loan Agreement, the “Loan Documents”), and any amendments to said documents or any action taken or not taken by the Lender with respect thereto or with respect to the collateral. Without limiting the generality of the foregoing, Borrower hereby releases and forever discharges Lender, its affiliates, and each of its officers, managers, agents, employees, attorneys, insurers, successors and assigns, from any and all liabilities, or causes of action, known or unknown, arising out of any action or inaction with respect to the Loan Documents.

 

3.       Except as modified hereby, the Loan Agreement is hereby ratified and affirmed in all respects.

 

NANOPHASE TECHNOLOGIES CORPORATION   BEACHCORP, LLC  
           
By: /s/ Jess Jankowski   By: /s/ Bradford T. Whitmore  
  Jess Jankowski     Bradford T. Whitmore  
  President & Chief Executive Officer     Manager  

   

Acknowledged:

 

SOLÉSENCE, LLC  
     
By: /s/ Jess Jankowski  
Name: Jess Jankowski  
Its: President & Chief Executive Officer  

 

 

 EX-10.2 3 ex10-2.htm REPLACEMENT PROMISSORY NOTE WITH BEACHCORP,LLC

 

Nanophase Technologies Corporation 10-Q

 

Exhibit 10.2

 

REPLACEMENT PROMISSORY NOTE 

(Revolving Note)

 

Principal Amount: $5,200,000.00 Date of Note: November 13, 2023

 

PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to BEACHCORP, LLC, a Delaware limited liability company (“Lender”), or order, in lawful money of the United States of America, the principal amount of FIVE MILLION TWO HUNDRED THOUSAND AND 00/100 DOLLARS ($5,200,000.00) (or so much thereof as may be outstanding) together with interest on the unpaid principal balance from the date hereof, until paid in full.

 

LOAN. This Note evidences Borrower’s Revolving Loans under the Business Loan Agreement dated as of January 28, 2022 between Borrower and Lender (as it may be amended from time to time, the “Loan Agreement”). Capitalized terms used herein, but not otherwise defined herein, shall have the meaning given them in the Loan Agreement.

 

PAYMENT. Borrower will repay the Loan(s) evidenced hereby in accordance with the terms of the Loan Agreement.

 

INTEREST.

 

(a)       Interest on the Loans. Borrower shall pay interest on the Loan(s) in accordance with the terms of the Loan Agreement.

 

(b)       Default Interest. Notwithstanding the above provisions, if an Event of Default is in existence, all outstanding amounts of principal and, to the extent permitted by law, all overdue interest, in respect of each and every Loan shall bear interest, payable on demand, at the Default Rate under the Loan Agreement.

 

EVENTS OF DEFAULT. A default in the performance of any obligation hereunder or any Event of Default under the Loan Agreement shall constitute an Event of Default hereunder.

 

LENDER'S RIGHTS. Upon the occurrence of an Event of Default, Lender may declare the entire unpaid principal balance on this Note and all accrued unpaid interest immediately due, without notice, and then Borrower will pay that amount, together with any Prepayment Fee which Borrower would be required to pay. Lender may hire or pay someone else to help collect this Note if Borrower does not pay. Borrower also will pay Lender that amount. This includes, subject to any limits under applicable law, Lender's attorneys' fees and legal expenses whether or not there is a lawsuit, including attorneys' fees and legal expenses for bankruptcy proceedings (including efforts to modify or vacate any automatic stay or injunction), appeals, and any anticipated post-judgment collection services. Borrower also will pay any court costs, in addition to all other sums provided by law. This Note has been delivered to Lender and accepted by Lender in the State of Illinois. If there is a lawsuit, Borrower agrees upon Lender's request to submit to the jurisdiction and venue of the courts having situs in Cook or Will County, the State of Illinois. LENDER AND BORROWER HEREBY WAIVE THE RIGHT TO ANY JURY TRIAL IN ANY ACTION,

 

1

 

 

PROCEEDING, OR COUNTERCLAIM BROUGHT BY EITHER LENDER OR BORROWER AGAINST THE OTHER. This Note shall be governed by and construed in accordance with the laws of the State of Illinois.

 

COLLATERAL; LOAN AGREEMENT. This Note is secured by the Collateral (as defined in the Loan Agreement). This Note is the Revolving Note referred to in the Loan Agreement.

 

SAVINGS CLAUSE. In no event shall the amount of interest or charges paid hereunder, together will all amounts reserved, charged, or taken by Lender as compensation for fees, services, or expenses incidental to making, negotiation, or collection of the loan evidenced hereby exceed the maximum rate of interest on the unpaid principal balance hereof, charges or compensation for fees, services, or expenses allowable by applicable law. If any sum is collected in excess of the applicable maximum rate or amount, the excess collected shall be applied to reduce the principal debt.

 

INDEMNITY. If the introduction of, or any change in, or in the interpretation of, or any change in its application to the Borrower of, any law or regulation, or compliance with any guideline from any governmental authority (whether or not having the force of law) has the effect of increasing the cost to the Lender of performing its obligations hereunder or otherwise reducing its effective return hereunder, then upon demand from time to time the Borrower shall compensate the Lender for such cost or reduction pursuant to a certificate reasonably prepared by the Lender.

 

GENERAL PROVISIONS. Lender may delay or forgo enforcing any of its rights or remedies under this Note without losing them. Borrower and any other Person who signs, guarantees or endorses this Note, to the extent allowed by law, waive presentment, demand for payment, protest and notice of dishonor. Upon any change in the terms of this Note, and unless otherwise expressly stated in writing, no party who signs this Note, whether as maker, guarantor, accommodation maker or endorser, shall be released from liability. All such parties agree that Lender may renew, extend (repeatedly and for any length of time) or modify this Loan, or release any party or guarantor or Collateral; or impair, fail to realize upon or perfect Lender's security interest in the Collateral; and take any other action deemed necessary by Lender without the consent of or notice to anyone.

 

LENDER'S DISCRETION. Whenever this Note requires either Lender's consent, election, approval or similar action or otherwise vests in Lender the authority to make decisions and/or determinations, such actions shall be made or withheld in Lender's sole and absolute discretion, unless specifically provided otherwise and the granting of any consent, election, approval or similar action by Lender in any instance shall not constitute continuing consent, election, approval or similar action in subsequent instances where such is required.

 

ILLINOIS INSURANCE NOTICE. Unless Borrower provides Lender with evidence of the insurance coverage required by the Security Agreements, Lender may purchase insurance at Borrower's expense to protect Lender's interests in the Collateral. This insurance may, but need not, protect Borrower's interests. The coverage that Lender purchases may not pay any claim that Borrower makes or any claim that is made against Borrower in connection with the Collateral. Borrower may later cancel any insurance purchased by Lender, but only after providing Lender with evidence that Borrower has obtained insurance as required by their agreement. If Lender

 

2

 

 

purchases insurance for the Collateral, Borrower will be responsible for the costs of that insurance, including interest and any other charges Lender may impose in connection with the placement of the insurance, until the effective date of the cancellation or expiration of the insurance. The costs of the insurance may be added to Borrower's total outstanding balance or obligation. The costs of the insurance may be more than the cost of insurance Borrower may be able to obtain on Borrower's own.

 

REPLACEMENT NOTE. This Note replaces that certain Promissory Note (Revolving Note) from Borrower to Lender dated as of January 28, 2022 (the “Prior Note”), and nothing herein shall be deemed to forgive the indebtedness evidenced by the Prior Note.

 

PRIOR TO SIGNING THIS NOTE, BORROWER READ AND UNDERSTOOD ALL THE PROVISIONS OF THIS NOTE. BORROWER AGREES TO THE TERMS OF THE PROMISSORY NOTE AND ACKNOWLEDGES RECEIPT OF A COMPLETED COPY OF THE PROMISSORY NOTE.

 

BORROWER:  
   
NANOPHASE TECHNOLOGIES CORPORATION  
     
By: /s/ Jess Jankowski  
Name: Jess Jankowski  
Its: President & Chief Executive Officer  

  

Address:

 

1319 Marquette Drive 

Romeoville, IL 60446

 

3

 

 

 EX-10.3 4 ex10-3.htm FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT WITH BEACHCORP, LLC

 

Nanophase Technologies Corporation 10-Q

 

Exhibit 10.3

 

FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT

 

This First Amendment is dated as of November 13, 2023 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of BEACHCORP, LLC, a Delaware limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 ( as amended, “Loan Agreement”) between Borrower and Lender (the “Loan Agreement”).

 

1.              Borrower and Lender hereby agree to amend the Loan Agreement as follows:

 

(a)Section 1.1(b) is hereby amended in its entirety to read as follows:

 

(b)       Revolving Loans. Lender will make Loans on a revolving basis (individually a “Revolving Loan” and collectively the “Revolving Loans”) to Borrower until the Revolving Maturity Date in such amounts as Borrower may request in accordance with this Agreement; provided that the aggregate outstanding principal amount of Revolving Loans may not exceed at any time the lesser of (i) the $5,200,000.00 and (ii) the Borrowing Base, as calculated using the Borrower’s inventory balances calculated in conjunction with the closing of its financial statements for each month. Each Revolving Loan shall be in the minimum amount of $10,000.00. Borrower shall pay interest on the Loans in accordance with Section 1.5 hereof, with payment thereof in arrears to be made on the last day of each calendar quarter, with the first such payment due on December 31, 2023. Each Revolving Loan shall be repaid in full on the sooner of (a) a determination that the Revolving Loans exceed the Borrowing Base established based on the most recently provided Borrowing Base Certificate, and (b) the Revolving Maturity Date. The Revolving Loans shall be evidenced by the Revolving Note. The Revolving Loans may be prepaid at any time without penalty or fee.

 

(b)            Section 7.1 is hereby amended by amending the definition of “Borrowing Base” in its entirety to read as follows:

 

“Borrowing Base. The words “Borrowing Base” mean an amount equal to fifty-five percent (55%) percent of all Eligible Inventory (net of such reserves and allowances as the Lender deems necessary in its discretion).”

 

(c)             Section 7.1 is hereby amended by amending the definition of “Revolving Maturity Date” in its entirety to read as follows:

 

“Revolving Maturity Date. The words “Revolving Maturity Date” mean “March 31, 2025.”

 

(d)           Section 7.1 is hereby amended by amending the definition of “Revolving Note” in its entirety to read as follows:

 

“Revolving Note. The words “Revolving Note” mean the Replacement Promissory Note (Revolving Note) from Borrower to Lender dated as of November __, 2023 in the principal amount of $5,200,000.00, together with all renewals of, extensions of, modifications of, refinancings of, consolidations of, and substitutions for such promissory note.”

 

1

 

 

2.              Borrower represents to the Lender that it has no defenses, setoffs, claims or counterclaims of any kind or nature whatsoever against Lender in connection with the Loan Agreement or any Related Documents (as defined therein (collectively with the Loan Agreement, the “Loan Documents”), and any amendments to said documents or any action taken or not taken by the Lender with respect thereto or with respect to the collateral. Without limiting the generality of the foregoing, Borrower hereby releases and forever discharges Lender, its affiliates, and each of its officers, managers, agents, employees, attorneys, insurers, successors and assigns, from any and all liabilities, or causes of action, known or unknown, arising out of any action or inaction with respect to the Loan Documents.

 

3.              Except as modified hereby, the Loan Agreement is hereby ratified and affirmed in all respects.

 

NANOPHASE TECHNOLOGIES CORPORATION   BEACHCORP, LLC  
           
By: /s/ Jess Jankowski   By: /s/ Bradford T. Whitmore  
  Jess Jankowski     Bradford T. Whitmore  
  President & Chief Executive Officer     Manager  

  

Acknowledged:

 

SOLÉSENCE, LLC  
     
By: /s/ Jess Jankowski  
Name: Jess Jankowski  
Its: President & Chief Executive Officer  

 

2

 EX-10.4 5 ex10-4.htm FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT WITH STRANDLER, LLC

 

Nanophase Technologies Corporation 10-Q

 

Exhibit 10.4

 

FIRST AMENDMENT TO BUSINESS LOAN AGREEMENT

 

This First Amendment is dated as of November 13, 2023 and is by and between NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”) in favor of STRANDLER, LLC, a South Dakota limited liability company (“Lender”) and amends that certain Business Loan Agreement dated as of January 28, 2022 ( as amended, “Loan Agreement”) between Borrower and Lender (the “Loan Agreement”).

 

1.Borrower and Lender hereby agree to amend the Loan Agreement as follows:

 

(a)Section 1.1(b) is hereby amended by replacing the date “March 31, 2024” with the date “March 31, 2025”.

 

(b)Section 7.1 is hereby amended by amending the definition of “Term Maturity Date” in its entirety to read as follows:

 

“Term Maturity Date. The words “Term Maturity Date” mean “March 31, 2025.”

 

2.               Borrower represents to the Lender that it has no defenses, setoffs, claims or counterclaims of any kind or nature whatsoever against Lender in connection with the Loan Agreement or any Related Documents (as defined therein (collectively with the Loan Agreement, the “Loan Documents”), and any amendments to said documents or any action taken or not taken by the Lender with respect thereto or with respect to the collateral. Without limiting the generality of the foregoing, Borrower hereby releases and forever discharges Lender, its affiliates, and each of its officers, managers, agents, employees, attorneys, insurers, successors and assigns, from any and all liabilities, or causes of action, known or unknown, arising out of any action or inaction with respect to the Loan Documents.

 

3.              Except as modified hereby, the Loan Agreement is hereby ratified and affirmed in all respects.

 

NANOPHASE TECHNOLOGIES CORPORATION   STRANDLER, LLC  
           
By: /s/ Jess Jankowski   By: /s/ Bradford T. Whitmore  
  Jess Jankowski     Bradford T. Whitmore  
  President & Chief Executive Officer     Manager  

  

Acknowledged:

 

SOLÉSENCE, LLC  
     
By: /s/ Jess Jankowski  
Name: Jess Jankowski  
Its: President & Chief Executive Officer  

 

1

 EX-10.5 6 ex10-5.htm PROMISSORY NOTE WITH STRANDLER, LLC

 

Nanophase Technologies Corporation 10-Q

 

Exhibit 10.5

 

PROMISSORY NOTE 

(Bridge Note)

 

Principal Amount: $2,000,000.00 Date of Note: November 13, 2023

 

PROMISE TO PAY. NANOPHASE TECHNOLOGIES CORPORATION, a Delaware corporation (“Borrower”), hereby promises to pay to STRANDLER, LLC, a South Dakota limited liability company (“Lender”), or order, in lawful money of the United States of America, the principal amount of TWO MILLION AND 00/100 DOLLARS ($2,000,000.00) together with interest on the unpaid principal balance from the date hereof, until paid in full.

 

PAYMENT. Borrower will repay the loan evidenced hereby (the “Loan”) on the earlier of (a) May 13, 2024 or (b) the receipt by Borrower of all proceeds under the Borrower’s rights offering (the “Rights Offering”) approved by the Borrower’s board of directors on November 8, 2023 (the “Maturity Date”).

 

INTEREST.

 

(a)       Interest on the Loan. Borrower shall pay interest on the Loan from the date funded until the Maturity Date (whether by acceleration or otherwise) at the Prime Rate plus 0.75% floating.

 

(b)       Default Interest. Notwithstanding the above provisions, if an Event of Default is in existence, all outstanding amounts of principal and, to the extent permitted by law, all overdue interest, in respect of each and every Loan shall bear interest, payable on demand, at the rate then in effect plus five percent (5%).

 

EVENTS OF DEFAULT. Borrower will be in default (an “Event of Default”) if any of the following happens: (a) Borrower fails to make any payment when due. (b) Borrower breaks any promise Borrower has made to Lender, or Borrower fails to perform promptly at the time and strictly in the manner provided in this Note or any agreement related to this Note, or in any other agreement or loan Borrower has with Lender. (c) Borrower defaults under any loan, extension of credit, security agreement, purchase or sales agreement, or any other agreement, in favor of any other creditor or person that may materially affect any of Borrower's property or Borrower's ability to repay this Note or perform Borrower's obligations under this Note or any document, instrument or agreement related hereto (the “Related Documents”). (d) Any representation or statement made or furnished to Lender by Borrower or on Borrower's behalf is false or misleading in any material respect. (e) Borrower becomes insolvent, a receiver is appointed for any part of Borrower's property, Borrower makes an assignment for the benefit of creditors, or any proceeding is commenced either by Borrower or against Borrower under any bankruptcy or insolvency laws. (f) Any creditor tries to take any of Borrower's property on or in which Lender has a lien or security interest. This includes a garnishment of any of Borrower's accounts, including deposit accounts, with Lender. (g) Any of the events described in this default section occurs with respect to any guarantor of this Note. (h) A material adverse change occurs in the business or financial condition of Borrower.

 

1

 

 

LENDER'S RIGHTS. Upon the occurrence of an Event of Default, Lender may declare the entire unpaid principal balance on this Note and all accrued unpaid interest immediately due, without notice, and then Borrower will pay that amount. Lender may hire or pay someone else to help collect this Note if Borrower does not pay. Borrower also will pay Lender that amount. This includes, subject to any limits under applicable law, Lender's attorneys' fees and legal expenses whether or not there is a lawsuit, including attorneys' fees and legal expenses for bankruptcy proceedings (including efforts to modify or vacate any automatic stay or injunction), appeals, and any anticipated post-judgment collection services. Borrower also will pay any court costs, in addition to all other sums provided by law. This Note has been delivered to Lender and accepted by Lender in the State of Illinois. If there is a lawsuit, Borrower agrees upon Lender's request to submit to the jurisdiction and venue of the courts having situs in Cook or Will County, the State of Illinois. LENDER AND BORROWER HEREBY WAIVE THE RIGHT TO ANY JURY TRIAL IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM BROUGHT BY EITHER LENDER OR BORROWER AGAINST THE OTHER. This Note shall be governed by and construed in accordance with the laws of the State of Illinois.

 

COLLATERAL. This Note is secured by the Collateral as defined in the Commercial Security Agreement dated as of January 28, 2022, as amended from time to time between, among others, Borrower and Lender.

 

SAVINGS CLAUSE. In no event shall the amount of interest or charges paid hereunder, together will all amounts reserved, charged, or taken by Lender as compensation for fees, services, or expenses incidental to making, negotiation, or collection of the loan evidenced hereby exceed the maximum rate of interest on the unpaid principal balance hereof, charges or compensation for fees, services, or expenses allowable by applicable law. If any sum is collected in excess of the applicable maximum rate or amount, the excess collected shall be applied to reduce the principal debt.

 

INDEMNITY. If the introduction of, or any change in, or in the interpretation of, or any change in its application to the Borrower of, any law or regulation, or compliance with any guideline from any governmental authority (whether or not having the force of law) has the effect of increasing the cost to the Lender of performing its obligations hereunder or otherwise reducing its effective return hereunder, then upon demand from time to time the Borrower shall compensate the Lender for such cost or reduction pursuant to a certificate reasonably prepared by the Lender.

 

GENERAL PROVISIONS. Lender may delay or forgo enforcing any of its rights or remedies under this Note without losing them. Borrower and any other Person who signs, guarantees or endorses this Note, to the extent allowed by law, waive presentment, demand for payment, protest and notice of dishonor. Upon any change in the terms of this Note, and unless otherwise expressly stated in writing, no party who signs this Note, whether as maker, guarantor, accommodation maker or endorser, shall be released from liability. All such parties agree that Lender may renew, extend (repeatedly and for any length of time) or modify this Loan, or release any party or guarantor or

 

2

 

 

Collateral; or impair, fail to realize upon or perfect Lender's security interest in the Collateral; and take any other action deemed necessary by Lender without the consent of or notice to anyone.

 

LENDER'S DISCRETION. Whenever this Note requires either Lender's consent, election, approval or similar action or otherwise vests in Lender the authority to make decisions and/or determinations, such actions shall be made or withheld in Lender's sole and absolute discretion, unless specifically provided otherwise and the granting of any consent, election, approval or similar action by Lender in any instance shall not constitute continuing consent, election, approval or similar action in subsequent instances where such is required.

 

ILLINOIS INSURANCE NOTICE. Unless Borrower provides Lender with evidence of the insurance coverage required by the Security Agreements, Lender may purchase insurance at Borrower's expense to protect Lender's interests in the Collateral. This insurance may, but need not, protect Borrower's interests. The coverage that Lender purchases may not pay any claim that Borrower makes or any claim that is made against Borrower in connection with the Collateral. Borrower may later cancel any insurance purchased by Lender, but only after providing Lender with evidence that Borrower has obtained insurance as required by their agreement. If Lender purchases insurance for the Collateral, Borrower will be responsible for the costs of that insurance, including interest and any other charges Lender may impose in connection with the placement of the insurance, until the effective date of the cancellation or expiration of the insurance. The costs of the insurance may be added to Borrower's total outstanding balance or obligation. The costs of the insurance may be more than the cost of insurance Borrower may be able to obtain on Borrower's own.

 

PRIOR TO SIGNING THIS NOTE, BORROWER READ AND UNDERSTOOD ALL THE PROVISIONS OF THIS NOTE. BORROWER AGREES TO THE TERMS OF THE PROMISSORY NOTE AND ACKNOWLEDGES RECEIPT OF A COMPLETED COPY OF THE PROMISSORY NOTE.

 

BORROWER:

 

NANOPHASE TECHNOLOGIES CORPORATION  
     
By: /s/ Jess Jankowski  
Name: Jess Jankowski  
Its: President & Chief Executive Officer  

  

Address:

 

1319 Marquette Drive 

Romeoville, IL 60446

 

3

 

 EX-31.1 7 ex31-1.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 

Nanophase Technologies Corporation 10-Q

 

Exhibit 31.1

 

Certification of the Chief Executive Officer
Pursuant to
Rules 13a-14(a) and 15d-14(a) under the Exchange Act

 

I, Jess A. Jankowski, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Nanophase Technologies Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 14, 2023

 

  /s/ JESS A. JANKOWSKI  
    Jess A. Jankowski  
    (principal executive officer, and principal financial officer)  

 

 

 EX-31.2 8 ex31-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

 

Nanophase Technologies Corporation 10-Q

 

Exhibit 31.2

 

Certification of the Principal Financial Officer
Pursuant to
Rules 13a-14(a) and 15d-14(a) under the Exchange Act

 

I, Jess Jankowski, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Nanophase Technologies Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 14, 2023

 

  /s/ JESS A. JANKOWSKI  
    Jess A. Jankowski  
    (principal executive officer, and principal financial officer)  

 

 

 EX-32 9 ex32.htm CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

 

Nanophase Technologies Corporation 10-Q

 

Exhibit 32

 

Certification Pursuant to 18 U.S.C. Section 1350
(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)

 

In connection with this quarterly report of Nanophase Technologies Corporation (the “Company”) on Form 10-Q for the quarter ending September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jess A. Jankowski, Chief Executive Officer, and acting as Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to our knowledge:

 

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: November 14, 2023

 

  /s/ JESS A. JANKOWSKI  
       Jess A. Jankowski  
       Chief Executive Officer  
  (principal executive officer, and principal financial officer)  

 

 

 EX-101.SCH 10 nanx-20230930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Notes and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Significant Customers and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Business Segmentation and Geographical Distribution link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Accounting Standards Adopted During 2023 link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Notes and Lines of Credit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Significant Customers and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Business Segmentation and Geographical Distribution (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Revenues (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Earnings Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Notes and lines of credit consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Related party interest summary: (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Notes and Lines of Credit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Inventories consist of the following: (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Inventories (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022: (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Accounts receivable balances for these three customers were approximately: (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Significant Customers and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Accounting Standards Adopted During 2023 (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 nanx-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 12 nanx-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 13 nanx-20230930_lab.xml XBRL LABEL FILE Product and Service [Axis] Product [Member] Product and Service, Other [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Timing of Transfer of Good or Service [Axis] Transferred over Time [Member] Transferred at Point in Time [Member] Credit Facility [Axis] Libertyville Bank and Trust [Member] Libertyville Bank and Trust One [Member] Strandler, LLC [Member] Beachcorp, LLC One [Member] Beachcorp, LLC Two [Member] Beachcorp, LLC Three [Member] Variable Rate [Axis] Prime Rate [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Business Loan Agreement [Member] Revolving Credit Facility [Member] Counterparty Name [Axis] Beachcorp, LLC [Member] Inventory Facility [Member] TI Promissory Note [Member] Bridge Note [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Long-Term Debt, Type [Axis] Promissory Note [Member] Related Party, Type [Axis] Customer [Axis] Customer One [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer Two [Member] Customer Three [Member] Customers One through Three [Member] Supply Commitment [Axis] Supply Commitment [Member] Geographical [Axis] Non-US [Member] Solesence [Member] Personal Care ingredients [Member] Advanced Materials [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption, Adjustment [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash Trade accounts receivable, less allowance for doubtful accounts of $270 for September 30, 2023, and $139 for December 31, 2022 Inventories, net Prepaid expenses and other current assets Total current assets Equipment and leasehold improvements, net Operating leases, right of use Other assets, net Total assets LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Lines of credit, related party Accounts payable Current portion of operating lease obligations Current portion of deferred revenue Accrued expenses Total current liabilities Long-term portion of operating lease obligations Long-term debt, related party Long-term portion of deferred revenue Asset retirement obligations Total long-term liabilities Shareholders’ equity: Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding Common stock, $.01 par value, 60,000,000 shares authorized; 49,627,254 and 49,320,680 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated deficit Total shareholders’ equity Total liabilities and shareholders’ equity Allowance for doubtful accounts Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Statement [Table] Statement [Line Items] Revenue: Total revenue Operating expense: Cost of revenue Gross profit Research and development expense Selling, general and administrative expense Loss from operations Interest expense Loss before provision for income taxes Provision for income taxes Net loss Net loss per basic share Weighted average number of basic common shares outstanding Net loss per diluted share Weighted average number of diluted common shares outstanding Balance at beginning Balance at beginning (in shares) Issuance of shares and stock option exercises Issuance of shares and stock option exercises (in shares) Stock-based compensation Cumulative effect of accounting changes related to expected credit losses Net income (loss) Balance at ending Balance at ending (in shares) Statement of Cash Flows [Abstract] Operating activities: Net loss Adjustments to reconcile net loss to cash used in operating activities: Depreciation and amortization Share-based compensation Changes in assets and liabilities related to operations: Trade accounts receivable Inventories Prepaid expenses and other assets Accounts payable Accrued expenses Deferred revenue Change in right-of-use asset and lease liability, net Net cash provided by (used in) operating activities Investing activities: Acquisition of equipment and leasehold improvements Net cash used in investing activities Financing activities: Principal payments on finance leases Proceeds from line of credit, related party Payments to line of credit, related party Proceeds from term loan, related party Payments to term loan, related party Proceeds from exercise of stock options Net cash (used in) provided by financing activities Decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental cash flow information:  Interest paid Supplemental non-cash investing and financing activities: Accounts payable incurred for the purchase of equipment and leasehold improvements Early termination of operating lease Right-of-use assets obtained in exchange for lease liabilities Accounting Policies [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Revenue from Contract with Customer [Abstract] Revenues Earnings Per Share [Abstract] Earnings Per Share Investments, All Other Investments [Abstract] Financial Instruments Debt Disclosure [Abstract] Notes and Lines of Credit Inventory Disclosure [Abstract] Inventories Risks and Uncertainties [Abstract] Significant Customers and Contingencies Segment Reporting [Abstract] Business Segmentation and Geographical Distribution Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Accounting Changes and Error Corrections [Abstract] Accounting Standards Adopted During 2023 Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows: Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: Notes and lines of credit consist of the following: Related party interest summary: Inventories consist of the following: The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022: Accounts receivable balances for these three customers were approximately: The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows: Accounts Receivable Contract Assets Contract Liabilities Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue recognized included in contract liability balance at beginning of period Revenue Numerator: (in Thousands) Denominator: Weighted average number of basic shares outstanding Weighted average additional shares assuming conversion of in-the-money stock options to common shares and assumed repurchase of common shares by the Company Weighted average number of diluted common shares outstanding Basic earnings per common share: Net loss per share – basic Diluted earnings per common share: Net loss per share – diluted Anti-dilutive shares Line of Credit Facility [Table] Line of Credit Facility [Line Items] Rate Total Borrowing Capacity Outstanding Borrowed Balance Debt Instrument, Basis Spread on Variable Rate Line of Credit Facility, Expiration Date Line of Credit Percentage of Eligible inventory Interest expense, related parties Accrued interest expense, related parties Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Debt Instrument, Face Amount Raw materials Finished goods Total inventories, net Reserve against reported inventory Concentration Risk [Table] Concentration Risk [Line Items] Revenue from customers Total Supply Commitment [Table] Supply Commitment [Line Items] Equipment sale - net book value Equipment sale- original book value Revenue from External Customers by Products and Services [Table] Revenue from External Customer [Line Items] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues Accounting Standards Update and Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Accounting Standards Update [Extensible Enumeration] Retained earnings The element represents advanced materials member. The element represents customer one member. The element represents customer three member. The element represents customer two member. The element represents equipment sale original book value of equipment and upgrades. The element represents solesence member. The element represents personal care ingredients member. Beachcorp, LLC Two. The element represents line of credit percentage of eligible inventory. The element represents equipment sale net book value equipment. The element represents business loan agreement member. The element represents beachcorp l l c member. The element represents libertyville bank and trust member. The element represents libertyville bank and trust one member. Beachcorp, LLC One. The element represents strandler l l c member. Inventory Facility. Amount of accrued interest expense related parties. Beachcorp, LLC Three. TI Promissory Note. Early termination of operating lease amount. Bridge Note. The element represents promissory note member. Customers One through Three. Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer and earned during the period for which consideration from customer has been received or is due. Accounting Standards Update 2016-13 [Member] Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Stockholders' Equity, Other Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Repayments of Related Party Debt Repayments of Other Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Revenues [Default Label] EX-101.PRE 14 nanx-20230930_pre.xml XBRL PRESENTATION FILE XML 15 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 14, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 000-22333  
Entity Registrant Name Nanophase Technologies Corporation  
Entity Central Index Key 0000883107  
Entity Tax Identification Number 36-3687863  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 1319 Marquette Drive  
Entity Address, City or Town Romeoville  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60446  
City Area Code (630)  
Local Phone Number 771-6708  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   49,627,254
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 1,188 $ 2,186
Trade accounts receivable, less allowance for doubtful accounts of $270 for September 30, 2023, and $139 for December 31, 2022 3,199 4,734
Inventories, net 10,123 8,839
Prepaid expenses and other current assets 1,040 866
Total current assets 15,550 16,625
Equipment and leasehold improvements, net 8,607 7,949
Operating leases, right of use 8,187 8,978
Other assets, net 3 6
Total assets 32,347 33,558
Current liabilities:    
Lines of credit, related party 6,338 7,282
Accounts payable 6,270 6,363
Current portion of operating lease obligations 1,303
Current portion of deferred revenue 2,619 2,167
Accrued expenses 1,130 1,023
Total current liabilities 17,660 16,835
Long-term portion of operating lease obligations 9,475 9,823
Long-term debt, related party 1,000 1,000
Long-term portion of deferred revenue 45 21
Asset retirement obligations 236 230
Total long-term liabilities 10,756 11,074
Shareholders’ equity:    
Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding
Common stock, $.01 par value, 60,000,000 shares authorized; 49,627,254 and 49,320,680 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively 496 493
Additional paid-in capital 105,970 105,226
Accumulated deficit (102,535) (100,070)
Total shareholders’ equity 3,931 5,649
Total liabilities and shareholders’ equity $ 32,347 $ 33,558
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 270 $ 139
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized 24,088 24,088
Preferred stock, issued 0 0
Preferred stock, outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized 60,000,000 60,000,000
Common stock, issued 49,627,254 49,320,680
Common stock, outstanding 49,627,254 49,320,680
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:        
Total revenue $ 7,958 $ 9,678 $ 29,286 $ 29,056
Operating expense:        
Cost of revenue 6,428 7,185 21,932 21,659
Gross profit 1,530 2,493 7,354 7,397
Research and development expense 1,057 848 3,052 2,310
Selling, general and administrative expense 1,695 2,279 5,951 5,493
Loss from operations (1,222) (634) (1,649) (406)
Interest expense 214 116 613 232
Loss before provision for income taxes (1,436) (750) (2,262) (638)
Provision for income taxes
Net loss $ (1,436) $ (750) $ (2,262) $ (638)
Net loss per basic share $ (0.03) $ (0.02) $ (0.05) $ (0.01)
Weighted average number of basic common shares outstanding 49,598,581 49,174,673 49,532,395 49,068,709
Net loss per diluted share $ (0.03) $ (0.02) $ (0.05) $ (0.01)
Weighted average number of diluted common shares outstanding 49,598,581 49,174,673 49,532,395 49,068,709
Product [Member]        
Revenue:        
Total revenue $ 7,746 $ 9,673 $ 28,925 $ 28,515
Product and Service, Other [Member]        
Revenue:        
Total revenue $ 212 $ 5 $ 361 $ 541
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed) - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at beginning at Dec. 31, 2021 $ 489 $ 104,423 $ (97,447) $ 7,465
Balance at beginning (in shares) at Dec. 31, 2021 48,893,573      
Issuance of shares and stock option exercises $ 1 72 73
Issuance of shares and stock option exercises (in shares)   133,168      
Stock-based compensation 148 148
Net income (loss) 62 62
Balance at ending at Mar. 31, 2022 $ 490 104,643 (97,385) 7,748
Balance at ending (in shares) at Mar. 31, 2022 49,026,741      
Balance at beginning at Dec. 31, 2021 $ 489 104,423 (97,447) 7,465
Balance at beginning (in shares) at Dec. 31, 2021 48,893,573      
Net income (loss)         (638)
Balance at ending at Sep. 30, 2022 $ 492 105,012 (98,085) 7,419
Balance at ending (in shares) at Sep. 30, 2022 49,216,180      
Balance at beginning at Mar. 31, 2022 $ 490 104,643 (97,385) 7,748
Balance at beginning (in shares) at Mar. 31, 2022 49,026,741      
Issuance of shares and stock option exercises $ 1 33 34
Issuance of shares and stock option exercises (in shares)   110,289      
Stock-based compensation 155 155
Net income (loss) 50 50
Balance at ending at Jun. 30, 2022 $ 491 104,831 (97,335) 7,987
Balance at ending (in shares) at Jun. 30, 2022 49,137,030      
Issuance of shares and stock option exercises $ 1 31 32
Issuance of shares and stock option exercises (in shares)   79,150      
Stock-based compensation 150 150
Net income (loss) (750) (750)
Balance at ending at Sep. 30, 2022 $ 492 105,012 (98,085) 7,419
Balance at ending (in shares) at Sep. 30, 2022 49,216,180      
Balance at beginning at Dec. 31, 2022 $ 493 105,226 (100,070) 5,649
Balance at beginning (in shares) at Dec. 31, 2022 49,320,680      
Issuance of shares and stock option exercises $ 2 99 101
Issuance of shares and stock option exercises (in shares) 199,891      
Stock-based compensation 209 209
Cumulative effect of accounting changes related to expected credit losses (203) (203)
Net income (loss) (1,159) (1,159)
Balance at ending at Mar. 31, 2023 $ 495 105,534 (101,432) 4,597
Balance at ending (in shares) at Mar. 31, 2023 49,520,571      
Balance at beginning at Dec. 31, 2022 $ 493 105,226 (100,070) 5,649
Balance at beginning (in shares) at Dec. 31, 2022 49,320,680      
Net income (loss)         (2,262)
Balance at ending at Sep. 30, 2023 $ 496 105,970 (102,535) 3,931
Balance at ending (in shares) at Sep. 30, 2023 49,627,254      
Balance at beginning at Mar. 31, 2023 $ 495 105,534 (101,432) 4,597
Balance at beginning (in shares) at Mar. 31, 2023 49,520,571      
Issuance of shares and stock option exercises $ 1 33 34
Issuance of shares and stock option exercises (in shares) 68,633      
Stock-based compensation 195 195
Net income (loss) 333 333
Balance at ending at Jun. 30, 2023 $ 496 105,762 (101,099) 5,159
Balance at ending (in shares) at Jun. 30, 2023 49,589,204      
Issuance of shares and stock option exercises 19 19
Issuance of shares and stock option exercises (in shares) 38,050      
Stock-based compensation 189 189
Net income (loss) (1,436) (1,436)
Balance at ending at Sep. 30, 2023 $ 496 $ 105,970 $ (102,535) $ 3,931
Balance at ending (in shares) at Sep. 30, 2023 49,627,254      
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Operating activities:    
Net loss $ (2,262) $ (638)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 524 413
Share-based compensation 593 453
Changes in assets and liabilities related to operations:    
Trade accounts receivable 1,333 (1,431)
Inventories (1,284) (3,501)
Prepaid expenses and other assets (174) (69)
Accounts payable (422) 1,398
Accrued expenses 113 401
Deferred revenue 476 (75)
Change in right-of-use asset and lease liability, net 1,747 652
Net cash provided by (used in) operating activities 644 (2,397)
Investing activities:    
Acquisition of equipment and leasehold improvements (852) (1,798)
Net cash used in investing activities (852) (1,798)
Financing activities:    
Principal payments on finance leases (100)
Proceeds from line of credit, related party 23,304 25,075
Payments to line of credit, related party (24,248) (21,068)
Proceeds from term loan, related party 1,338
Payments to term loan, related party (1,338)
Proceeds from exercise of stock options 154 141
Net cash (used in) provided by financing activities (790) 4,048
Decrease in cash and cash equivalents (998) (147)
Cash and cash equivalents at beginning of period 2,186 657
Cash and cash equivalents at end of period 1,188 510
Supplemental cash flow information:    
 Interest paid 553 232
Supplemental non-cash investing and financing activities:    
Accounts payable incurred for the purchase of equipment and leasehold improvements 329 432
Early termination of operating lease 73
Right-of-use assets obtained in exchange for lease liabilities $ 36
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation

(1) Basis of Presentation

 

The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly-owned subsidiary, Solésence, LLC (“Solésence,” or our “Solésence® subsidiary”). Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

 

These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission.
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Description of Business
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

(2) Description of Business

 

Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets. Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy. We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary. In terms of our life sciences focus, we have seen demand significantly decrease for our medical diagnostics ingredients. Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category.  

 

 We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.

 

Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies. Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. 

 

Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.

 

While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. 
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Revenues
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenues

 (3) Revenues

 

Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.

 

We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.

 

 Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows:

 

      Accounts Receivable     Contract Assets     Contract Liabilities  
Balance, December 31, 2021     $ 3,937     $ 179     $ 1,444  
Balance, December 31, 2022       4,734       —       2,188  
Balance, September 30, 2023       3,199       —       2,664  

 

 

Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $414 and $295, for the three months ended September 30, 2023 and 2022, respectively, and $2,438 and $507 for the nine months ended September 30, 2023 and 2022, respectively.

 

Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Other revenue recognized over time was $212 and $5, for the three months ended September 30, 2023 and 2022, respectively, and $361 and $191 for the nine months ended September 30, 2023 and 2022, respectively. Other revenue recognized at a point in time was $350 for the nine months September 30, 2022.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Earnings Per Share

(4) Earnings Per Share

 

Options to purchase approximately 853,000 and 728,000 shares of common stock that were outstanding as of September 30, 2023 were not included in the computation of diluted earnings per share for the three and nine-months ended September 30, 2023. The inclusion of these shares for the three and nine months ended September 30, 2023 would have resulted in an anti-dilutive effect and were thus omitted from disclosure. Options to purchase approximately 1,871,000 and 1,901,000 shares of common stock that were outstanding as of September 30, 2022 were not included in the computation of earnings per share for the three months and nine months ended September 30, 2022, respectively, as inclusion would have had an anti-dilutive impact due to losses.

 

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: 

 

                             
   Three months ended September 30,   Nine months ended September 30, 
   2023   2022   2023   2022 
                 
Numerator: (in Thousands)                    
Net loss  $(1,436)  $(750)  $(2,262)  $(638)
                     
Denominator:                    
Weighted average number of basic shares outstanding   49,598,581    49,174,673    49,532,395    49,068,709 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares and assumed repurchase of common shares by the Company   —    —    —    — 
Weighted average number of diluted common shares outstanding   49,598,581    49,174,673    49,532,395    49,068,709 
                     
Basic earnings per common share:                    
Net loss per share – basic  $(0.03)  $(0.02)  $(0.05)  $(0.01)
Diluted earnings per common share:                    
Net loss per share – diluted  $(0.03)  $(0.02)  $(0.05)  $(0.01)

 
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Financial Instruments
 9 Months Ended
Sep. 30, 2023
Investments, All Other Investments [Abstract]  
Financial Instruments

(5) Financial Instruments

 

We follow ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.

 

 Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 6. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature of these accounts. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.

 

There were no financial instruments adjusted to fair value on September 30, 2023 and December 31, 2022.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Notes and Lines of Credit
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Notes and Lines of Credit

(6) Notes and Lines of Credit

 

 Notes and lines of credit consist of the following:

 

       As of September 30, 2023   As of December 31, 2022 
   Rate   Total Borrowing Capacity   Outstanding Borrowed Balance   Total Borrowing Capacity   Outstanding Borrowed Balance 
Libertyville Bank & Trust (1)   9.50%  $30   $—   $—   $— 
Libertyville Bank & Trust (2)   9.50%   500    —    —    — 
Strandler, LLC(3)   9.25%   1,000    1,000    1,000    1,000 
Beachcorp, LLC (4)   9.25%   3,229    2,338    4,392    4,282 
Beachcorp, LLC (5)   9.25%   4,000    4,000    4,000    3,000 
Beachcorp, LLC (6)   9.25%   —    —    —    — 

 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.

 

2)The Company maintains a credit agreement with Libertyville to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2023. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.

 

4)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.

 

5)On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.

 

6)On May 1, 2023 the Company entered into a non-revolving promissory note (“TI Promissory Note”) with Beachcorp, LLC. The maximum borrowing amount under the TI Promissory Note is $1,750. The interest rate for the TI Promissory Note is at the prime rate plus 0.75%, and it matures on September 30, 2023. This loan is for work being done at the Bolingbrook facility which is expected to be reimbursed from the landlord as part of the lease agreement. On July 21, 2023, the TI Promissory Note and accrued interest was repaid in full after reimbursement from the landlord for approved tenant improvements.

 

Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank & Trust.

 

 

On November 13, 2023, as part of a comprehensive financing transaction, the Company entered into a non-revolving promissory note (Bridge Note) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is $2,000. The interest rate for the Bridge Loan is at the prime rate plus 0.75%, and it matures on the earlier of May 13, 2024 or the closing of the Rights Offering. The Company is required to repay the Bridge Note upon completion of a planned Rights Offering, or at maturity, whichever comes first. As part of this financing transaction, the maturity dates of the New Term Loan Agreement, A/R Loan Agreement and Inventory Facility were extended to March 31, 2025. Additionally, the maximum borrowing amount under the Inventory Facility was increased to $5,200, and the borrowing base was increased to up to 55% of the value of qualified inventory of the Company.

 

Related party interest summary:

 

                             
   Three months ended September 30,   Nine months ended September 30, 
   2023   2022   2023   2022 
                 
Interest expense, related parties  $199   $111   $560   $218 
Accrued interest expense, related parties   57    39    57    39 

 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventories

(7) Inventories

 

Inventories consist of the following:

 

   September 30,
2023		   December 31,
2022		 
         
Raw materials  $7,013   $6,797 
Finished goods   3,110    2,041 
Total inventories, net  $10,123   $8,839 

 

        The Company had reserves for excess and obsolete inventory of $670 and $500 as of September 30, 2023 and December 31, 2022, respectively.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Customers and Contingencies
 9 Months Ended
Sep. 30, 2023
Risks and Uncertainties [Abstract]  
Significant Customers and Contingencies

(8) Significant Customers and Contingencies

 

The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022:

 

       Three months ended
September 30,		   Nine months ended
September 30,		 
Customer #   Product Category  2023   2022   2023   2022 
1   Personal Care Ingredients   30%   30%   31%   30%
2   Solésence®   18%   18%   14%   17%
3   Solésence®   21%   19%   14%   16%
    Total   69%   67%   59%   63%

 

 

Accounts receivable balances for these three customers were approximately:

 

Customer #   Product Category  September 30,
2023		   September 30,
2022		 
1   Personal Care Ingredients  $320   $943 
2   Solésence®   545    439 
3   Solésence®   1,047    1,717 
    Total  $1,912   $3,099 

 

We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in “triggering” the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either 115% of the equipment’s net book value or the greater of 30% of the original book value of such equipment, and any associated upgrades to it, or 115% of the equipment’s net book value, depending on the equipment and related products.

 

If a triggering event were to occur and BASF elected to proceed with the equipment sale mentioned above, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Business Segmentation and Geographical Distribution
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Business Segmentation and Geographical Distribution

 (9) Business Segmentation and Geographical Distribution

 

Revenue from international sources approximated $731 and $2,918 for the three and nine months ended September 30, 2023, respectively, compared to $495 and $955 for the three and nine months ended September 30, 2022, respectively. All of this revenue was product revenue.  

 

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows:

 

   Three months ended September 30,   Nine months ended September 30, 
Product Category  2023   2022   2023   2022 
Solésence  $5,016   $5,932   $17,839   $18,591 
Personal Care Ingredients   2,364    2,903    8,944    8,589 
Advanced Materials   578    843    2,503    1,876 
Total Sales  $7,958   $9,678   $29,286   $29,056 

 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

 

(10) Commitments and Contingencies 

 

On August 9, 2022, BASF filed a complaint against Nanophase in New Jersey state court (the “New Jersey Complaint”), alleging that Nanophase had breached the 1999 Zinc Oxide Supply Agreement (the “Agreement”). BASF alleges several issues, the one having the biggest potential impact on Nanophase being a claim that our sales through Solésence violate the exclusivity provision of the Agreement. BASF seeks an unspecified amount of damages, a permanent injunction enjoining sales to any party (other than BASF) of a broad range of zinc oxide products that BASF contends are within the scope of the exclusivity provision, counsel fees and litigation expenses. On September 7, 2022, Nanophase filed a Complaint for Declaratory Judgement in Illinois state court (the “Illinois Complaint”), asking for a declaration that contrary to BASF’s allegation, the exclusivity provision of the Agreement does not apply to all products containing zinc oxide as an ingredient for uses designated under the Agreement, nor does the exclusivity provision prohibit Nanophase’s sales of Solésence products containing zinc oxide as an ingredient. Both companies filed Motions to Dismiss (MTD) the other’s respective complaint. Nanophase’s MTD BASF’s New Jersey Complaint was denied on procedural grounds on February 10, 2023, with the New Jersey court superficially noting that it did not consider whether BASF could prove its claims. On February 28, 2023, Nanophase filed its answer to BASF’s New Jersey Complaint, denying all wrongdoing and, as mandated by New Jersey procedural requirements, counterclaims including a request for a declaration similar to that Nanophase sought in its Illinois Complaint. On March 16, 2023, the Illinois court granted BASF’s MTD Nanophase’s Illinois Complaint, finding it duplicative of the New Jersey litigation. Discovery in that litigation is ongoing. Management believes at this time that the allegations of BASF’s complaint are without merit and are unsupported by the terms of the Agreement and governing law. Per ASC 450 for the period ending September 30, 2023, an estimated contingent loss was not recorded, and an estimated range of loss is not disclosed as the outcome is not probable at this time and nor is a range of loss estimable. 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Accounting Standards Adopted During 2023
 9 Months Ended
Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]  
Accounting Standards Adopted During 2023

 

(11) Accounting Standards Adopted During 2023

 

On January 1, 2023, the Company adopted ASU 2016-13 “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.

 

This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of $203.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Revenues (Tables)
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows:

 Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows:

 

      Accounts Receivable     Contract Assets     Contract Liabilities  
Balance, December 31, 2021     $ 3,937     $ 179     $ 1,444  
Balance, December 31, 2022       4,734       —       2,188  
Balance, September 30, 2023       3,199       —       2,664  
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:

Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: 

 

                             
   Three months ended September 30,   Nine months ended September 30, 
   2023   2022   2023   2022 
                 
Numerator: (in Thousands)                    
Net loss  $(1,436)  $(750)  $(2,262)  $(638)
                     
Denominator:                    
Weighted average number of basic shares outstanding   49,598,581    49,174,673    49,532,395    49,068,709 
Weighted average additional shares assuming conversion of in-the-money stock options to common shares and assumed repurchase of common shares by the Company   —    —    —    — 
Weighted average number of diluted common shares outstanding   49,598,581    49,174,673    49,532,395    49,068,709 
                     
Basic earnings per common share:                    
Net loss per share – basic  $(0.03)  $(0.02)  $(0.05)  $(0.01)
Diluted earnings per common share:                    
Net loss per share – diluted  $(0.03)  $(0.02)  $(0.05)  $(0.01)
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Notes and Lines of Credit (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Notes and lines of credit consist of the following:

 Notes and lines of credit consist of the following:

 

       As of September 30, 2023   As of December 31, 2022 
   Rate   Total Borrowing Capacity   Outstanding Borrowed Balance   Total Borrowing Capacity   Outstanding Borrowed Balance 
Libertyville Bank & Trust (1)   9.50%  $30   $—   $—   $— 
Libertyville Bank & Trust (2)   9.50%   500    —    —    — 
Strandler, LLC(3)   9.25%   1,000    1,000    1,000    1,000 
Beachcorp, LLC (4)   9.25%   3,229    2,338    4,392    4,282 
Beachcorp, LLC (5)   9.25%   4,000    4,000    4,000    3,000 
Beachcorp, LLC (6)   9.25%   —    —    —    — 

 

 

1)Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.

 

2)The Company maintains a credit agreement with Libertyville to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2023. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.

 

3)On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.

 

4)On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.

 

5)On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.

 

6)On May 1, 2023 the Company entered into a non-revolving promissory note (“TI Promissory Note”) with Beachcorp, LLC. The maximum borrowing amount under the TI Promissory Note is $1,750. The interest rate for the TI Promissory Note is at the prime rate plus 0.75%, and it matures on September 30, 2023. This loan is for work being done at the Bolingbrook facility which is expected to be reimbursed from the landlord as part of the lease agreement. On July 21, 2023, the TI Promissory Note and accrued interest was repaid in full after reimbursement from the landlord for approved tenant improvements.
Related party interest summary:

Related party interest summary:

 

                             
   Three months ended September 30,   Nine months ended September 30, 
   2023   2022   2023   2022 
                 
Interest expense, related parties  $199   $111   $560   $218 
Accrued interest expense, related parties   57    39    57    39 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Tables)
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventories consist of the following:

Inventories consist of the following:

 

   September 30,
2023		   December 31,
2022		 
         
Raw materials  $7,013   $6,797 
Finished goods   3,110    2,041 
Total inventories, net  $10,123   $8,839 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Customers and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2023
Risks and Uncertainties [Abstract]  
The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022:

The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022:

 

       Three months ended
September 30,		   Nine months ended
September 30,		 
Customer #   Product Category  2023   2022   2023   2022 
1   Personal Care Ingredients   30%   30%   31%   30%
2   Solésence®   18%   18%   14%   17%
3   Solésence®   21%   19%   14%   16%
    Total   69%   67%   59%   63%
Accounts receivable balances for these three customers were approximately:

Accounts receivable balances for these three customers were approximately:

 

Customer #   Product Category  September 30,
2023		   September 30,
2022		 
1   Personal Care Ingredients  $320   $943 
2   Solésence®   545    439 
3   Solésence®   1,047    1,717 
    Total  $1,912   $3,099 
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Business Segmentation and Geographical Distribution (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows:

Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows:

 

   Three months ended September 30,   Nine months ended September 30, 
Product Category  2023   2022   2023   2022 
Solésence  $5,016   $5,932   $17,839   $18,591 
Personal Care Ingredients   2,364    2,903    8,944    8,589 
Advanced Materials   578    843    2,503    1,876 
Total Sales  $7,958   $9,678   $29,286   $29,056 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows: (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]      
Accounts Receivable $ 3,199 $ 4,734 $ 3,937
Contract Assets 179
Contract Liabilities $ 2,664 $ 2,188 $ 1,444
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Revenues (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]        
Revenue recognized included in contract liability balance at beginning of period $ 414 $ 295 $ 2,438 $ 507
Revenue 7,958 9,678 29,286 29,056
Product and Service, Other [Member]        
Disaggregation of Revenue [Line Items]        
Revenue 212 5 361 541
Product and Service, Other [Member] | Transferred over Time [Member]        
Disaggregation of Revenue [Line Items]        
Revenue $ 212 $ 5 $ 361 191
Product and Service, Other [Member] | Transferred at Point in Time [Member]        
Disaggregation of Revenue [Line Items]        
Revenue       $ 350
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Numerator: (in Thousands)                
Net loss $ (1,436) $ 333 $ (1,159) $ (750) $ 50 $ 62 $ (2,262) $ (638)
Denominator:                
Weighted average number of basic shares outstanding 49,598,581     49,174,673     49,532,395 49,068,709
Weighted average additional shares assuming conversion of in-the-money stock options to common shares and assumed repurchase of common shares by the Company        
Weighted average number of diluted common shares outstanding 49,598,581     49,174,673     49,532,395 49,068,709
Basic earnings per common share:                
Net loss per share – basic $ (0.03)     $ (0.02)     $ (0.05) $ (0.01)
Diluted earnings per common share:                
Net loss per share – diluted $ (0.03)     $ (0.02)     $ (0.05) $ (0.01)
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings Per Share (Details Narrative) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Earnings Per Share [Abstract]        
Anti-dilutive shares 853,000 1,871,000 728,000 1,901,000
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Notes and lines of credit consist of the following: (Details) - USD ($)
$ in Thousands
 9 Months Ended
May 01, 2023
Jan. 28, 2022
Sep. 30, 2023
Dec. 31, 2022
Jan. 26, 2022
Libertyville Bank and Trust [Member]          
Line of Credit Facility [Line Items]          
Rate [1]     9.50%    
Total Borrowing Capacity [1]     $ 30  
Outstanding Borrowed Balance [1]      
Libertyville Bank and Trust [Member] | Prime Rate [Member]          
Line of Credit Facility [Line Items]          
Debt Instrument, Basis Spread on Variable Rate     1.00%    
Libertyville Bank and Trust One [Member]          
Line of Credit Facility [Line Items]          
Rate [2]     9.50%    
Total Borrowing Capacity [2]     $ 500  
Outstanding Borrowed Balance [2]      
Line of Credit Facility, Expiration Date     Dec. 22, 2023    
Libertyville Bank and Trust One [Member] | Prime Rate [Member]          
Line of Credit Facility [Line Items]          
Debt Instrument, Basis Spread on Variable Rate     1.00%    
Strandler, LLC [Member]          
Line of Credit Facility [Line Items]          
Rate [3]     9.25%    
Total Borrowing Capacity [3]     $ 1,000 1,000  
Outstanding Borrowed Balance [3]     $ 1,000 1,000  
Line of Credit Facility, Expiration Date     Mar. 31, 2024    
Strandler, LLC [Member] | Prime Rate [Member]          
Line of Credit Facility [Line Items]          
Debt Instrument, Basis Spread on Variable Rate     0.75%    
Beachcorp, LLC One [Member]          
Line of Credit Facility [Line Items]          
Rate [4]     9.25%    
Total Borrowing Capacity [4]     $ 3,229 4,392  
Outstanding Borrowed Balance [4]     $ 2,338 4,282  
Beachcorp, LLC Two [Member]          
Line of Credit Facility [Line Items]          
Rate [5]     9.25%    
Total Borrowing Capacity [5]     $ 4,000 4,000  
Outstanding Borrowed Balance [5]     $ 4,000 3,000  
Beachcorp, LLC Three [Member]          
Line of Credit Facility [Line Items]          
Rate [6]     9.25%    
Total Borrowing Capacity [6]      
Outstanding Borrowed Balance [6]      
Revolving Credit Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]          
Line of Credit Facility [Line Items]          
Total Borrowing Capacity   $ 8,000     $ 6,000
Line of Credit Facility, Expiration Date   Mar. 31, 2024      
Revolving Credit Facility [Member] | Prime Rate [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]          
Line of Credit Facility [Line Items]          
Debt Instrument, Basis Spread on Variable Rate   0.75%      
Inventory Facility [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]          
Line of Credit Facility [Line Items]          
Total Borrowing Capacity   $ 4,000      
Line of Credit Facility, Expiration Date   Mar. 31, 2024      
Line of Credit Percentage of Eligible inventory   50.00%      
Inventory Facility [Member] | Prime Rate [Member] | Business Loan Agreement [Member] | Beachcorp, LLC [Member]          
Line of Credit Facility [Line Items]          
Debt Instrument, Basis Spread on Variable Rate   0.75%      
TI Promissory Note [Member] | Beachcorp, LLC [Member]          
Line of Credit Facility [Line Items]          
Total Borrowing Capacity $ 1,750        
Line of Credit Facility, Expiration Date Sep. 30, 2023        
TI Promissory Note [Member] | Prime Rate [Member] | Beachcorp, LLC [Member]          
Line of Credit Facility [Line Items]          
Debt Instrument, Basis Spread on Variable Rate 0.75%        
[1] Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.
[2] The Company maintains a credit agreement with Libertyville to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2023. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.
[3] On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore.
[4] On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024.
[5] On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024.
[6] On May 1, 2023 the Company entered into a non-revolving promissory note (“TI Promissory Note”) with Beachcorp, LLC. The maximum borrowing amount under the TI Promissory Note is $1,750. The interest rate for the TI Promissory Note is at the prime rate plus 0.75%, and it matures on September 30, 2023. This loan is for work being done at the Bolingbrook facility which is expected to be reimbursed from the landlord as part of the lease agreement. On July 21, 2023, the TI Promissory Note and accrued interest was repaid in full after reimbursement from the landlord for approved tenant improvements.
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Related party interest summary: (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Debt Disclosure [Abstract]        
Interest expense, related parties $ 199 $ 111 $ 560 $ 218
Accrued interest expense, related parties $ 57 $ 39 $ 57 $ 39
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Notes and Lines of Credit (Details Narrative) - Subsequent Event [Member]
$ in Thousands
Nov. 13, 2023
USD ($)
Promissory Note [Member] | Strandler, LLC [Member]  
Debt Instrument [Line Items]  
Debt Instrument, Face Amount Mar. 31, 2025
Bridge Note [Member] | Strandler, LLC [Member]  
Debt Instrument [Line Items]  
Line of Credit Facility, Maximum Borrowing Capacity $ 2,000
Line of Credit Facility, Expiration Date May 13, 2024
Bridge Note [Member] | Strandler, LLC [Member] | Prime Rate [Member]  
Debt Instrument [Line Items]  
Debt Instrument, Basis Spread on Variable Rate 0.75%
Inventory Facility [Member] | Strandler, LLC [Member]  
Debt Instrument [Line Items]  
Line of Credit Facility, Maximum Borrowing Capacity $ 5,200
Line of Credit Percentage of Eligible inventory 55.00%
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories consist of the following: (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 7,013 $ 6,797
Finished goods 3,110 2,041
Total inventories, net $ 10,123 $ 8,839
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Inventories (Details Narrative) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Reserve against reported inventory $ 670 $ 500
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.23.3
The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022: (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Customer One [Member]        
Concentration Risk [Line Items]        
Revenue from customers 30.00% 30.00% 31.00% 30.00%
Customer Two [Member]        
Concentration Risk [Line Items]        
Revenue from customers 18.00% 18.00% 14.00% 17.00%
Customer Three [Member]        
Concentration Risk [Line Items]        
Revenue from customers 21.00% 19.00% 14.00% 16.00%
Customers One through Three [Member]        
Concentration Risk [Line Items]        
Revenue from customers 69.00% 67.00% 59.00% 63.00%
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts receivable balances for these three customers were approximately: (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Sep. 30, 2022
Total $ 1,912 $ 3,099
Customer One [Member]    
Total 320 943
Customer Two [Member]    
Total 545 439
Customer Three [Member]    
Total $ 1,047 $ 1,717
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Customers and Contingencies (Details Narrative)
Sep. 30, 2023
Supply Commitment [Line Items]  
Equipment sale - net book value 115.00%
Supply Commitment [Member]  
Supply Commitment [Line Items]  
Equipment sale - net book value 115.00%
Equipment sale- original book value 30.00%
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.23.3
The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows: (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue from External Customer [Line Items]        
Total revenue $ 7,958 $ 9,678 $ 29,286 $ 29,056
Solesence [Member]        
Revenue from External Customer [Line Items]        
Total revenue 5,016 5,932 17,839 18,591
Personal Care ingredients [Member]        
Revenue from External Customer [Line Items]        
Total revenue 2,364 2,903 8,944 8,589
Advanced Materials [Member]        
Revenue from External Customer [Line Items]        
Total revenue $ 578 $ 843 $ 2,503 $ 1,876
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Business Segmentation and Geographical Distribution (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Non-US [Member]        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenues $ 731 $ 495 $ 2,918 $ 955
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Accounting Standards Adopted During 2023 (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Sep. 30, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2016-13 [Member]  
Retained earnings $ 100,070 $ 102,535
Cumulative Effect, Period of Adoption, Adjustment [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Retained earnings $ 203  
XML 53 nanx-10q_093023_htm.xml IDEA: XBRL DOCUMENT 0000883107 2023-01-01 2023-09-30 0000883107 2023-11-14 0000883107 2023-09-30 0000883107 2022-12-31 0000883107 2023-07-01 2023-09-30 0000883107 2022-07-01 2022-09-30 0000883107 2022-01-01 2022-09-30 0000883107 us-gaap:ProductMember 2023-07-01 2023-09-30 0000883107 us-gaap:ProductMember 2022-07-01 2022-09-30 0000883107 us-gaap:ProductMember 2023-01-01 2023-09-30 0000883107 us-gaap:ProductMember 2022-01-01 2022-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2022-07-01 2022-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-09-30 0000883107 us-gaap:PreferredStockMember 2021-12-31 0000883107 us-gaap:CommonStockMember 2021-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000883107 us-gaap:RetainedEarningsMember 2021-12-31 0000883107 2021-12-31 0000883107 us-gaap:PreferredStockMember 2022-12-31 0000883107 us-gaap:CommonStockMember 2022-12-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000883107 us-gaap:RetainedEarningsMember 2022-12-31 0000883107 2023-06-30 0000883107 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000883107 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000883107 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000883107 2022-01-01 2022-03-31 0000883107 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000883107 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000883107 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000883107 2022-04-01 2022-06-30 0000883107 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000883107 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000883107 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000883107 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000883107 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000883107 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000883107 2023-01-01 2023-03-31 0000883107 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000883107 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000883107 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000883107 2023-04-01 2023-06-30 0000883107 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000883107 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000883107 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000883107 us-gaap:PreferredStockMember 2022-03-31 0000883107 us-gaap:CommonStockMember 2022-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000883107 us-gaap:RetainedEarningsMember 2022-03-31 0000883107 2022-03-31 0000883107 us-gaap:PreferredStockMember 2022-06-30 0000883107 us-gaap:CommonStockMember 2022-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000883107 us-gaap:RetainedEarningsMember 2022-06-30 0000883107 2022-06-30 0000883107 us-gaap:PreferredStockMember 2022-09-30 0000883107 us-gaap:CommonStockMember 2022-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000883107 us-gaap:RetainedEarningsMember 2022-09-30 0000883107 2022-09-30 0000883107 us-gaap:PreferredStockMember 2023-03-31 0000883107 us-gaap:CommonStockMember 2023-03-31 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000883107 us-gaap:RetainedEarningsMember 2023-03-31 0000883107 2023-03-31 0000883107 us-gaap:PreferredStockMember 2023-06-30 0000883107 us-gaap:CommonStockMember 2023-06-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000883107 us-gaap:RetainedEarningsMember 2023-06-30 0000883107 us-gaap:PreferredStockMember 2023-09-30 0000883107 us-gaap:CommonStockMember 2023-09-30 0000883107 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000883107 us-gaap:RetainedEarningsMember 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2023-07-01 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2022-07-01 2022-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-09-30 0000883107 us-gaap:ProductAndServiceOtherMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-09-30 0000883107 nanx:LibertyvilleBankAndTrustMember 2023-09-30 0000883107 nanx:LibertyvilleBankAndTrustMember 2022-12-31 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-09-30 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2022-12-31 0000883107 nanx:StrandlerLLCMember 2023-09-30 0000883107 nanx:StrandlerLLCMember 2022-12-31 0000883107 nanx:BeachcorpLLCOneMember 2023-09-30 0000883107 nanx:BeachcorpLLCOneMember 2022-12-31 0000883107 nanx:BeachcorpLLCTwoMember 2023-09-30 0000883107 nanx:BeachcorpLLCTwoMember 2022-12-31 0000883107 nanx:BeachcorpLLCThreeMember 2023-09-30 0000883107 nanx:BeachcorpLLCThreeMember 2022-12-31 0000883107 nanx:LibertyvilleBankAndTrustMember us-gaap:PrimeRateMember 2023-01-01 2023-09-30 0000883107 nanx:LibertyvilleBankAndTrustOneMember us-gaap:PrimeRateMember 2023-01-01 2023-09-30 0000883107 nanx:LibertyvilleBankAndTrustOneMember 2023-01-01 2023-09-30 0000883107 nanx:StrandlerLLCMember us-gaap:PrimeRateMember 2023-01-01 2023-09-30 0000883107 nanx:StrandlerLLCMember 2023-01-01 2023-09-30 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2022-01-26 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2022-01-28 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember us-gaap:RevolvingCreditFacilityMember nanx:BusinessLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:InventoryFacilityMember nanx:BusinessLoanAgreementMember 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:InventoryFacilityMember nanx:BusinessLoanAgreementMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:InventoryFacilityMember nanx:BusinessLoanAgreementMember us-gaap:PrimeRateMember 2022-01-27 2022-01-28 0000883107 nanx:BeachcorpLLCMember nanx:TIPromissoryNoteMember 2023-05-01 0000883107 nanx:BeachcorpLLCMember nanx:TIPromissoryNoteMember us-gaap:PrimeRateMember 2023-04-30 2023-05-01 0000883107 nanx:BeachcorpLLCMember nanx:TIPromissoryNoteMember 2023-04-30 2023-05-01 0000883107 nanx:StrandlerLLCMember nanx:BridgeNoteMember us-gaap:SubsequentEventMember 2023-11-13 0000883107 nanx:StrandlerLLCMember nanx:BridgeNoteMember us-gaap:SubsequentEventMember us-gaap:PrimeRateMember 2023-11-12 2023-11-13 0000883107 nanx:StrandlerLLCMember nanx:BridgeNoteMember us-gaap:SubsequentEventMember 2023-11-12 2023-11-13 0000883107 nanx:PromissoryNoteMember nanx:StrandlerLLCMember us-gaap:SubsequentEventMember 2023-11-12 2023-11-13 0000883107 nanx:StrandlerLLCMember nanx:InventoryFacilityMember us-gaap:SubsequentEventMember 2023-11-13 0000883107 nanx:StrandlerLLCMember nanx:InventoryFacilityMember us-gaap:SubsequentEventMember 2023-11-12 2023-11-13 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000883107 nanx:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000883107 nanx:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000883107 nanx:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0000883107 nanx:CustomersOneThroughThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000883107 nanx:CustomerOneMember 2023-09-30 0000883107 nanx:CustomerOneMember 2022-09-30 0000883107 nanx:CustomerTwoMember 2023-09-30 0000883107 nanx:CustomerTwoMember 2022-09-30 0000883107 nanx:CustomerThreeMember 2023-09-30 0000883107 nanx:CustomerThreeMember 2022-09-30 0000883107 us-gaap:SupplyCommitmentMember 2023-09-30 0000883107 us-gaap:NonUsMember 2023-07-01 2023-09-30 0000883107 us-gaap:NonUsMember 2023-01-01 2023-09-30 0000883107 us-gaap:NonUsMember 2022-07-01 2022-09-30 0000883107 us-gaap:NonUsMember 2022-01-01 2022-09-30 0000883107 nanx:SolesenceMember 2023-07-01 2023-09-30 0000883107 nanx:SolesenceMember 2022-07-01 2022-09-30 0000883107 nanx:SolesenceMember 2023-01-01 2023-09-30 0000883107 nanx:SolesenceMember 2022-01-01 2022-09-30 0000883107 nanx:PersonalCareIngredientsMember 2023-07-01 2023-09-30 0000883107 nanx:PersonalCareIngredientsMember 2022-07-01 2022-09-30 0000883107 nanx:PersonalCareIngredientsMember 2023-01-01 2023-09-30 0000883107 nanx:PersonalCareIngredientsMember 2022-01-01 2022-09-30 0000883107 nanx:AdvancedMaterialsMember 2023-07-01 2023-09-30 0000883107 nanx:AdvancedMaterialsMember 2022-07-01 2022-09-30 0000883107 nanx:AdvancedMaterialsMember 2023-01-01 2023-09-30 0000883107 nanx:AdvancedMaterialsMember 2022-01-01 2022-09-30 0000883107 2022-01-01 2022-12-31 0000883107 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2022-12-31 iso4217:USD shares iso4217:USD shares pure 0000883107 false --12-31 2023 Q3 http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member 10-Q true 2023-09-30 false 000-22333 Nanophase Technologies Corporation DE 36-3687863 1319 Marquette Drive Romeoville IL 60446 (630) 771-6708 Yes Yes Non-accelerated Filer true false false 49627254 1188000 2186000 270000 139000 3199000 4734000 10123000 8839000 1040000 866000 15550000 16625000 8607000 7949000 8187000 8978000 3000 6000 32347000 33558000 6338000 7282000 6270000 6363000 1303000 2619000 2167000 1130000 1023000 17660000 16835000 9475000 9823000 1000000 1000000 45000 21000 236000 230000 10756000 11074000 0.01 0.01 24088 24088 0 0 0 0 0.01 0.01 60000000 60000000 49627254 49627254 49320680 49320680 496000 493000 105970000 105226000 -102535000 -100070000 3931000 5649000 32347000 33558000 7746000 9673000 28925000 28515000 212000 5000 361000 541000 7958000 9678000 29286000 29056000 6428000 7185000 21932000 21659000 1530000 2493000 7354000 7397000 1057000 848000 3052000 2310000 1695000 2279000 5951000 5493000 -1222000 -634000 -1649000 -406000 214000 116000 613000 232000 -1436000 -750000 -2262000 -638000 -1436000 -750000 -2262000 -638000 -0.03 -0.02 -0.05 -0.01 49598581 49174673 49532395 49068709 -0.03 -0.02 -0.05 -0.01 49598581 49174673 49532395 49068709 48893573 489000 104423000 -97447000 7465000 133168 1000 72000 73000 148000 148000 62000 62000 49026741 490000 104643000 -97385000 7748000 110289 1000 33000 34000 155000 155000 50000 50000 49137030 491000 104831000 -97335000 7987000 79150 1000 31000 32000 150000 150000 -750000 -750000 49216180 492000 105012000 -98085000 7419000 49320680 493000 105226000 -100070000 5649000 199891 2000 99000 101000 209000 209000 203000 203000 -1159000 -1159000 49520571 495000 105534000 -101432000 4597000 68633 1000 33000 34000 195000 195000 333000 333000 49589204 496000 105762000 -101099000 5159000 5159000 38050 19000 19000 189000 189000 -1436000 -1436000 -1436000 49627254 496000 105970000 -102535000 3931000 3931000 -2262000 -638000 524000 413000 593000 453000 -1333000 1431000 1284000 3501000 174000 69000 -422000 1398000 113000 401000 476000 -75000 1747000 652000 644000 -2397000 852000 1798000 -852000 -1798000 100000 23304000 25075000 24248000 21068000 1338000 1338000 154000 141000 -790000 4048000 -998000 -147000 2186000 657000 1188000 510000 553000 232000 329000 432000 73000 36000 <p id="xdx_80F_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zutZNcraEXzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(1) <span id="xdx_82D_zhCjboXpsOa8">Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited consolidated condensed interim financial statements of Nanophase Technologies Corporation (“Nanophase”, “Company”, “we”, “our”, or “us”) reflect all adjustments (consisting of normal recurring adjustments) which, in the opinion of management, are necessary for a fair statement of our financial position and operating results for the interim periods presented. All statements include the results from both Nanophase and our wholly-owned subsidiary, Solésence, LLC (“Solésence,” or our “Solésence® subsidiary”). Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission.</p> <p id="xdx_80E_eus-gaap--NatureOfOperations_zQZnbQ0j9LTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(2) <span id="xdx_826_znDFRsGA3gf5">Description of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nanophase Technologies Corporation (“Nanophase,” “Company,” “we,” “our,” or “us”) is a science-driven company which, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence beauty science subsidiary”), is focused in various beauty- and life-science markets. Using consumer health as our end-goal and science and innovation to guide the path, skin health and medical diagnostics combined currently make up the great majority of our business and drive our forward growth strategy. We offer engineered materials, formulation development and commercial manufacturing through an integrated family of technologies. Our expertise in materials engineering allows us to effectively coat and disperse particles on a nano and “non-nano” scale for use in a variety of skin health markets, including for use in sunscreens as active ingredients and as fully developed prestige skin care and cosmetics products, marketed and sold through our Solésence beauty science subsidiary. In terms of our life sciences focus, we have seen demand significantly decrease for our medical diagnostics ingredients. Additionally, we continue to sell products in legacy markets, including architectural coatings, industrial coating applications, abrasion-resistant additives, plastics additives, and surface finishing technologies (polishing) applications, all of which, along with medical diagnostics, fall into the advanced materials product category.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We target markets, primarily related to skin health products and ingredients, as well as diagnostic life sciences ingredients where we believe our materials and products offer practical and competitive minerals-based solutions. We traditionally work closely with current customers in these target markets to identify their material and performance requirements. We market our materials to various end-use applications manufacturers, and our Solésence® products to cosmetics and skin care brands.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently developed technologies have made certain new products possible and opened potential new markets. During 2015 we were granted a patent on a new type of particle surface treatment (coating) — now called Active Stress Defense ™ Technology — which became the cornerstone of our new product development in personal care, with first revenue recognized during 2016. Active Stress Defense™ now refers to a suite of three proprietary technologies — Original Active Stress Defense™, Kleair™, and Bloom™ — all three of which either utilize a unique and proprietary, mineral-based technology or work synergistically with one of our unique and proprietary, mineral-based technologies to improve performance and/or aesthetics. Our ongoing innovation efforts include new IP in areas that advance environmental protection, align with market needs, and complement our existing technologies. Through the creation of our Solésence beauty science subsidiary, we utilize our technology suite to manufacture and sell fully developed solutions to targeted customers in the skin care industry, typically in prestige skin care and cosmetics markets, in addition to the ingredients we have traditionally sold in the personal care area. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our primary strategic focus has been the North American market, we currently sell materials to customers overseas and have been working to expand our reach within foreign markets. Our common stock trades on the OTCQB marketplace under the symbol NANX.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While product sales comprise the majority of our revenue, we also recognize revenue from other sources from time to time. These activities are not expected to drive the long-term growth of the business. For this reason, we classify such revenue as “other revenue” in our Consolidated Statements of Operations, as it does not represent revenue directly from the sale of our products. </p> <p id="xdx_80E_eus-gaap--RevenueFromContractWithCustomerTextBlock_zsN42rGjzEei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <b>(3) <span id="xdx_82F_z9ohPxtPdkn3">Revenues</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration we expect to receive in exchange for those goods. When our ingredients and finished products are shipped, with control being transferred at the shipping point almost universally, is the point in time at which we recognize the related revenue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling, general and administrative expenses. Customers’ deposits, deferred revenue and other receipts are deferred and recognized when the revenue is realized and earned. Cash payments to customers are classified as reductions of revenue in our statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_893_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zH7jtwpCKbW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <span id="xdx_8B8_zDDYr7Saqbmg">Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_481_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLoss_iI_pn3n3_z4ORlBrKTTwi" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_911_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLoss_zy4erk6kiXd4">Accounts Receivable</span></b></span></td> <td> </td> <td> </td> <td colspan="2" id="xdx_482_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_zPZH0UqrFHqk" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_914_eus-gaap--ContractWithCustomerAssetNet_zkjJn748zGO6">Contract Assets</span></b></span></td> <td> </td> <td> </td> <td colspan="2" id="xdx_481_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_zNeRyhbCQ35i" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_912_eus-gaap--ContractWithCustomerLiability_z92LT1dYDAei">Contract Liabilities</span></b></span></td> <td> </td></tr> <tr id="xdx_417_20211231_zO65687iKFn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%"><span style="font-size: 10pt">Balance, December 31, 2021</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 10%; text-align: right"><span style="font-size: 10pt">3,937</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 10%; text-align: right"><span style="font-size: 10pt">179</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 10%; text-align: right"><span style="font-size: 10pt">1,444</span></td> <td style="width: 1%"> </td></tr> <tr id="xdx_414_20221231_zXPvpJzs73Y7" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Balance, December 31, 2022</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">4,734</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0586">—</span></span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">2,188</span></td> <td> </td></tr> <tr id="xdx_418_20230930_zY9YbjDCmK5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Balance, September 30, 2023</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">3,199</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0589">—</span></span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">2,664</span></td> <td> </td></tr> </table> <p id="xdx_8AE_zcg67mCJ5E0f" style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue recognized in the reporting period that was included in the contract liability balance at the beginning of the period was $<span id="xdx_90F_ecustom--ContractWithCustomerLiabilityRevenueRecognizedNet_pn3n3_c20230701__20230930_zkmbw8K50XAa" title="Revenue recognized included in contract liability balance at beginning of period">414</span> and $<span id="xdx_905_ecustom--ContractWithCustomerLiabilityRevenueRecognizedNet_pn3n3_c20220701__20220930_zPWSFwqEteUg" title="Revenue recognized included in contract liability balance at beginning of period">295</span>, for the three months ended September 30, 2023 and 2022, respectively, and $<span id="xdx_90A_ecustom--ContractWithCustomerLiabilityRevenueRecognizedNet_pn3n3_c20230101__20230930_zkAV84TNM6nh" title="Revenue recognized included in contract liability balance at beginning of period">2,438</span> and $<span id="xdx_908_ecustom--ContractWithCustomerLiabilityRevenueRecognizedNet_pn3n3_c20220101__20220930_zkugSQmOQQSg" title="Revenue recognized included in contract liability balance at beginning of period">507</span> for the nine months ended September 30, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other revenue may include revenue from technology license fees and paid development projects. Technology license fees and paid development projects are recognized over time when the obligations under the agreed upon contractual arrangements are performed on our part.  Other revenue recognized over time was <span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230701__20230930__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zWIdKbCousai" title="Revenue">$212</span> and <span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220701__20220930__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zhjEbmexbn5i" title="Revenue">$5</span>, for the three months ended September 30, 2023 and 2022, respectively, and <span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20230101__20230930__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zepDfnr2UXIj" title="Revenue">$361</span> and <span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zGcK4sNmOlEc" title="Revenue">$191</span> for the nine months ended September 30, 2023 and 2022, respectively. Other revenue recognized at a point in time was <span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20220101__20220930__srt--ProductOrServiceAxis__us-gaap--ProductAndServiceOtherMember__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zE6zMWFm8gjc" title="Revenue">$350</span> for the nine months September 30, 2022.</p> <p id="xdx_893_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zH7jtwpCKbW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <span id="xdx_8B8_zDDYr7Saqbmg">Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td> </td> <td colspan="2" id="xdx_481_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLoss_iI_pn3n3_z4ORlBrKTTwi" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_911_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLoss_zy4erk6kiXd4">Accounts Receivable</span></b></span></td> <td> </td> <td> </td> <td colspan="2" id="xdx_482_eus-gaap--ContractWithCustomerAssetNet_iI_pn3n3_zPZH0UqrFHqk" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_914_eus-gaap--ContractWithCustomerAssetNet_zkjJn748zGO6">Contract Assets</span></b></span></td> <td> </td> <td> </td> <td colspan="2" id="xdx_481_eus-gaap--ContractWithCustomerLiability_iI_pn3n3_zNeRyhbCQ35i" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_912_eus-gaap--ContractWithCustomerLiability_z92LT1dYDAei">Contract Liabilities</span></b></span></td> <td> </td></tr> <tr id="xdx_417_20211231_zO65687iKFn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%"><span style="font-size: 10pt">Balance, December 31, 2021</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 10%; text-align: right"><span style="font-size: 10pt">3,937</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 10%; text-align: right"><span style="font-size: 10pt">179</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 10%; text-align: right"><span style="font-size: 10pt">1,444</span></td> <td style="width: 1%"> </td></tr> <tr id="xdx_414_20221231_zXPvpJzs73Y7" style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 10pt">Balance, December 31, 2022</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">4,734</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0586">—</span></span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">2,188</span></td> <td> </td></tr> <tr id="xdx_418_20230930_zY9YbjDCmK5i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Balance, September 30, 2023</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">3,199</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0589">—</span></span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-size: 10pt">2,664</span></td> <td> </td></tr> </table> 3937000 179000 1444000 4734000 2188000 3199000 2664000 414000 295000 2438000 507000 212000 5000 361000 191000 350000 <p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_ztUlV3NALbvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(4) <span id="xdx_828_zha9bObTY0u4">Earnings Per Share</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Options to purchase approximately <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930_zwXdgGCGXo7d" title="Anti-dilutive shares">853,000</span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930_z1sDVSQQLrSb">728,000</span> shares of common stock that were outstanding as of September 30, 2023 were not included in the computation of diluted earnings per share for the three and nine-months ended September 30, 2023. The inclusion of these shares for the three and nine months ended September 30, 2023 would have resulted in an anti-dilutive effect and were thus omitted from disclosure. Options to purchase approximately <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930_zMNHoGjYwxYe">1,871,000</span> and <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930_ziRaaOtCy3Gl">1,901,000</span> shares of common stock that were outstanding as of September 30, 2022 were not included in the computation of earnings per share for the three months and nine months ended September 30, 2022, respectively, as inclusion would have had an anti-dilutive impact due to losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zAoMXoR9b3h7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B5_ziP9YUcAQWS9">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_495_20230701__20230930_zM7cNopZAWCi" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49B_20220701__20220930_zb2OmDveLJvj" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20230101__20230930_zoSCqEfCQs74" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20220101__20220930_zccHZF5B7vig" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zAZtRpXcodL5" style="vertical-align: bottom"> <td style="text-decoration: underline; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Numerator: (in Thousands)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_zzZX09MVoZLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(1,436</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(750</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(2,262</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(638</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zX6jGD5Qd9p2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; padding-left: 0.125in; text-indent: -0.125in">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pp0p0_maCzc9h_zLtjx8Cye1h8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Weighted average number of basic shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,598,581</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,174,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,532,395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,068,709</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pp0p0_maCzc9h_zxHA5ySPPzH6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted average additional shares assuming conversion of in-the-money stock options to common shares and assumed repurchase of common shares by the Company</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0641">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pp0p0_mtCzc9h_zIiwskKq0Wg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,598,581</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,174,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,532,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,068,709</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareBasicAbstract_iB_zKiBjDnpkdi7" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-left: 0.125in; text-indent: -0.125in">Basic earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_i01_pp2p0_uUSDPShares_zsUKMIm6dXJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Net loss per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.03</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDilutedAbstract_iB_zmQLE5eYdoGi" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-left: 0.125in; text-indent: -0.125in">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_i01_pp2p0_uUSDPShares_zFhPD33Zskii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Net loss per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.03</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A7_z1HLcAbRxsA2" style="margin-top: 0; margin-bottom: 0"> </p> 853000 728000 1871000 1901000 <p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zAoMXoR9b3h7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B5_ziP9YUcAQWS9">Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_495_20230701__20230930_zM7cNopZAWCi" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49B_20220701__20220930_zb2OmDveLJvj" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49C_20230101__20230930_zoSCqEfCQs74" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49E_20220101__20220930_zccHZF5B7vig" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zAZtRpXcodL5" style="vertical-align: bottom"> <td style="text-decoration: underline; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Numerator: (in Thousands)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_zzZX09MVoZLb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(1,436</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(750</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(2,262</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(638</td><td style="width: 1%; padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zX6jGD5Qd9p2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; padding-left: 0.125in; text-indent: -0.125in">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pp0p0_maCzc9h_zLtjx8Cye1h8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Weighted average number of basic shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,598,581</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,174,673</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,532,395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,068,709</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_pp0p0_maCzc9h_zxHA5ySPPzH6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted average additional shares assuming conversion of in-the-money stock options to common shares and assumed repurchase of common shares by the Company</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0641">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01T_pp0p0_mtCzc9h_zIiwskKq0Wg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-indent: -0.125in">Weighted average number of diluted common shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,598,581</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,174,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,532,395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49,068,709</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareBasicAbstract_iB_zKiBjDnpkdi7" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-left: 0.125in; text-indent: -0.125in">Basic earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareBasic_i01_pp2p0_uUSDPShares_zsUKMIm6dXJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Net loss per share – basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.03</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareDilutedAbstract_iB_zmQLE5eYdoGi" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-left: 0.125in; text-indent: -0.125in">Diluted earnings per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareDiluted_i01_pp2p0_uUSDPShares_zFhPD33Zskii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Net loss per share – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.03</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.05</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -1436000 -750000 -2262000 -638000 49598581 49174673 49532395 49068709 49598581 49174673 49532395 49068709 -0.03 -0.02 -0.05 -0.01 -0.03 -0.02 -0.05 -0.01 <p id="xdx_802_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zXSHGWFrtPC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(5) <span id="xdx_82C_zy6oZbJ9a4ba">Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We follow ASC Topic 820, <i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The fair value framework requires the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our financial instruments include cash, any cash equivalents, accounts receivable, accounts payable and accrued expenses, along with any short-term and long-term borrowings as described in Note 6. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable and accrued expenses are reasonable estimates of their fair value due to the short-term nature of these accounts. The fair value of short-term and long-term debt approximates carrying value based on comparison of terms to similar debt offering in the marketplace.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no financial instruments adjusted to fair value on September 30, 2023 and December 31, 2022.</p> <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_zhdDGF0PSGQe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(6) <span id="xdx_82F_z4skUHcVQBU2">Notes and Lines of Credit</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_896_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_ziWPWB76ffaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <span id="xdx_8BB_zgx0lepXsLG8">Notes and lines of credit consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Rate</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Borrowing Capacity</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding Borrowed Balance</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Borrowing Capacity</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding Borrowed Balance</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left"><span style="font-size: 10pt">Libertyville Bank &amp; Trust <sup>(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_900_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zeGbOZSlQRw4" title="Line of Credit Facility, Commitment Fee Percentage">9.50</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_z4xmWnzkr6l4" style="width: 10%; text-align: right" title="Available">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zd8FkcLLJDs9" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zwB1IPM6FnYf" style="width: 10%; text-align: right" title="Available"><span style="-sec-ix-hidden: xdx2ixbrl0680">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zfK3y74Orwkh" style="width: 10%; text-align: right" title="Outsanding balance"><span style="-sec-ix-hidden: xdx2ixbrl0682">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Libertyville Bank &amp; Trust <sup>(2)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zqWDm5igDai9">9.50</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zwojT0WPsZ7g" style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zskcschEXCl7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zYTzGb5SswM" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zPYS0kuZGc67" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0687">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Strandler, LLC<sup>(3)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_z8WHrga2gVf">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_zKtOmmWr67gg" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_zYDjk7R1PKpc" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_zxUX34WubXc9" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_zdYQytJd5lE5" style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Beachcorp, LLC <sup>(4)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zkoCmIr1CUxl">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zWTiZLudimX8" style="text-align: right">3,229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zC9n1dDANEKl" style="text-align: right">2,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zaqFoQDymq6i" style="text-align: right">4,392</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zEW2Jfw3JZBh" style="text-align: right">4,282</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Beachcorp, LLC <sup>(5)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_zG1cuiauia1j">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_zM2b5PJPat2i" style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_zqt0eR0VKK4l" style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_zcZoaQc6yu45" style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_z20EGjddq4t8" style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Beachcorp, LLC <sup>(6)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_ze1joZLrf9c" title="Rate">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_zfJbR1C9Wvpi" style="text-align: right" title="Total Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0706">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_zac0yV3kfTj4" style="text-align: right" title="Outstanding Borrowed Balance"><span style="-sec-ix-hidden: xdx2ixbrl0708">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_zvLa7SOj1Vp6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_zvhI3i7xlJa" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0C_zWfJjFRRpt55" style="width: 0.25in">1)</td><td id="xdx_F15_zwmnTjLDksUe" style="text-align: justify">Since July 2014, we have maintained a bank-issued letter of credit for up to <span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zCUQnsGoVx5k">$30</span> in borrowings, with interest at the prime rate plus <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zT3h5Xcox3f4" title="Basis spread variable interest rate">1</span>%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0E_zmGr0TfDpEX7" style="width: 0.25in">2)</td><td id="xdx_F17_zh5Tn8g2EHZ5" style="text-align: justify">The Company maintains a credit agreement with Libertyville to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus <span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z0DtQgqoY9G6" title="Basis spread variable interest rate">1</span>%. This credit agreement has a maturity of <span id="xdx_905_eus-gaap--LineOfCreditFacilityExpirationDate1_pid_dp_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zxlpbpDKrqQg">December 22, 2023</span>. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0B_zTajFWIp8Xzk" style="width: 0.25in">3)</td><td id="xdx_F16_zfZ8Nf50kKq5" style="text-align: justify">On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zmBheo6nV1Q7" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and it matures on <span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationDate1_pid_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zTybwNHtMiOd">March 31, 2024</span>. Strandler, LLC is also an affiliate of Bradford T. Whitmore.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F08_z3592fU7gzef" style="width: 0.25in">4)</td><td id="xdx_F12_ziGAFONg6lj" style="text-align: justify">On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&amp;R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from <span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220126__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zcFnpWohMuE6">$6,000</span> to <span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zsjlj5Fe8xmg">$8,000</span>, reduce the interest rate to the prime rate plus <span id="xdx_906_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zXM2bPeSRF4" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and extend the maturity of the A/R Revolver Facility to <span id="xdx_903_eus-gaap--LineOfCreditFacilityExpirationDate1_pid_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zSyCENYXsYk4">March 31, 2024</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F09_z7mfO4kIajgh" style="width: 0.25in">5)</td><td id="xdx_F1B_z9Tx9j2TQUKl" style="text-align: justify">On January 28, 2022 the Company entered into the A&amp;R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is <span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zkbRJEOYKV83">$4,000</span>, with a borrowing base consisting of up to <span id="xdx_90A_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1Nx4sWYMH4j">50</span>% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus <span id="xdx_907_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z1RGecgCBm9">0.75</span>%, and it matures on <span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zFudWb0yRJ98">March 31, 2024</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0F_zAz4YK7cJDu7" style="width: 0.25in">6)</td><td id="xdx_F1C_z3TcmxX6HKc7" style="text-align: justify">On May 1, 2023 the Company entered into a non-revolving promissory note (“TI Promissory Note”) with Beachcorp, LLC. The maximum borrowing amount under the TI Promissory Note is <span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20230501__us-gaap--CreditFacilityAxis__custom--TIPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1DuoYtQmfba">$1,750</span>. The interest rate for the TI Promissory Note is at the prime rate plus <span id="xdx_909_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230430__20230501__us-gaap--CreditFacilityAxis__custom--TIPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zcWt8oQUi7Re">0.75</span>%, and it matures on <span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationDate1_c20230430__20230501__us-gaap--CreditFacilityAxis__custom--TIPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zCVCmT3BEI5e">September 30, 2023</span>. This loan is for work being done at the Bolingbrook facility which is expected to be reimbursed from the landlord as part of the lease agreement. On July 21, 2023, the TI Promissory Note and accrued interest was repaid in full after reimbursement from the landlord for approved tenant improvements.</td></tr></table> <p id="xdx_8AE_z6QS5KuRInRk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beachcorp, LLC and Strandler, LLC are affiliates of Mr. Bradford T. Whitmore, who beneficially owns a majority of the Company’s common stock and is the brother of Ms. R. Janet Whitmore, a director of the Company and the chair of the Company’s board of directors. The A/R Revolver Facility, the Inventory Facility and the New Term Loan are all secured by all the unencumbered assets of the Company and subordinated to the Company’s credit facility with Libertyville Bank &amp; Trust.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 13, 2023, as part of a comprehensive financing transaction, the Company entered into a non-revolving promissory note (Bridge Note) with Strandler, LLC. The maximum borrowing amount under the Bridge Note is <span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZugxvZIE6ej">$2,000</span>. The interest rate for the Bridge Loan is at the prime rate plus <span id="xdx_909_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8cfEmz0FIkb">0.75</span>%, and it matures on the earlier of <span id="xdx_909_eus-gaap--LineOfCreditFacilityExpirationDate1_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--BridgeNoteMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkfhVuNvhzsc">May 13, 2024</span> or the closing of the Rights Offering. The Company is required to repay the Bridge Note upon completion of a planned Rights Offering, or at maturity, whichever comes first. As part of this financing transaction, the maturity dates of the New Term Loan Agreement, A/R Loan Agreement and Inventory Facility were extended to <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20231112__20231113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StrandlerLLCMember_zT8M7aqG4VTi" title="Debt Instrument, Face Amount">March 31, 2025</span>. Additionally, the maximum borrowing amount under the Inventory Facility was increased to <span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20231113__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlNUm3zt1VHg" title="Line of Credit Facility, Maximum Borrowing Capacity">$5,200</span>, and the borrowing base was increased to up to <span id="xdx_90F_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20231112__20231113__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--StrandlerLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2PKZVcdopNl">55</span>% of the value of qualified inventory of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zR6ucOzVTOd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BC_z4zwJXsZxC41">Related party interest summary:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20230701__20230930_zJr0rhzYf491" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_499_20220701__20220930_zsBXTFSSfPJc" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_496_20230101__20230930_zEdI5sqM0NFc" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20220101__20220930_zvCLnEAx2YKk" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--InterestExpenseOther_pn3n3_zxei8mMlEAc4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">199</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">560</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">218</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccruedInterestExpenseRelatedParties_zaF9jzqkaF25" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued interest expense, related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zyNGlpreCV25" style="margin: 0"> </p> <p id="xdx_896_eus-gaap--ScheduleOfLineOfCreditFacilitiesTextBlock_ziWPWB76ffaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <span id="xdx_8BB_zgx0lepXsLG8">Notes and lines of credit consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Rate</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Borrowing Capacity</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding Borrowed Balance</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Borrowing Capacity</td><td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Outstanding Borrowed Balance</td><td style="font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left"><span style="font-size: 10pt">Libertyville Bank &amp; Trust <sup>(1)</sup></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_900_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zeGbOZSlQRw4" title="Line of Credit Facility, Commitment Fee Percentage">9.50</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_z4xmWnzkr6l4" style="width: 10%; text-align: right" title="Available">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zd8FkcLLJDs9" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zwB1IPM6FnYf" style="width: 10%; text-align: right" title="Available"><span style="-sec-ix-hidden: xdx2ixbrl0680">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_fKDEp_zfK3y74Orwkh" style="width: 10%; text-align: right" title="Outsanding balance"><span style="-sec-ix-hidden: xdx2ixbrl0682">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Libertyville Bank &amp; Trust <sup>(2)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zqWDm5igDai9">9.50</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zwojT0WPsZ7g" style="text-align: right">500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zskcschEXCl7" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zYTzGb5SswM" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_fKDIp_zPYS0kuZGc67" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0687">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt">Strandler, LLC<sup>(3)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_z8WHrga2gVf">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_zKtOmmWr67gg" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_zYDjk7R1PKpc" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_zxUX34WubXc9" style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_fKDMp_zdYQytJd5lE5" style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Beachcorp, LLC <sup>(4)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zkoCmIr1CUxl">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zWTiZLudimX8" style="text-align: right">3,229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zC9n1dDANEKl" style="text-align: right">2,338</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zaqFoQDymq6i" style="text-align: right">4,392</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCOneMember_fKDQp_zEW2Jfw3JZBh" style="text-align: right">4,282</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 10pt">Beachcorp, LLC <sup>(5)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_zG1cuiauia1j">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_zM2b5PJPat2i" style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_zqt0eR0VKK4l" style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_zcZoaQc6yu45" style="text-align: right">4,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCTwoMember_fKDUp_z20EGjddq4t8" style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 10pt">Beachcorp, LLC <sup>(6)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_ze1joZLrf9c" title="Rate">9.25</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_zfJbR1C9Wvpi" style="text-align: right" title="Total Borrowing Capacity"><span style="-sec-ix-hidden: xdx2ixbrl0706">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LineOfCredit_iI_pn3n3_c20230930__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_zac0yV3kfTj4" style="text-align: right" title="Outstanding Borrowed Balance"><span style="-sec-ix-hidden: xdx2ixbrl0708">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_zvLa7SOj1Vp6" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--LineOfCredit_iI_pn3n3_c20221231__us-gaap--CreditFacilityAxis__custom--BeachcorpLLCThreeMember_fKDYp_zvhI3i7xlJa" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">—</span></td><td style="text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0C_zWfJjFRRpt55" style="width: 0.25in">1)</td><td id="xdx_F15_zwmnTjLDksUe" style="text-align: justify">Since July 2014, we have maintained a bank-issued letter of credit for up to <span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember_zCUQnsGoVx5k">$30</span> in borrowings, with interest at the prime rate plus <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zT3h5Xcox3f4" title="Basis spread variable interest rate">1</span>%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0E_zmGr0TfDpEX7" style="width: 0.25in">2)</td><td id="xdx_F17_zh5Tn8g2EHZ5" style="text-align: justify">The Company maintains a credit agreement with Libertyville to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus <span id="xdx_904_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z0DtQgqoY9G6" title="Basis spread variable interest rate">1</span>%. This credit agreement has a maturity of <span id="xdx_905_eus-gaap--LineOfCreditFacilityExpirationDate1_pid_dp_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--LibertyvilleBankAndTrustOneMember_zxlpbpDKrqQg">December 22, 2023</span>. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0B_zTajFWIp8Xzk" style="width: 0.25in">3)</td><td id="xdx_F16_zfZ8Nf50kKq5" style="text-align: justify">On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus <span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zmBheo6nV1Q7" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and it matures on <span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationDate1_pid_c20230101__20230930__us-gaap--CreditFacilityAxis__custom--StrandlerLLCMember_zTybwNHtMiOd">March 31, 2024</span>. Strandler, LLC is also an affiliate of Bradford T. Whitmore.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F08_z3592fU7gzef" style="width: 0.25in">4)</td><td id="xdx_F12_ziGAFONg6lj" style="text-align: justify">On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&amp;R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from <span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220126__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zcFnpWohMuE6">$6,000</span> to <span id="xdx_908_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zsjlj5Fe8xmg">$8,000</span>, reduce the interest rate to the prime rate plus <span id="xdx_906_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zXM2bPeSRF4" title="Debt Instrument, Basis Spread on Variable Rate">0.75</span>%, and extend the maturity of the A/R Revolver Facility to <span id="xdx_903_eus-gaap--LineOfCreditFacilityExpirationDate1_pid_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zSyCENYXsYk4">March 31, 2024</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F09_z7mfO4kIajgh" style="width: 0.25in">5)</td><td id="xdx_F1B_z9Tx9j2TQUKl" style="text-align: justify">On January 28, 2022 the Company entered into the A&amp;R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is <span id="xdx_902_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zkbRJEOYKV83">$4,000</span>, with a borrowing base consisting of up to <span id="xdx_90A_ecustom--LineOfCreditPercentageOfEligibleInventory_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1Nx4sWYMH4j">50</span>% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus <span id="xdx_907_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_z1RGecgCBm9">0.75</span>%, and it matures on <span id="xdx_906_eus-gaap--LineOfCreditFacilityExpirationDate1_dd_c20220127__20220128__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember__us-gaap--CreditFacilityAxis__custom--InventoryFacilityMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zFudWb0yRJ98">March 31, 2024</span>.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td id="xdx_F0F_zAz4YK7cJDu7" style="width: 0.25in">6)</td><td id="xdx_F1C_z3TcmxX6HKc7" style="text-align: justify">On May 1, 2023 the Company entered into a non-revolving promissory note (“TI Promissory Note”) with Beachcorp, LLC. The maximum borrowing amount under the TI Promissory Note is <span id="xdx_90F_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20230501__us-gaap--CreditFacilityAxis__custom--TIPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_z1DuoYtQmfba">$1,750</span>. The interest rate for the TI Promissory Note is at the prime rate plus <span id="xdx_909_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230430__20230501__us-gaap--CreditFacilityAxis__custom--TIPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zcWt8oQUi7Re">0.75</span>%, and it matures on <span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationDate1_c20230430__20230501__us-gaap--CreditFacilityAxis__custom--TIPromissoryNoteMember__srt--CounterpartyNameAxis__custom--BeachcorpLLCMember_zCVCmT3BEI5e">September 30, 2023</span>. This loan is for work being done at the Bolingbrook facility which is expected to be reimbursed from the landlord as part of the lease agreement. On July 21, 2023, the TI Promissory Note and accrued interest was repaid in full after reimbursement from the landlord for approved tenant improvements.</td></tr></table> 0.0950 30000 0.0950 500000 0.0925 1000000 1000000 1000000 1000000 0.0925 3229000 2338000 4392000 4282000 0.0925 4000000 4000000 4000000 3000000 0.0925 30000 0.01 0.01 2023-12-22 0.0075 2024-03-31 6000000 8000000 0.0075 2024-03-31 4000000 0.50 0.0075 2024-03-31 1750000 0.0075 2023-09-30 2000000 0.0075 2024-05-13 2025-03-31 5200000 0.55 <p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zR6ucOzVTOd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BC_z4zwJXsZxC41">Related party interest summary:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20230701__20230930_zJr0rhzYf491" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_499_20220701__20220930_zsBXTFSSfPJc" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_496_20230101__20230930_zEdI5sqM0NFc" style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td style="font-weight: bold; text-align: center"> </td> <td id="xdx_49D_20220101__20220930_zvCLnEAx2YKk" style="font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--InterestExpenseOther_pn3n3_zxei8mMlEAc4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Interest expense, related parties</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">199</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">560</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">218</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccruedInterestExpenseRelatedParties_zaF9jzqkaF25" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued interest expense, related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39</td><td style="text-align: left"> </td></tr> </table> 199000 111000 560000 218000 57000 39000 57000 39000 <p id="xdx_806_eus-gaap--InventoryDisclosureTextBlock_zUVQtwvzr3sf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b>(7) <span id="xdx_827_zFLSsvqQu8Kj">Inventories</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><b> </b></p> <p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zZsdwZh21XE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_z1TEaQOdbiz2">Inventories consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20230930_zB2aJsbxPWqg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20221231_zteBjQH6mSQl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_maCzDsw_zhooy5NARZu9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,013</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,797</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_maCzDsw_zwmjo3O7efXd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,110</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,041</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNet_iTI_mtCzDsw_zlh2MWguFvi4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total inventories, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,123</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,839</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zKEGrcTd04We" style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company had reserves for excess and obsolete inventory of <span id="xdx_90A_eus-gaap--InventoryValuationReserves_iI_pn3n3_c20230930_zrFWp3QJ5sN6" title="Reserve against reported inventory">$670</span> and <span id="xdx_902_eus-gaap--InventoryValuationReserves_iI_pn3n3_c20221231_zeUeOohUXk59" title="Reserve against reported inventory">$500</span> as of September 30, 2023 and December 31, 2022, respectively.</p> <p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zZsdwZh21XE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_z1TEaQOdbiz2">Inventories consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20230930_zB2aJsbxPWqg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20221231_zteBjQH6mSQl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_maCzDsw_zhooy5NARZu9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,013</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,797</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_maCzDsw_zwmjo3O7efXd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,110</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,041</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryNet_iTI_mtCzDsw_zlh2MWguFvi4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total inventories, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">10,123</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">8,839</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 7013000 6797000 3110000 2041000 10123000 8839000 670000 500000 <p id="xdx_80E_eus-gaap--ConcentrationRiskDisclosureTextBlock_z2P6AZTvAihf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(8) <span id="xdx_82E_ziUt8mlBawG5">Significant Customers and Contingencies</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_89B_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zXVj4CwCp1me" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zaQcLsawTZSd">The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended <br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended <br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 41%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zVRlHuoWj5z5" title="Revenue from customers">30</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zVjxDMif7Bnb" title="Revenue from customers">30</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvk195x1qo6k" title="Revenue from customers">31</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zSf3WR9vlDR3" title="Revenue from customers">30</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zpn25AygHyq9" title="Revenue from customers">18</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zEMYZiEoWpB7" title="Revenue from customers">18</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z6XRRZyL11ql" title="Revenue from customers">14</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRa3P5AN7Dei" title="Revenue from customers">17</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">Solésence®</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z0YCPbW4jXql" title="Revenue from customers">21</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zkg2mjEJvcyd" title="Revenue from customers">19</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1OEhEvufUdl" title="Revenue from customers">14</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1tvQzpiLGjc" title="Revenue from customers">16</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zPWO7sAL6A6e" title="Revenue from customers">69</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zIIJm5wlX0R" title="Revenue from customers">67</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zuWqbSyJP3c7" title="Revenue from customers">59</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zkKifMjbFQg3" title="Revenue from customers">63</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A0_zHqlIRZ4gu5a" style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_89E_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zbKrHFvydRI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zohx0Am7Js35">Accounts receivable balances for these three customers were approximately:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2023</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 7%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 65%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20230930__srt--MajorCustomersAxis__custom--CustomerOneMember_zjwfzwQcXEBd" title="Total">320</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_900_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20220930__srt--MajorCustomersAxis__custom--CustomerOneMember_zPeSYHDcQtPb" title="Total">943</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember_zrSW6St55Gp9" title="Total">545</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20220930__srt--MajorCustomersAxis__custom--CustomerTwoMember_zlZT1YRCDmGc" title="Total">439</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">Solésence®</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember_zV7Vil8ectvf" title="Total">1,047</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20220930__srt--MajorCustomersAxis__custom--CustomerThreeMember_zxPtwGDbt3U3" title="Total">1,717</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20230930_zrC4QdZX7N5b" title="Total">1,912</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20220930_zUadpsF9VLN" title="Total">3,099</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zfJgrE3PLzl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt; background-color: white">We currently have exclusive supply agreements with BASF Corporation (“BASF”), our largest customer, that have contingencies outlined which could potentially result in “triggering” the sale of production equipment from the Company to the customer intended to provide capacity sufficient to meet the customer’s production needs. This outcome may occur if we fail to meet certain performance requirements. In the event of an equipment sale, upon incurring a triggering event, the equipment would be sold to the customer at either <span id="xdx_909_ecustom--EquipmentSaleNetBookValueEquipment_iI_pid_dp_uPure_c20230930__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_zNnowYbs8Tf2" title="Equipment sale - net book value">115</span>% of the equipment’s net book value or the greater of <span id="xdx_90A_ecustom--EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades_iI_pid_dp_uPure_c20230930__us-gaap--SupplyCommitmentAxis__us-gaap--SupplyCommitmentMember_zn21OWZsnST9" title="Equipment sale- original book value">30</span>% of the original book value of such equipment, and any associated upgrades to it, or <span id="xdx_90F_ecustom--EquipmentSaleNetBookValueEquipment_iI_pid_dp_uPure_c20230930_zl4D4KYQOMfl" title="Equipment sale - net book value">115</span>% of the equipment’s net book value, depending on the equipment and related products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 35.7pt; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If a triggering event were to occur and BASF elected to proceed with the equipment sale mentioned above, we would lose both significant revenue and the ability to generate significant revenue to replace that which was lost in the near term. Replacement of necessary equipment that could be purchased and removed by the customer pursuant to this triggering event could take in excess of twelve months. Any additional capital outlays required to rebuild capacity would probably be greater than the proceeds from the purchase of the assets as dictated by our agreement with the customer. Similar consequences would occur if we were determined to have materially breached certain other provisions of the supply agreement with BASF. Any such event would also likely result in the loss of many of our key staff and line employees due to economic realities. We believe that our employees are a critical component of our success, and it could be difficult to replace them quickly. Given the occurrence of any such event, we might not be able to hire and retain skilled employees given the stigma relating to such an event and its impact on us.</p> <p id="xdx_89B_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zXVj4CwCp1me" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zaQcLsawTZSd">The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.3pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended <br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended <br/> September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 41%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zVRlHuoWj5z5" title="Revenue from customers">30</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zVjxDMif7Bnb" title="Revenue from customers">30</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zvk195x1qo6k" title="Revenue from customers">31</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zSf3WR9vlDR3" title="Revenue from customers">30</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zpn25AygHyq9" title="Revenue from customers">18</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zEMYZiEoWpB7" title="Revenue from customers">18</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z6XRRZyL11ql" title="Revenue from customers">14</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zRa3P5AN7Dei" title="Revenue from customers">17</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">Solésence®</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z0YCPbW4jXql" title="Revenue from customers">21</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zkg2mjEJvcyd" title="Revenue from customers">19</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1OEhEvufUdl" title="Revenue from customers">14</span></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1tvQzpiLGjc" title="Revenue from customers">16</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zPWO7sAL6A6e" title="Revenue from customers">69</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zIIJm5wlX0R" title="Revenue from customers">67</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zuWqbSyJP3c7" title="Revenue from customers">59</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--CustomersOneThroughThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zkKifMjbFQg3" title="Revenue from customers">63</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.30 0.30 0.31 0.30 0.18 0.18 0.14 0.17 0.21 0.19 0.14 0.16 0.69 0.67 0.59 0.63 <p id="xdx_89E_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zbKrHFvydRI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8BA_zohx0Am7Js35">Accounts receivable balances for these three customers were approximately:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer #</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2023</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold"> </td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 7%; text-align: center">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 65%; text-align: left">Personal Care Ingredients</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20230930__srt--MajorCustomersAxis__custom--CustomerOneMember_zjwfzwQcXEBd" title="Total">320</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_900_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20220930__srt--MajorCustomersAxis__custom--CustomerOneMember_zPeSYHDcQtPb" title="Total">943</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td style="text-align: left"> </td><td> </td> <td>Solésence®</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember_zrSW6St55Gp9" title="Total">545</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20220930__srt--MajorCustomersAxis__custom--CustomerTwoMember_zlZT1YRCDmGc" title="Total">439</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">Solésence®</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember_zV7Vil8ectvf" title="Total">1,047</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20220930__srt--MajorCustomersAxis__custom--CustomerThreeMember_zxPtwGDbt3U3" title="Total">1,717</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20230930_zrC4QdZX7N5b" title="Total">1,912</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent_iI_c20220930_zUadpsF9VLN" title="Total">3,099</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 320000 943000 545000 439000 1047000 1717000 1912000 3099000 1.15 0.30 1.15 <p id="xdx_800_eus-gaap--SegmentReportingDisclosureTextBlock_zq7jKoh0ZUvd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <b>(9) <span id="xdx_822_zx076VxLwp4i">Business Segmentation and Geographical Distribution</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue from international sources approximated <span id="xdx_90B_eus-gaap--Revenues_pn3n3_c20230701__20230930__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zAGHHQMeE43f" title="Revenues">$731</span> and <span id="xdx_907_eus-gaap--Revenues_pn3n3_c20230101__20230930__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zaWfP6di1Fih" title="Revenues">$2,918</span> for the three and nine months ended September 30, 2023, respectively, compared to <span id="xdx_909_eus-gaap--Revenues_pn3n3_c20220701__20220930__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zCvdbaJTIXyg" title="Revenues">$495</span> and <span id="xdx_908_eus-gaap--Revenues_pn3n3_c20220101__20220930__srt--StatementGeographicalAxis__us-gaap--NonUsMember_zYZjPHd5g4K" title="Revenues">$955</span> for the three and nine months ended September 30, 2022, respectively. All of this revenue was product revenue.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z7VNw3JNjab8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. <span id="xdx_8B6_zSXqVcOUJOnc">The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Solésence</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--ProductOrServiceAxis__custom--SolesenceMember_zpwSuH1o42a1" style="width: 12%; text-align: right" title="Total revenue">5,016</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--ProductOrServiceAxis__custom--SolesenceMember_zWEUaJKMcWx8" style="width: 12%; text-align: right" title="Total revenue">5,932</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--ProductOrServiceAxis__custom--SolesenceMember_zYdXsm3cjfBj" style="width: 12%; text-align: right" title="Total revenue">17,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--ProductOrServiceAxis__custom--SolesenceMember_zk879SbDHova" style="width: 12%; text-align: right" title="Total revenue">18,591</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_znOtrDfvj6Xc" style="text-align: right" title="Total revenue">2,364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zBfbsYju4RM8" style="text-align: right" title="Total revenue">2,903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zJXekCVVMp32" style="text-align: right" title="Total revenue">8,944</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zRPjxE6s7Y64" style="text-align: right" title="Total revenue">8,589</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zGqqeTtC05al" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">578</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zOytufE4aZC6" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">843</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_z0hEZJ5Be6A3" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">2,503</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zZPc5xkKUQO8" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">1,876</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930_zDfId2deMzi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">7,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930_ziTugjxOYHe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">9,678</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930_zMAX5lAUm4c4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">29,286</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930_zX9YKNAgL3sb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">29,056</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zRB1OwfeeQE3" style="margin-top: 0; margin-bottom: 0"> </p> 731000 2918000 495000 955000 <p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_z7VNw3JNjab8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations comprise a single business segment and all of our long-lived assets are located within the United States. We categorize our revenue stream into three main product categories, Personal Care Ingredients, Advanced Materials and Solésence. <span id="xdx_8B6_zSXqVcOUJOnc">The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Product Category</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Solésence</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--ProductOrServiceAxis__custom--SolesenceMember_zpwSuH1o42a1" style="width: 12%; text-align: right" title="Total revenue">5,016</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--ProductOrServiceAxis__custom--SolesenceMember_zWEUaJKMcWx8" style="width: 12%; text-align: right" title="Total revenue">5,932</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--ProductOrServiceAxis__custom--SolesenceMember_zYdXsm3cjfBj" style="width: 12%; text-align: right" title="Total revenue">17,839</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--ProductOrServiceAxis__custom--SolesenceMember_zk879SbDHova" style="width: 12%; text-align: right" title="Total revenue">18,591</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Personal Care Ingredients</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_znOtrDfvj6Xc" style="text-align: right" title="Total revenue">2,364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zBfbsYju4RM8" style="text-align: right" title="Total revenue">2,903</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zJXekCVVMp32" style="text-align: right" title="Total revenue">8,944</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--ProductOrServiceAxis__custom--PersonalCareIngredientsMember_zRPjxE6s7Y64" style="text-align: right" title="Total revenue">8,589</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Advanced Materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zGqqeTtC05al" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">578</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zOytufE4aZC6" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">843</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_z0hEZJ5Be6A3" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">2,503</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--ProductOrServiceAxis__custom--AdvancedMaterialsMember_zZPc5xkKUQO8" style="border-bottom: Black 1pt solid; text-align: right" title="Total revenue">1,876</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total Sales</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930_zDfId2deMzi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">7,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930_ziTugjxOYHe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">9,678</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930_zMAX5lAUm4c4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">29,286</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930_zX9YKNAgL3sb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total revenue">29,056</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5016000 5932000 17839000 18591000 2364000 2903000 8944000 8589000 578000 843000 2503000 1876000 7958000 9678000 29286000 29056000 <p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zP3fGu3Q5UIi" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-size: 10pt"><b>(10)</b></span></td> <td id="xdx_82C_zdxHFilrv9Bf" style="text-align: justify"><span style="font-size: 10pt"><b>Commitments and Contingencies</b> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">On August 9, 2022, BASF filed a complaint against Nanophase in New Jersey state court (the “New Jersey Complaint”), alleging that Nanophase had breached the 1999 Zinc Oxide Supply Agreement (the “Agreement”). BASF alleges several issues, the one having the biggest potential impact on Nanophase being a claim that our sales through Solésence violate the exclusivity provision of the Agreement. BASF seeks an unspecified amount of damages, a permanent injunction enjoining sales to any party (other than BASF) of a broad range of zinc oxide products that BASF contends are within the scope of the exclusivity provision, counsel fees and litigation expenses. On September 7, 2022, Nanophase filed a Complaint for Declaratory Judgement in Illinois state court (the “Illinois Complaint”), asking for a declaration that contrary to BASF’s allegation, the exclusivity provision of the Agreement does not apply to all products containing zinc oxide as an ingredient for uses designated under the Agreement, nor does the exclusivity provision prohibit Nanophase’s sales of Solésence products containing zinc oxide as an ingredient. Both companies filed Motions to Dismiss (MTD) the other’s respective complaint. Nanophase’s MTD BASF’s New Jersey Complaint was denied on procedural grounds on February 10, 2023, with the New Jersey court superficially noting that it did not consider whether BASF could prove its claims. On February 28, 2023, Nanophase filed its answer to BASF’s New Jersey Complaint, denying all wrongdoing and, as mandated by New Jersey procedural requirements, counterclaims including a request for a declaration similar to that Nanophase sought in its Illinois Complaint. On March 16, 2023, the Illinois court granted BASF’s MTD Nanophase’s Illinois Complaint, finding it duplicative of the New Jersey litigation. Discovery in that litigation is ongoing. Management believes at this time that the allegations of BASF’s complaint are without merit and are unsupported by the terms of the Agreement and governing law. Per ASC 450 for the period ending September 30, 2023, an estimated contingent loss was not recorded, and an estimated range of loss is not disclosed as the outcome is not probable at this time and nor is a range of loss estimable.</span> </p> <p id="xdx_80E_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_znDVyskt81Va" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-size: 10pt"><b>(11)</b></span></td> <td id="xdx_826_zurs6HvciEO2" style="text-align: justify"><span style="font-size: 10pt"><b>Accounting Standards Adopted During 2023</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">On January 1, 2023, the Company adopted <span id="xdx_909_eus-gaap--AccountingStandardsUpdateExtensibleList_dxL_c20220101__20221231_zxpekOFO8WFg" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23AccountingStandardsUpdate201613Member"><span style="-sec-ix-hidden: xdx2ixbrl0883">ASU 2016-13</span></span> “<i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>” which updates the manner in which entities assess expected losses from financial instruments exposed to credit risk. While this update has a greater impact on issuers with loans, notes, and credit card receivables, the scope of Topic 326 extends to both financial assets measured at amortized cost as well as available-for-sale debt securities. As such, trade receivables are subject to the Topic’s provisions, requiring entities to consider past events, current conditions, and reasonable and supportable forecasts in determining the amount of expected loss over the life of the respective financial instrument. Nanophase uses the loss-rate method in developing its allowance for credit losses, which involves identifying pools of assets with similar risk characteristics, reviewing historical losses within the last three years, and consideration of reasonable and supportable forecasts. Changes in estimates, developing trends, and other new information can have a material impact on future evaluations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">This differs from prior allocation methodologies in that in addition to solely considering an aging schedule for amounts to reserve, management must now also consider current events as well as the future macroeconomic environment when making such loss assessments. On January 1, 2023, the Company applied the accounting change retrospectively with an opening adjustment to retained earnings in the amount of <span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20221231__srt--CumulativeEffectPeriodOfAdoptionAxis__srt--CumulativeEffectPeriodOfAdoptionAdjustmentMember_zX3qEALIBlV" title="Retained earnings">$203</span>.</span></p> -203000 Since July 2014, we have maintained a bank-issued letter of credit for up to $30 in borrowings, with interest at the prime rate plus 1%, to support our obligations under our Romeoville, Illinois facility lease agreement. No borrowings have been incurred under this promissory note. It is our intention to renew this note annually. Because there were no amounts outstanding on the note at any time during 2023 or 2022, we have recorded no related liability on our balance sheet. The Company maintains a credit agreement with Libertyville to support our obligations under our newly leased manufacturing and warehouse space in Bolingbrook, Illinois. Interest on drawn balances will be at the prime rate plus 1%. This credit agreement has a maturity of December 22, 2023. We expect to renew this agreement annually, as the lease requires. This credit agreement is secured by all the unencumbered assets of the Company, and has superior collateral rights to those credit facilities with Beachcorp, LLC and Strandler, LLC. On January 28, 2022 the Company entered into an additional Business Loan Agreement (the “New Term Loan Agreement”) with Strandler, LLC, which effectively transferred or assigned the previously existing Term Loan to Strandler, LLC from Beachcorp, LLC. Interest on the New Term Loan is at the prime rate plus 0.75%, and it matures on March 31, 2024. Strandler, LLC is also an affiliate of Bradford T. Whitmore. On January 28, 2022 the Company entered into an Amended and Restated Business Loan Agreement (the “A&R Loan Agreement”), which amends and restates the Master Agreement between the Company and Beachcorp, LLC, and a new promissory note in order to evidence the A/R Revolver facility, including an amendment to expand the limit on the A/R Revolver Facility from $6,000 to $8,000, reduce the interest rate to the prime rate plus 0.75%, and extend the maturity of the A/R Revolver Facility to March 31, 2024. On January 28, 2022 the Company entered into the A&R Loan Agreement and a new revolving loan agreement (“Inventory Facility”) with Beachcorp, LLC, and a new promissory note in order to evidence the Inventory Facility. The maximum borrowing amount under the Inventory Facility is $4,000, with a borrowing base consisting of up to 50% of the value of qualified inventory of the Company. The interest rate for the Inventory Revolver is at the prime rate plus 0.75%, and it matures on March 31, 2024. On May 1, 2023 the Company entered into a non-revolving promissory note (“TI Promissory Note”) with Beachcorp, LLC. The maximum borrowing amount under the TI Promissory Note is $1,750. The interest rate for the TI Promissory Note is at the prime rate plus 0.75%, and it matures on September 30, 2023. This loan is for work being done at the Bolingbrook facility which is expected to be reimbursed from the landlord as part of the lease agreement. On July 21, 2023, the TI Promissory Note and accrued interest was repaid in full after reimbursement from the landlord for approved tenant improvements. EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " 8A&Y78]:*%)L! "4%P $P @ %J LP0 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 +@ N 'D, VPP ! end XML 55 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 160 148 1 true 37 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://nanophase.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) Sheet http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) Sheet http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://nanophase.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Description of Business Sheet http://nanophase.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 00000009 - Disclosure - Revenues Sheet http://nanophase.com/role/Revenues Revenues Notes 9 false false R10.htm 00000010 - Disclosure - Earnings Per Share Sheet http://nanophase.com/role/EarningsPerShare Earnings Per Share Notes 10 false false R11.htm 00000011 - Disclosure - Financial Instruments Sheet http://nanophase.com/role/FinancialInstruments Financial Instruments Notes 11 false false R12.htm 00000012 - Disclosure - Notes and Lines of Credit Notes http://nanophase.com/role/NotesAndLinesOfCredit Notes and Lines of Credit Notes 12 false false R13.htm 00000013 - Disclosure - Inventories Sheet http://nanophase.com/role/Inventories Inventories Notes 13 false false R14.htm 00000014 - Disclosure - Significant Customers and Contingencies Sheet http://nanophase.com/role/SignificantCustomersAndContingencies Significant Customers and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Business Segmentation and Geographical Distribution Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution Business Segmentation and Geographical Distribution Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://nanophase.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Accounting Standards Adopted During 2023 Sheet http://nanophase.com/role/AccountingStandardsAdoptedDuring2023 Accounting Standards Adopted During 2023 Notes 17 false false R18.htm 00000018 - Disclosure - Revenues (Tables) Sheet http://nanophase.com/role/RevenuesTables Revenues (Tables) Tables http://nanophase.com/role/Revenues 18 false false R19.htm 00000019 - Disclosure - Earnings Per Share (Tables) Sheet http://nanophase.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://nanophase.com/role/EarningsPerShare 19 false false R20.htm 00000020 - Disclosure - Notes and Lines of Credit (Tables) Notes http://nanophase.com/role/NotesAndLinesOfCreditTables Notes and Lines of Credit (Tables) Tables http://nanophase.com/role/NotesAndLinesOfCredit 20 false false R21.htm 00000021 - Disclosure - Inventories (Tables) Sheet http://nanophase.com/role/InventoriesTables Inventories (Tables) Tables http://nanophase.com/role/Inventories 21 false false R22.htm 00000022 - Disclosure - Significant Customers and Contingencies (Tables) Sheet http://nanophase.com/role/SignificantCustomersAndContingenciesTables Significant Customers and Contingencies (Tables) Tables http://nanophase.com/role/SignificantCustomersAndContingencies 22 false false R23.htm 00000023 - Disclosure - Business Segmentation and Geographical Distribution (Tables) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables Business Segmentation and Geographical Distribution (Tables) Tables http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution 23 false false R24.htm 00000024 - Disclosure - Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows: (Details) Sheet http://nanophase.com/role/ContractBalancesAtSeptember302023December312022AndDecember312021AreAsFollowsDetails Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows: (Details) Details 24 false false R25.htm 00000025 - Disclosure - Revenues (Details Narrative) Sheet http://nanophase.com/role/RevenuesDetailsNarrative Revenues (Details Narrative) Details http://nanophase.com/role/RevenuesTables 25 false false R26.htm 00000026 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) Sheet http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details) Details 26 false false R27.htm 00000027 - Disclosure - Earnings Per Share (Details Narrative) Sheet http://nanophase.com/role/EarningsPerShareDetailsNarrative Earnings Per Share (Details Narrative) Details http://nanophase.com/role/EarningsPerShareTables 27 false false R28.htm 00000028 - Disclosure - Notes and lines of credit consist of the following: (Details) Notes http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails Notes and lines of credit consist of the following: (Details) Details 28 false false R29.htm 00000029 - Disclosure - Related party interest summary: (Details) Sheet http://nanophase.com/role/RelatedPartyInterestSummaryDetails Related party interest summary: (Details) Details 29 false false R30.htm 00000030 - Disclosure - Notes and Lines of Credit (Details Narrative) Notes http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative Notes and Lines of Credit (Details Narrative) Details http://nanophase.com/role/NotesAndLinesOfCreditTables 30 false false R31.htm 00000031 - Disclosure - Inventories consist of the following: (Details) Sheet http://nanophase.com/role/InventoriesConsistOfFollowingDetails Inventories consist of the following: (Details) Details 31 false false R32.htm 00000032 - Disclosure - Inventories (Details Narrative) Sheet http://nanophase.com/role/InventoriesDetailsNarrative Inventories (Details Narrative) Details http://nanophase.com/role/InventoriesTables 32 false false R33.htm 00000033 - Disclosure - The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022: (Details) Sheet http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022: (Details) Details 33 false false R34.htm 00000034 - Disclosure - Accounts receivable balances for these three customers were approximately: (Details) Sheet http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails Accounts receivable balances for these three customers were approximately: (Details) Details 34 false false R35.htm 00000035 - Disclosure - Significant Customers and Contingencies (Details Narrative) Sheet http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative Significant Customers and Contingencies (Details Narrative) Details http://nanophase.com/role/SignificantCustomersAndContingenciesTables 35 false false R36.htm 00000036 - Disclosure - The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows: (Details) Sheet http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows: (Details) Details 36 false false R37.htm 00000037 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative) Sheet http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative Business Segmentation and Geographical Distribution (Details Narrative) Details http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables 37 false false R38.htm 00000038 - Disclosure - Accounting Standards Adopted During 2023 (Details Narrative) Sheet http://nanophase.com/role/AccountingStandardsAdoptedDuring2023DetailsNarrative Accounting Standards Adopted During 2023 (Details Narrative) Details 38 false false All Reports Book All Reports nanx-10q_093023.htm nanx-20230930.xsd nanx-20230930_cal.xml nanx-20230930_def.xml nanx-20230930_lab.xml nanx-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nanx-10q_093023.htm": { "nsprefix": "nanx", "nsuri": "http://nanophase.com/20230930", "dts": { "inline": { "local": [ "nanx-10q_093023.htm" ] }, "schema": { "local": [ "nanx-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "nanx-20230930_cal.xml" ] }, "definitionLink": { "local": [ "nanx-20230930_def.xml" ] }, "labelLink": { "local": [ "nanx-20230930_lab.xml" ] }, "presentationLink": { "local": [ "nanx-20230930_pre.xml" ] } }, "keyStandard": 142, "keyCustom": 6, "axisStandard": 16, "axisCustom": 0, "memberStandard": 16, "memberCustom": 19, "hidden": { "total": 105, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 99, "http://nanophase.com/20230930": 1 }, "contextCount": 160, "entityCount": 1, "segmentCount": 37, "elementCount": 299, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 519, "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://nanophase.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R2": { "role": "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed)", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R3": { "role": "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited Consolidated Condensed) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R4": { "role": "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed)", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited Consolidated Condensed)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "unique": true } }, "R5": { "role": "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed)", "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited Consolidated Condensed)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "unique": true } }, "R6": { "role": "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed)", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited Consolidated Condensed)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "unique": true } }, "R7": { "role": "http://nanophase.com/role/BasisOfPresentation", "longName": "00000007 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R8": { "role": "http://nanophase.com/role/DescriptionOfBusiness", "longName": "00000008 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R9": { "role": "http://nanophase.com/role/Revenues", "longName": "00000009 - Disclosure - Revenues", "shortName": "Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R10": { "role": "http://nanophase.com/role/EarningsPerShare", "longName": "00000010 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R11": { "role": "http://nanophase.com/role/FinancialInstruments", "longName": "00000011 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R12": { "role": "http://nanophase.com/role/NotesAndLinesOfCredit", "longName": "00000012 - Disclosure - Notes and Lines of Credit", "shortName": "Notes and Lines of Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R13": { "role": "http://nanophase.com/role/Inventories", "longName": "00000013 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R14": { "role": "http://nanophase.com/role/SignificantCustomersAndContingencies", "longName": "00000014 - Disclosure - Significant Customers and Contingencies", "shortName": "Significant Customers and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R15": { "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution", "longName": "00000015 - Disclosure - Business Segmentation and Geographical Distribution", "shortName": "Business Segmentation and Geographical Distribution", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R16": { "role": "http://nanophase.com/role/CommitmentsAndContingencies", "longName": "00000016 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R17": { "role": "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023", "longName": "00000017 - Disclosure - Accounting Standards Adopted During 2023", "shortName": "Accounting Standards Adopted During 2023", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R18": { "role": "http://nanophase.com/role/RevenuesTables", "longName": "00000018 - Disclosure - Revenues (Tables)", "shortName": "Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R19": { "role": "http://nanophase.com/role/EarningsPerShareTables", "longName": "00000019 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R20": { "role": "http://nanophase.com/role/NotesAndLinesOfCreditTables", "longName": "00000020 - Disclosure - Notes and Lines of Credit (Tables)", "shortName": "Notes and Lines of Credit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R21": { "role": "http://nanophase.com/role/InventoriesTables", "longName": "00000021 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R22": { "role": "http://nanophase.com/role/SignificantCustomersAndContingenciesTables", "longName": "00000022 - Disclosure - Significant Customers and Contingencies (Tables)", "shortName": "Significant Customers and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R23": { "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables", "longName": "00000023 - Disclosure - Business Segmentation and Geographical Distribution (Tables)", "shortName": "Business Segmentation and Geographical Distribution (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R24": { "role": "http://nanophase.com/role/ContractBalancesAtSeptember302023December312022AndDecember312021AreAsFollowsDetails", "longName": "00000024 - Disclosure - Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows: (Details)", "shortName": "Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R25": { "role": "http://nanophase.com/role/RevenuesDetailsNarrative", "longName": "00000025 - Disclosure - Revenues (Details Narrative)", "shortName": "Revenues (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "nanx:ContractWithCustomerLiabilityRevenueRecognizedNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "nanx:ContractWithCustomerLiabilityRevenueRecognizedNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R26": { "role": "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails", "longName": "00000026 - Disclosure - Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details)", "shortName": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://nanophase.com/role/EarningsPerShareDetailsNarrative", "longName": "00000027 - Disclosure - Earnings Per Share (Details Narrative)", "shortName": "Earnings Per Share (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R28": { "role": "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "longName": "00000028 - Disclosure - Notes and lines of credit consist of the following: (Details)", "shortName": "Notes and lines of credit consist of the following: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2023-09-30_custom_LibertyvilleBankAndTrustMember", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_custom_LibertyvilleBankAndTrustMember", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R29": { "role": "http://nanophase.com/role/RelatedPartyInterestSummaryDetails", "longName": "00000029 - Disclosure - Related party interest summary: (Details)", "shortName": "Related party interest summary: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:InterestExpenseOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:InterestExpenseOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R30": { "role": "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative", "longName": "00000030 - Disclosure - Notes and Lines of Credit (Details Narrative)", "shortName": "Notes and Lines of Credit (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2023-11-122023-11-13_us-gaap_SubsequentEventMember_custom_PromissoryNoteMember_custom_StrandlerLLCMember", "name": "us-gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-11-122023-11-13_us-gaap_SubsequentEventMember_custom_PromissoryNoteMember_custom_StrandlerLLCMember", "name": "us-gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R31": { "role": "http://nanophase.com/role/InventoriesConsistOfFollowingDetails", "longName": "00000031 - Disclosure - Inventories consist of the following: (Details)", "shortName": "Inventories consist of the following: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R32": { "role": "http://nanophase.com/role/InventoriesDetailsNarrative", "longName": "00000032 - Disclosure - Inventories (Details Narrative)", "shortName": "Inventories (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:InventoryValuationReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:InventoryValuationReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R33": { "role": "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details", "longName": "00000033 - Disclosure - The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022: (Details)", "shortName": "The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2023-07-012023-09-30_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_custom_CustomerOneMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R34": { "role": "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "longName": "00000034 - Disclosure - Accounts receivable balances for these three customers were approximately: (Details)", "shortName": "Accounts receivable balances for these three customers were approximately: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R35": { "role": "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative", "longName": "00000035 - Disclosure - Significant Customers and Contingencies (Details Narrative)", "shortName": "Significant Customers and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "nanx:EquipmentSaleNetBookValueEquipment", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "nanx:EquipmentSaleNetBookValueEquipment", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R36": { "role": "http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails", "longName": "00000036 - Disclosure - The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows: (Details)", "shortName": "The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_custom_SolesenceMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "unique": true } }, "R37": { "role": "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative", "longName": "00000037 - Disclosure - Business Segmentation and Geographical Distribution (Details Narrative)", "shortName": "Business Segmentation and Geographical Distribution (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_NonUsMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_NonUsMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true, "unique": true } }, "R38": { "role": "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023DetailsNarrative", "longName": "00000038 - Disclosure - Accounting Standards Adopted During 2023 (Details Narrative)", "shortName": "Accounting Standards Adopted During 2023 (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "nanx-10q_093023.htm", "unique": true } } }, "tag": { "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r548" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r546" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r484" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r541" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r76", "r218", "r219", "r485", "r571" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Other assets, net", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r109" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r517", "r577" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Numerator: (in Thousands)" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r14", "r32" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Financial Instruments", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at ending", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r53", "r56", "r57", "r74", "r437", "r453", "r474", "r475", "r520", "r532", "r563", "r569", "r581", "r592" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r278", "r279", "r280", "r424", "r564", "r565", "r566", "r579", "r592" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r25", "r27", "r37", "r38", "r196", "r484", "r554" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r517", "r577" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r560" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r25", "r27", "r37", "r38", "r196", "r484" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r6", "r101", "r117", "r118", "r119", "r133", "r134", "r135", "r140", "r149", "r151", "r169", "r206", "r214", "r258", "r278", "r279", "r280", "r285", "r286", "r302", "r304", "r305", "r306", "r307", "r310", "r320", "r337", "r338", "r339", "r340", "r341", "r342", "r363", "r409", "r410", "r411", "r424", "r473" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r546" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r24", "r25", "r27", "r28", "r37", "r81", "r484" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ContractBalancesAtSeptember302023December312022AndDecember312021AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Contract Assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r259", "r261", "r273" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r25", "r27", "r37", "r38", "r196", "r419", "r484" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments on finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r356", "r357" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingencies" ], "lang": { "en-us": { "role": { "label": "Significant Customers and Contingencies", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r73" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails", "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r192", "r369", "r401", "r402", "r403", "r404", "r405", "r406", "r496", "r512", "r521", "r556", "r572", "r573", "r577", "r587" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r549" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r546" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r533" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Issuance of shares and stock option exercises", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r6", "r52", "r53", "r80", "r424", "r473", "r481", "r531" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r54", "r520", "r590" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://nanophase.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "Inventories consist of the following:", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r9", "r59", "r60", "r61" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails", "http://nanophase.com/role/RevenuesDetailsNarrative" ], "auth_ref": [ "r192", "r369", "r401", "r402", "r403", "r404", "r405", "r406", "r496", "r512", "r521", "r556", "r572", "r573", "r577", "r587" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r106", "r114", "r129", "r202", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r295", "r297", "r329", "r520", "r574", "r575", "r583" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r132", "r230", "r231", "r232", "r233", "r234", "r236", "r241", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r254", "r347", "r507", "r508", "r509", "r510", "r511", "r562" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r69" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average additional shares assuming conversion of in-the-money stock options to common shares and assumed repurchase of common shares by the Company", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r158", "r159", "r160", "r164", "r277" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r14", "r33", "r34", "r39", "r40", "r42", "r43", "r78", "r79", "r132", "r230", "r231", "r232", "r233", "r234", "r236", "r241", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r254", "r347", "r507", "r508", "r509", "r510", "r511", "r562" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r19", "r69", "r127" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Adopted During 2023", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r92", "r93", "r96", "r104", "r137", "r138", "r141", "r142", "r152", "r153", "r207", "r208", "r287", "r288", "r289", "r308", "r318", "r324", "r325", "r326", "r334", "r335", "r336", "r352", "r353", "r364", "r373", "r374", "r375", "r413", "r414", "r415", "r416", "r418" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets obtained in exchange for lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r358", "r519" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Accounts payable incurred for the purchase of equipment and leasehold improvements", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r20", "r21", "r22" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Operating expense:" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r130", "r131", "r233", "r257", "r367", "r502", "r504" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r133", "r134", "r135", "r169", "r369", "r421", "r425", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r454", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r525" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Basic earnings per common share:" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r53" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r14" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "auth_ref": [ "r196", "r514", "r577", "r587", "r588" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Issuance of shares and stock option exercises (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r6", "r52", "r53", "r80", "r422", "r473", "r481" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistribution" ], "lang": { "en-us": { "role": { "label": "Business Segmentation and Geographical Distribution", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r170", "r171", "r172", "r173", "r174", "r180", "r184", "r188", "r189", "r190", "r191", "r192", "r193", "r196" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://nanophase.com/role/DescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Description of Business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r91", "r97" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r495" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r294" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Common stock, $.01 par value, 60,000,000 shares authorized; 49,627,254 and 49,320,680 shares issued and outstanding on September 30, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r53", "r393", "r520" ] }, "us-gaap_ProceedsFromOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromOtherDebt", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Proceeds from term loan, related party", "documentation": "Amount of cash inflow from debt classified as other." } } }, "auth_ref": [ "r17" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r53", "r435" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r6", "r53", "r435", "r453", "r592", "r593" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "auth_ref": [ "r194", "r195", "r426", "r427", "r428", "r477", "r478", "r479", "r480", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r497", "r513", "r524", "r577", "r587" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r547" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Diluted earnings per common share:" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r6", "r15", "r101", "r117", "r118", "r119", "r133", "r134", "r135", "r140", "r149", "r151", "r169", "r206", "r214", "r258", "r278", "r279", "r280", "r285", "r286", "r302", "r304", "r305", "r306", "r307", "r310", "r320", "r337", "r338", "r339", "r340", "r341", "r342", "r363", "r409", "r410", "r411", "r424", "r473" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r544", "r546", "r547" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed", "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Inventories, net", "totalLabel": "Total inventories, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r113", "r499", "r520" ] }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [ "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023DetailsNarrative" ], "auth_ref": [ "r101", "r136", "r146", "r152", "r206", "r214", "r278", "r279", "r280", "r285", "r286", "r302", "r304", "r305", "r307", "r309", "r310", "r314", "r317", "r320", "r321", "r361" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Proceeds from line of credit, related party", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r17" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://nanophase.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r154", "r165", "r166", "r167" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r545" ] }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "auth_ref": [ "r101", "r136", "r146", "r152", "r206", "r214", "r278", "r279", "r280", "r285", "r286", "r302", "r304", "r305", "r307", "r309", "r310", "r314", "r317", "r320", "r321", "r361" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r594", "r595", "r596", "r597" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://nanophase.com/role/EarningsPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r165" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r547" ] }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdateExtensibleList", "presentation": [ "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Extensible Enumeration]", "documentation": "Indicates amendment to accounting standards." } } }, "auth_ref": [ "r99", "r100", "r101", "r102", "r103", "r139", "r140", "r141", "r200", "r201", "r203", "r204", "r205", "r206", "r209", "r210", "r211", "r212", "r213", "r217", "r278", "r279", "r280", "r285", "r286", "r291", "r292", "r293", "r299", "r300", "r301", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r319", "r320", "r321", "r322", "r323", "r327", "r328", "r330", "r331", "r332", "r333", "r344", "r345", "r348", "r349", "r350", "r359", "r360", "r361", "r362", "r363", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r567" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r101", "r133", "r134", "r135", "r140", "r149", "r151", "r206", "r214", "r278", "r279", "r280", "r285", "r286", "r302", "r305", "r306", "r310", "r320", "r409", "r411", "r424", "r592" ] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": [ "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "auth_ref": [ "r101", "r136", "r146", "r152", "r206", "r214", "r278", "r279", "r280", "r285", "r286", "r302", "r304", "r305", "r307", "r309", "r310", "r314", "r317", "r320", "r321", "r361" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r535" ] }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Expiration Date", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": [ "r11" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Long-term debt, related party", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r111" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r123", "r125", "r126" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://nanophase.com/role/Revenues" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r98", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r274" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r546" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r53" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r58", "r86", "r395", "r520", "r563", "r569", "r581" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r275", "r365", "r366", "r430", "r431", "r432", "r433", "r434", "r452", "r454", "r476" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Cost of revenue", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r66", "r369" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Equipment and leasehold improvements, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r390", "r396", "r520" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r44", "r281", "r585" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "nanx_AccruedInterestExpenseRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20230930", "localname": "AccruedInterestExpenseRelatedParties", "crdr": "credit", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Accrued interest expense, related parties", "documentation": "Amount of accrued interest expense related parties." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative\u00a0expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r67" ] }, "nanx_EarlyTerminationOfOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20230930", "localname": "EarlyTerminationOfOperatingLease", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Early termination of operating lease", "documentation": "Early termination of operating lease amount." } } }, "auth_ref": [] }, "nanx_ContractWithCustomerLiabilityRevenueRecognizedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://nanophase.com/20230930", "localname": "ContractWithCustomerLiabilityRevenueRecognizedNet", "crdr": "credit", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue recognized included in contract liability balance at beginning of period", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer and earned during the period for which consideration from customer has been received or is due." } } }, "auth_ref": [] }, "nanx_LineOfCreditPercentageOfEligibleInventory": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20230930", "localname": "LineOfCreditPercentageOfEligibleInventory", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Percentage of Eligible inventory", "documentation": "The element represents line of credit percentage of eligible inventory." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "auth_ref": [] }, "nanx_EquipmentSaleNetBookValueEquipment": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20230930", "localname": "EquipmentSaleNetBookValueEquipment", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment sale - net book value", "documentation": "The element represents equipment sale net book value equipment." } } }, "auth_ref": [] }, "nanx_EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades": { "xbrltype": "percentItemType", "nsuri": "http://nanophase.com/20230930", "localname": "EquipmentSaleOriginalBookValueOfEquipmentAndUpgrades", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equipment sale- original book value", "documentation": "The element represents equipment sale original book value of equipment and upgrades." } } }, "auth_ref": [] }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of diluted common shares outstanding", "totalLabel": "Weighted average number of diluted common shares outstanding", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r156", "r164" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [ "http://nanophase.com/role/InventoriesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reserve against reported inventory", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r31", "r559" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://nanophase.com/role/BasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r45", "r72", "r73" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ContractBalancesAtSeptember302023December312022AndDecember312021AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Contract Liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r259", "r260", "r273" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r35", "r36", "r276" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r4", "r178" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r578" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of basic common shares outstanding", "verboseLabel": "Weighted average number of basic shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r155", "r164" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r10", "r520" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r534" ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Lines of credit, related party", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r49", "r83" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net income (loss)", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r64", "r71", "r88", "r105", "r115", "r116", "r119", "r129", "r139", "r144", "r145", "r146", "r147", "r150", "r151", "r161", "r174", "r182", "r187", "r190", "r202", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r322", "r329", "r398", "r455", "r471", "r472", "r506", "r530", "r574" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r535" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Change in right-of-use asset and lease liability, net", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r555", "r561" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "auth_ref": [ "r130", "r131", "r233", "r257", "r367", "r503", "r504" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r133", "r134", "r135", "r169", "r369", "r421", "r425", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r448", "r449", "r450", "r451", "r452", "r454", "r456", "r457", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r525" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r512" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r537" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r538" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $.01 par value, 24,088 shares authorized, and no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r52", "r392", "r520" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/Inventories" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r216" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r542" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "The portion of total revenue from our significant customers are as follows for the periods ending September 30, 2023, and 2022:", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r24", "r25", "r27", "r28", "r37", "r81" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r522", "r523", "r526", "r527", "r528", "r529", "r589", "r592" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r63", "r87", "r174", "r182", "r187", "r190", "r389", "r397", "r506" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r343", "r368" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCredit" ], "lang": { "en-us": { "role": { "label": "Notes and Lines of Credit", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r77", "r128", "r229", "r235", "r236", "r237", "r238", "r239", "r240", "r245", "r252", "r253", "r255" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "negatedLabel": "Cumulative effect of accounting changes related to expected credit losses", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Accounts receivable balances for these three customers were approximately:", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r16" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Operating leases, right of use", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r354" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of equipment and leasehold improvements", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r68" ] }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAllOtherInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r25", "r27", "r37", "r38", "r196", "r484" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Supplemental non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r90", "r94", "r150", "r151", "r179", "r282", "r290", "r400" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r294" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023DetailsNarrative", "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r55", "r80", "r394", "r413", "r418", "r423", "r436", "r520" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r99", "r100", "r101", "r102", "r103", "r136", "r139", "r140", "r141", "r143", "r146", "r152", "r168", "r200", "r201", "r203", "r204", "r205", "r206", "r209", "r210", "r211", "r212", "r213", "r214", "r217", "r278", "r279", "r280", "r283", "r284", "r285", "r286", "r291", "r292", "r293", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r319", "r320", "r321", "r322", "r323", "r327", "r328", "r330", "r331", "r332", "r333", "r344", "r345", "r348", "r349", "r350", "r351", "r359", "r360", "r361", "r362", "r363", "r370", "r371", "r372", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities related to operations:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionTables" ], "lang": { "en-us": { "role": { "label": "The revenues, by category, for the three and nine months ended September 30, 2023 and 2022 are as follows:", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r577" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://nanophase.com/role/AccountingStandardsAdoptedDuring2023DetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items." } } }, "auth_ref": [ "r23", "r99", "r100", "r101", "r102", "r103", "r136", "r139", "r140", "r141", "r143", "r146", "r152", "r168", "r200", "r201", "r203", "r204", "r205", "r206", "r209", "r210", "r211", "r212", "r213", "r214", "r217", "r278", "r279", "r280", "r283", "r284", "r285", "r286", "r291", "r292", "r293", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r319", "r320", "r321", "r322", "r323", "r327", "r328", "r330", "r331", "r332", "r333", "r344", "r345", "r348", "r349", "r350", "r351", "r359", "r360", "r361", "r362", "r363", "r370", "r371", "r372", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r420" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails", "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total revenue", "verboseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r175", "r176", "r181", "r185", "r186", "r192", "r194", "r196", "r271", "r272", "r369" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Trade accounts receivable, less allowance for doubtful accounts of $270 for September 30, 2023, and $139 for December 31, 2022", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r197", "r198" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r13", "r107", "r129", "r202", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r296", "r297", "r298", "r329", "r520", "r574", "r583", "r584" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r536" ] }, "us-gaap_AssetRetirementObligationsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetRetirementObligationsNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Asset retirement obligations", "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees." } } }, "auth_ref": [ "r570" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r75", "r500" ] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferredAtPointInTimeMember", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Transferred at Point in Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": [ "r517" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferredOverTimeMember", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r517" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://nanophase.com/role/InventoriesConsistOfFollowingDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/InventoriesConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r75", "r501" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "lang": { "en-us": { "role": { "label": "Allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r112", "r199", "r215" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r272", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditTables" ], "lang": { "en-us": { "role": { "label": "Notes and lines of credit consist of the following:", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r539" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://nanophase.com/role/RevenuesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r272", "r512", "r513", "r514", "r515", "r516", "r517", "r518" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r41", "r89", "r120", "r177", "r346", "r458", "r530", "r591" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r8", "r46", "r47", "r48", "r50", "r129", "r202", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r296", "r297", "r298", "r329", "r574", "r583", "r584" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r540" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r52", "r435" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditTables" ], "lang": { "en-us": { "role": { "label": "Related party interest summary:", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r52", "r256" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r194", "r195", "r426", "r427", "r428", "r477", "r478", "r479", "r480", "r482", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r497", "r513", "r524", "r577", "r587" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "nanx_AdvancedMaterialsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "AdvancedMaterialsMember", "presentation": [ "http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Advanced Materials [Member]", "documentation": "The element represents advanced materials member." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12" ] }, "nanx_PersonalCareIngredientsMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "PersonalCareIngredientsMember", "presentation": [ "http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Personal Care ingredients [Member]", "documentation": "The element represents personal care ingredients member." } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentMember", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Member]", "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments." } } }, "auth_ref": [ "r51", "r85" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r52", "r435", "r453", "r592", "r593" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r65", "r129", "r174", "r182", "r187", "r190", "r202", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r329", "r506", "r574" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://nanophase.com/role/ContractBalancesAtSeptember302023December312022AndDecember312021AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional." } } }, "auth_ref": [ "r259", "r262", "r273", "r483" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r522", "r523", "r524", "r526", "r527", "r528", "r529", "r564", "r565", "r579", "r589", "r592" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r343", "r368" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "crdr": "debit", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current." } } }, "auth_ref": [ "r259", "r262", "r273" ] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Rate", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r7" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfOtherDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfOtherDebt", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments to term loan, related party", "label": "Repayments of Other Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other." } } }, "auth_ref": [ "r18" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r551" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total Borrowing Capacity", "verboseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r52", "r256" ] }, "nanx_BeachcorpLLCThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "BeachcorpLLCThreeMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Beachcorp, LLC Three [Member]", "documentation": "Beachcorp, LLC Three." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Revenue from customers", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r25", "r27", "r37", "r38", "r196" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r19", "r108", "r498" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Current portion of deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r557" ] }, "nanx_SolesenceMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "SolesenceMember", "presentation": [ "http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Solesence [Member]", "documentation": "The element represents solesence member." } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentTable", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Table]", "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has committed resources to supply goods or services to a customer. May include identification of the goods or services to be furnished, identity of the purchasing party, pricing, effects on pricing for failing to deliver the [minimum] quantities required to be furnished, cancellation rights, and termination provisions." } } }, "auth_ref": [ "r51", "r85" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r543" ] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Long-term portion of deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r558" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r196", "r553" ] }, "nanx_BusinessLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "BusinessLoanAgreementMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Business Loan Agreement [Member]", "documentation": "The element represents business loan agreement member." } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentLineItems", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentAxis", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Supply Commitment [Axis]", "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer." } } }, "auth_ref": [ "r51", "r85" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments to line of credit, related party", "label": "Repayments of Related Party Debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r18" ] }, "nanx_BeachcorpLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "BeachcorpLLCMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Beachcorp, LLC [Member]", "documentation": "The element represents beachcorp l l c member." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r550" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r535" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "auth_ref": [] }, "nanx_InventoryFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "InventoryFacilityMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory Facility [Member]", "documentation": "Inventory Facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r11", "r562" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Net loss per basic share", "verboseLabel": "Net loss per share \u2013 basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r122", "r144", "r145", "r146", "r147", "r148", "r155", "r157", "r162", "r163", "r164", "r168", "r321", "r322", "r388", "r399", "r505" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r562" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r535" ] }, "nanx_TIPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "TIPromissoryNoteMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "TI Promissory Note [Member]", "documentation": "TI Promissory Note." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r275", "r365", "r366", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r430", "r431", "r432", "r433", "r434", "r452", "r454", "r476", "r582" ] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseOther", "crdr": "debit", "presentation": [ "http://nanophase.com/role/RelatedPartyInterestSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense, related parties", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r26", "r196" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://nanophase.com/role/RevenuesTables" ], "lang": { "en-us": { "role": { "label": "Contract balances at September 30, 2023, December 31, 2022, and December 31, 2021 are as follows:", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r576" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://nanophase.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Earnings applicable to common stock and common stock shares used in the calculation of basic and diluted earnings per share are as follows:", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r568" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding Borrowed Balance", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r8", "r84", "r586" ] }, "nanx_BridgeNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "BridgeNoteMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bridge Note [Member]", "documentation": "Bridge Note." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r355" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r535" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r124" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed", "http://nanophase.com/role/EarningsApplicableToCommonStockAndCommonStockSharesUsedInCalculationOfBasicAndDilutedEarningsPerShareAreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Net loss per diluted share", "verboseLabel": "Net loss per share \u2013 diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r122", "r144", "r145", "r146", "r147", "r148", "r157", "r162", "r163", "r164", "r168", "r321", "r322", "r388", "r399", "r505" ] }, "nanx_PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "PromissoryNoteMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Promissory Note [Member]", "documentation": "The element represents promissory note member." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r124" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r196", "r514", "r577", "r587", "r588" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r535" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r547" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfCashFlowsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r69", "r70", "r71" ] }, "nanx_LibertyvilleBankAndTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "LibertyvilleBankAndTrustMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Libertyville Bank and Trust [Member]", "documentation": "The element represents libertyville bank and trust member." } } }, "auth_ref": [] }, "nanx_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "CustomerOneMember", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "The element represents customer one member." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r30", "r62" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r95", "r507", "r580" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r82", "r110", "r129", "r174", "r183", "r188", "r202", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r295", "r297", "r329", "r391", "r447", "r520", "r532", "r574", "r575", "r583" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r535" ] }, "nanx_BeachcorpLLCTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "BeachcorpLLCTwoMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Beachcorp, LLC Two [Member]", "documentation": "Beachcorp, LLC Two." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfOperationsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r174", "r182", "r187", "r190", "r506" ] }, "nanx_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "CustomerTwoMember", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "The element represents customer two member." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nanophase.com/role/ConsolidatedBalanceSheetsUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "label": "Long-term portion of operating lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r355" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://nanophase.com/role/RevenuesByCategoryForThreeAndNineMonthsEndedSeptember302023And2022AreAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customers by Products and Services [Table]", "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r29" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r552" ] }, "nanx_BeachcorpLLCOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "BeachcorpLLCOneMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Beachcorp, LLC One [Member]", "documentation": "Beachcorp, LLC One." } } }, "auth_ref": [] }, "nanx_StrandlerLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "StrandlerLLCMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails", "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Strandler, LLC [Member]", "documentation": "The element represents strandler l l c member." } } }, "auth_ref": [] }, "nanx_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "CustomerThreeMember", "presentation": [ "http://nanophase.com/role/AccountsReceivableBalancesForTheseThreeCustomersWereApproximatelyDetails", "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "documentation": "The element represents customer three member." } } }, "auth_ref": [] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://nanophase.com/role/ConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedCondensed" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning (in shares)", "periodEndLabel": "Balance at ending (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://nanophase.com/role/BusinessSegmentationAndGeographicalDistributionDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenues", "label": "Revenues [Default Label]", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r121", "r129", "r175", "r176", "r181", "r185", "r186", "r192", "r194", "r196", "r202", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r329", "r389", "r574" ] }, "nanx_LibertyvilleBankAndTrustOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "LibertyvilleBankAndTrustOneMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditConsistOfFollowingDetails" ], "lang": { "en-us": { "role": { "label": "Libertyville Bank and Trust One [Member]", "documentation": "The element represents libertyville bank and trust one member." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nanophase.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "nanx_CustomersOneThroughThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nanophase.com/20230930", "localname": "CustomersOneThroughThreeMember", "presentation": [ "http://nanophase.com/role/PortionOfTotalRevenueFromOurSignificantCustomersAreAsFollowsForPeriodsEndingSeptember302023And2022Details" ], "lang": { "en-us": { "role": { "label": "Customers One through Three [Member]", "documentation": "Customers One through Three." } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplyCommitmentArrangementMember", "presentation": [ "http://nanophase.com/role/SignificantCustomersAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": [ "r51", "r85" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://nanophase.com/role/NotesAndLinesOfCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r343", "r368" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481850/410-20-50-1" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 60 0001999371-23-000211-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001999371-23-000211-xbrl.zip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end